AU2013277441B2 - Omega-3 pentaenoic acid compositions and methods of use - Google Patents

Abstract

Orally administrable composition comprising fatty acids, wherein at least 50% by weight of the fatty acids comprise omega-3-fatty acids, salts or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA; C20:5-n3), docosapentaenoic acid (DPA; C22:5-n3), and docosahexaenoic acid (DHA; C22:6-n3), wherein the ratio of DHA to EPA (DHA:EPA) is less than 1:20, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1 are provided. These compositions can be used for the treatment or prophylaxis of dyslipidemic, cardiovascular, CNS, inflammatory, and other diseases/conditions or risk factors therefore.

Description

and Methdds of Use ^ fiMjsi^^ potl] TheIriisrt irtrtb.Istates U a imm®. rtaofi i-^rmtrtations. comprising ©mega-S-: fg%::Msls:r;fcr tie treatment of patients b%:, ^^'Ιοϋ^Ι^Ιϊψ.·:;«ιι nirtve or;· afflicted with art disease, «i whmm:.Wb< ds«rt is- » seiecfed from the group consisting of. hypemiglycendemia' hypefchOiest*roien«a. mi-md. riys'ipidamur coronary heart disease iCHDy vascular disease: cardiovascular disease; aeuto coronary ,g^d|^|^^saidltlisi^:. rtd failure; caidiac arrhythmias: coagulatory conditions aasoaafed with cardiac arrhyinmias.' 'isd^mSc dopirtsp rtdular dementia; h^r^a|^;:· · related disorders: nephropathy kidney or urinary tract disease: and other CNS disorders; autoimmune diseases: inflammatory diseases: asthma or other respirator)*' disease* dermatological disease; metabolic syndrome, diabetes, diabetes mnllitis or other foam of metabolic disease; liver disease: nemaiooholto fatty; liver' disease, disease of the gastrofetesnnal tract, disease of the mate or female ^productive system or minted secondary soaiko oman^ a cancer of any type. Including lymphomas and rnyeidmas;: an infection court fey a virus, bacterium, fidgus* pfetrta or other ntiaissiii and the treatment idifer prevention and/or reduebon of cardiac events aixffer card «ova scalar events .andfor vascular events andter symptoms. The present invention also relates to treatment-of such conditions n vnth con^mitanl treatments regimes nr cdfehidiftion products with other active pharmaceutical ingredients, [iiiSiJ In humandi fehdfegferoi aod triglycerides b. the bfeodstream. and cars be separated w-i ulbacvis'ifefegstfen into high-density lipoprotein 1¾¾¾ fpfermddym'dua^ky lipoprotein plIL)> tpyradensity lipoprotein {LOL| and yery^fot#ajeaafty1ipoprrifeiri ft/LDL) fractions.; Ohq|^|^,^t^i':'biglyc^?kf^·:· pya ^rphesirt in the lrt Irtrporatgd: feto VIOL, and released Into the plasma. High levels -of sttotesteroi (fotal-C}, LDL-chelesteruh and ap^rpdpmWd 8 |a momPrnrMi compfex for LDfechotestamf and VLOL-cboloefeml, as well as iOL-cholesterol in rare individuals suffering from a disorder resulting so significant iDt- dhofesteroi levels) promote human gfheiOsoferusis; these elevated levels are often mfeffnd M: W hypdr chafes loro iemli Doer© ased levels ®f' NOL^Ilplegtefd! si Us transport complex, apotipoprobw A, ns well as elevated levels of applspaprotein C-Ml and serum higiycendes (TO also associated w$h ψ% atheroisoierosis, Fbdhog cardiovascular martxkMy and mortality in Iwmans: ttan vat^: {frtety *#i LDLerholestesfot and TG ami invemeiy with fiefevei of HDL» chotedfefol, Ιό dddllom f^i^mhom-bave· fqp$· that &amp; •ail hyfNsftnglyceridernia ietev^ed t^S^ddts^ ilNroscl^fc d&amp;e&amp;se and related cundilorte, Therefore, rton-HOtr ehoieslerol and fasting TG reduction has also been spabtffed a treateedt ohiaeflva in NCEE ATP 111, Easting TG fe commonly gsod as a tey meaapfO fer TG in fipkt management because it minimises the txptiowxim® factor of TG reesmily ahso-'hO front m-dals, including the high variability of me content of meats and high variability of pcsteneal (poshpraodi at) sptkes Ιό TG.. In soma preferred embodiments, we refer to fasting TG levels when v»e refer to tbglycaddas or TG, P003] The NCEP ATP! 11 treatment guidelines identify HiMG-GoA rsditotasar inhibitors f statins") as the primary treatment option for hypbfebolesfemfemfa, Ini patieolsu vitl TG<SQf]fn||dL:1 L;lib^fol@slitgt Is : :th# pflmdry fmatmeoi parameter, Many -fNtfMtt .'fe^vfrp'te^vife^aiiid LBL-Phofestaml eomhiped with hip TG and low NDfecholesterol a condition else known as mix tan dysfcsdemie, Paints 1¾¾ byperoholesfemmia or mixed dyslipsderrva often present with high blood tevpfb of T-GGcIliPlesterol 0 e. greater than "!9D «x>‘iil> and TG «* *· levels cr 200 mpfctToe hlgbpf|. Tile use of diet end single-drug therapy dees net always deernase; LpG· < holesferol and TG adequately enough to roach targeted values In patients with mixed dystipidamla with or without a concomitant increase m triglycerides. In these parents a combined therapy regimen of a statin arid e second snfedysMbdmld agent is often doaired. This second agent has historicaliy boon a f-braid 1¾ gao"ifibro?si be^afibrats, or f&amp;nofsbrate? or extended release macm. Over tbo fdw V'.'ais, the use unxgs-3 fatty acid wmmmhsies m ve-vhe W,eo with a state's has boon growing mpklfy.dtipi'^-^ffb^fns about the tack of cotmthe benefits with fib-rates Cle, the REID sfedyf dTfpMealdd fetease niacin (i.e. the AlMdilGH ftddy|, Ιό patients: pthssotatid h|pddfiplyceniffimin. the use of ornegs-3 fatty acid concentrates ham alid:grown verausTibrafes and extesxfed release oteem. pi04| , efefca rw^rsnsel to as %h oks„ ^;^::|[^pv^^e:;#f;^'.

two main omegaA! fatty aads ecoiS^lil^ftw nerd lEPA » an^c! vk- ' DHA( ..\<h*co U n kU'Vt ? >k' ^ tat ^sre O ' do 0 *nlA ifods hadfo been found is .have.· Ix->r%efk;t«ii o*v ihe risk factors for «ordfovapcoiar dfseanas* aspenfaiy mild syp^Efo^sk>n, hy^^r^|c#Sd#mm and an the coagulation factor Vir phosphohpsd complex activity Omega-i fatly acids iowar sAiyfo tngtybhhdgfofTfo}!: ; InSiWi# oseforn HDt'aWilepfordiis fdfoef systolic pad dfasfoffe bleed press»: amt the fofee :mi®ic and Iswir: f hi :aetfyily :Of the biocsd cnagoletiofl factor Vli-phospholipid oornpfofo;;FsdS0f,::;i0fatpa-3 fsOy be wail tolerated* withoot giving rise to any severe side effects. P#®§| 'ί^^-r:f&amp;t&amp;:; Xfm:. most pjptrfcOft. anite foducifog their 3-letfer abbreviation oode, In this appticatha the use of any of the 3-Mfor abbreviations shall refer to the omgg&amp;~3 tatty acid, unless ofoerwtee mdieafocf i«.g. DPA or DPA 22‘5 ξη-3) or DPA 23;5~o3 or DP A 22:5r«3 or DPArfo, which all rotor to the omega-3 isomer of doeosapentaenoiC add)

fOSOSJ One form of omega-A fatty acids is a concentrate of omega-3, tong chain, polyunsaturated fatty adds front fish oil containing OHA EPA afo^t' eaters aa wall as ethyl asters of other ocoaga-3 fatty adds (beseritsed In USP33 for L0VA|At!: and is and lOVAZA®). Sochi a form of omega-1 tatty ahliwtphios at least §0% omafm3 fatly aolia of whfoh af faaol 30% EPAtDNA |M a mfmof ;f 2:1} and isdeaafoefo Pat SJS&amp;P7 and: foi93,59C LOWZAf fasoaga^^cd r#tyf aafofo) traateaal of patients with fsypeftngfooordamra with TG levels of SMmgfoL or higher. (0007} Another form of omega-3 fatty aod c-onoahtraia is sold under tfe trademark EFA0EU1 ® for the treatment of dydipidemia This product :is dsacrfbacf as 98% ERA ethyl ester \r% Lancet i Vet 369, Marti; 31 200? ! 090-10935 reporting on a tegm outcome study with ERADELty EPADEL# I» to contain less then 1% of any fatty ask1f other than EPA. (0088} Sfrnilar to EPADELG, another form of omega-3 fatty smd concentrate also consists almost entirely of EPA ethyl eater and is known under its feyeiopmgMgl stage name AMR101 or its trade- name VASCEPA13. Thtepmduclc is #ferifefe in 13$ patent application 20108)278879 as comprising at least 95% EPA (typically referee! to as 97% nr at toast 96% in comnoey roieasus nod refemnoas): and less than 1.% of any other fatty add, AM:R1Q1 was previously under development for the imminent of Huritingdion% Ofeapao hut tiled In phase I if cinife defetepmfet SfesequeMiy, AMR101 was feteretf in a and feked dyslipMeme, (0909] Yet another concentrate of omega·· 3, long chain, polyunsaturated fatty acids fem ife ml gonfehing ngproximMely 76% DHA ahd'· MiPA'tasy'-'fea 'Mty- ;asMS: i* known under us rtetfotopmonta! stage name EPANOVA'** This product is described gf femprSdng appAtklmitfily 60% iPAlgni :2fi% .DHA, ΕΡΑΝθν.ΑΤίίϊ mas prevteusiy under devetepmeut for tte. teslrpwi::.bl:Crohn’s Disease but Misd, fn pfefe 111 t meal <k veMgn emt Sutev ·] je^sy EPA\UVAm w -.-, utered *' a db'mcpnv nt program for hyperthQlyofebornia arrd mixed dystipidemfe (0910] Generally, the bioavailability and tbsrapgwhc: effect of omoga-3 fatty oompsL>?ifior»s is dpsa dependent, i,e.:; the higher the do$®:. the greater the therapeutic1 affect and hfoavallahlsty. However, the effect of each specific cmege-3 fatty sold composition may do ddfemni end therefore the level of morepsutic effect of one eemuoskkte at a given , cannot necessarily bo inferred horn the level of ther&amp;pefee effects of offer Pmega-3 fatly add ©oppositions- at the same or .simitar, dose, 10011] For instance, in the MARINE study, it was found that four capsules of AMR101 tVASCEFAft signdcanily reduced lasting TG .n patients with very high: tuglycafeiaTtpaSOfe'ig/db s (March 2011 ACC poster the MARINE study), similar to Mut 1 -gram capites feLOVAEA® hut fhf pdlehf mariner (ΕΟΥΑΖΑΦ gresenbing tnfernaison, December 21710): In this same study, AMR.101 iif* abd changed 1¾¾ «te LOYAZM9 shows a ;iarge pliNij^rif ft* puling the latter si a

TaiSA,A directly bofow «emptrat ilsa©

10012] In aaot%f stedy *t*h AMR101/VASCE^A% ANCHOR study, it was found that four t-gram capsules of AMRlOf significant^ raducec feting tg m patients on stairs thmopy with high tugfe'erkles (TO feO-499 rng.'9l4 smHai O ?ou* l-gram capsules of LOYAZAA Pot m u less pofer manner i Study n feA LQVAZAa pmseofeing information, December 2G10.L In this same study. AlviRiO! d mummed LDL-C at 4 crfeiy whste L OVAZAA shows a si gam cant IPL-C Increase In Piss mnm population AMR K* i ss also more pc mm than LOVAZAD In reducing noo-HDi. -cholesterol in ?fe population Table 8 d smelly he iom -..ompares these prop fee,

POISI The ·. msytt^i'llp^e^file of AMR1C! M patient imputations iodic-mcs that lix-re are mpnGcact nsriefos ¢-1 using an a invest pore ERA oil composition as opposed to an onvgs*-3 mixture as in LOVAZAOP, These berteftle traosfate tnto bettor tion-HBL- and LBLfehoiasfoml mdyeiion with the pure EPAform, wjhere these benoftis ore less or, in the cose ol:;'ifio'^L^.;;tffect. in#; opposite, 10014] The rapeplfy released results: feme Cfefefes EVCE^i; frit with: EPANOVA^·., in vary high lnityoihies|TClT 500 mg/dtp descrihfe a TG reduction of 14% versus baseline for if». 4 grim par lay dbsp Ap 26% virile baseline tor the 2 gram per lay 1¾¾ with 1¾¾. And i% f>aa-HDL reduction respectively. 11 appears that the T G-reducing potency of EPANOV'A1·* is smGm lo the potency of AMR 101 No data were reported by Qmteera on the LDL-C effect in the EVOLVE trial. |O01S| th# recently released results from Omthera's ESPRIT trial wall EPAfsipVA;'^, In patients with statin teamipy* described a TG reduction of '21% versus ba^ifne for ^gretri; p€f day idsl and; tifi varaua: hasehne for the 2 gram perlay dose, win 7% and 4% non-HDL reduchon tespecbvely, it appaaie that tie TGaiteuotep i^enef ef iPANOVA^ ^ similar to thej ppteney of AteRICfl No wpm reported 6y fli 11] From the comparison ot LGYAZA® versus AMR! 01 late, teem eppeate to be a benefit of ϋelpgvpyi¾.:i¾^¢teicehΐmte#idysijp¾^te:fea^^i^ov^:p^^ia" 3 mixtures with regard to iDL'Cnotesterol and rrOfvHDL-ct>ote-stero( effects W$th ihe NCEP ATP 41 ipdelines plade^i LDL-eholwteml and rMiii4fOLeteoieifetet reddctiin at the tpp of the ji^^h|:::^.l®rai«hy·. with TB<I00 tegAIL,. IGVAZAte tn this palaut oafegory. pilTJ lo another example, in the ECLIPSE Study,, the t)loav®lafelity of EFA^DVATM\ip:ioinparei: tp%DVA2A® under nigh fat meal and few fel conditions. £0018) In the ECLIPSE study 4 is toned that EPANGVA™ *s significantly more btoavaiable than LGYAZA^ after single dose admmistmfeon (tour oapaolea of 1 gram for both products), both by Cmax f maximum cxmoentraitea} amt ALfC; Care® under curve) measures (see Table C below, where Cmax and AUC are estimated from tee date points so Figures 1 and 21 Relative to LGVA2A€> under high fat. meal sonlilans, EPAflOVA^ is 1*17 x i»a b&amp;avaiSabte by ©rapt arte 12T by Aft© eompiPtiti: Under low tel meal eoiditlons, LOVAZft® has only 1S% AlfO and 121¾ CrnaA of the feieavoiiateiiy Versdr tOYAZAC) under flgh M meal mmdlttens, whereas EPANOVA1** under tew teLianai conditions has p% AUO and 63% Cmax of fha bin availability versus LOVAZAit under high fat E^ANQYA™ under low fat meal corrditiins has 62% AUC arte 4S% Cfna4όί tee bbavailabrliy; vmsos E PANOVA1** under liigh fat meal candliurm

[0013] Omega-3 tatty adds am known in bn tessoocte mriv acids'. Frwe am two ncne:- uf escerOal fatty acids (EFAst m human? Tnny are termed "ο^οηΐ^Γ ben sunn they cannot be synthesmed de novo· tn mammals These Otty m,z1 a sen r>e Ihfemdibydrted wilhip: a ierte, (put: the omega-6 (rbd}yinries dphhot be «nvart^lp ttM osttega-S sebarnohoan the omega-3 (n-3) series, ha serwerted to the omepe# >n?ns in humans 'the mam ERA’:· in die diet am ΟνΟοκ sc id of tin- emegu-Vd senes end alpha-iiooienk. acid oi tec omoga-3 sedes However, to fulfil most of their bktloQicet effects theseOpareor EFA&amp;must fo©-.^ia^>lls«cHoINta^tr letiiQ^riE^p:· fatty adds, : Esch fatty aeid prsMhiy tm ^:spMps telirtrrfh» bodf,· TdP sdphtld; fitemfere suggests that parieelady imppihiM fh $fe r4 els a# dihomo-gammalifioionjc acid (0(0.A, 2Ch3mS) arid araohidcmic add (ARA, 2Q:4m60 whte particularly important in the n-3 series am etc^spperSaer^d (ERA* EOtS-nS) and: ddeosahexaenpte note tDRA, 82&amp;4I3}» £0920] U.S, Patent No. 3,479,544 I# tourxi that ARA is highly desirable rather than undesirable and it may be helpful to administer ARA id 'association with ERA, This indention provides pharm^pg^tefrtimtttfeidPS? centainmg m.maapenfseneM. and or any appmpti-jte rianvah-m {hereinafter coilecrtvely referred to as ERA) and arachrdomc acid (ARA), as set out m the granted claims for this pateoc ARA may ho replaced· by one cm more of its precursors GK3LA or GtA In this reference, the ratio ot ERA to ARA Ss preferably between t 1 phd 20:1: [0S21I Patent appttagfoo ROTi® 20044)00242 dos&amp;te ftp: impImAnt or (fprOlylAiprt eomplslpg: mote tfenbOOft' ERA ,ιρίΐ lidd: than 2¾ OHiA> Ip at this inv&amp;piioa the ERA is repteeed with W*k:

Mmi application POTIML MvOS()291 SB M1701 -i) desenhes eombin&amp;tiorss #f Idigestilste ohgosaootendea :aed long diab psly« uosatomted fatty acsds such as AR.A, EPAf DA, and c^bkteppfb thereof'

Intaaiinni bamer integrity. improving banner fyr^ctbp, slim^idlbn gut maturation .andfb* reducing intestinal hamm wrtneabiMy. P023|; Bivan this ft^j^'Nnetfctai ebicacy and side-effect profile of oroega-d faiy acid eonoenbok-s these compositions am· moreesthgiy popular tbr the treatment of patients with dydipidemias However, With me increased popuiabty of omega-3· fatty &amp;etd conoenmnnn, there is an unmet mediae! need for omagaG hhty acid containing comparisons with improved P>oavauahHhy and a more Oiptf! ratio of patency in reducing TG versus the resulting cholesterol profib. Specifically: agents with both.a. higher AiwliBl di' and lessor increa^s :tn decfipAb in LDt^G1 and hpn-HDL»© than: DDVAZA# a® required.

SUMMARY OF THE IMVEMHQN I&amp;024] The present Invention pmvides an on?3y ediwii stable «imposition' comprising fatty acids, wherein at least 50% by weight of the tatty adds mm$mm· omega-Matty adds, salts, esters, or derivatives thereof* wherein the omega-3 fatty adds comprise eteosapentaengic add (EBA; €20:0-0¾ .;^oiop$^^1»^blc add {ORA: C22'5m3L and doeesade^aenoto add |I^Ap€&amp;IS»?tS}, OHA to ERA t,DHA;EPAji is loss than 1,20. and wherein the rabo of DHA to OPA fDHAiORA) Is iesa than 2:1, In some amdedmenti; fhe omly ddminisfraPfe composition mmpnsno additional fatty acids si>'h as herveoisaponfuenoic aetd ΙΪ^Μ: (ARA), and orheg»-«8^^^i^taav>i0;:';^db' .0ΡΑ), telMCoaApaatadnde acid tTPA|, aad/Pr garnmadlnobie »sd fGLA|. These compositions can be used for the treatment or pfbphyia^iS: of dysiipidemip. cardiovascular, central netvoos system {CNS}< inflammatory, and fiber dlseasedcortdlidhs or risk fictom therefore. These oompesiikma may atea be used for the hffeetlob d! syrhptorn# assoolafid mkh theds danilldhi: ffpl2§} The present Invention also pmvidos oorogosdons having an inmmvod pmfilc versos very high purity ERA compositions wftloh^contain few levels ^pmeg&amp;eideity acids end low levels of omega-3 fatty adddether than ERA, ETA, ΗΡΑ, 1PA, and DPA. Ϊ0026-] I h<> present invents π prov.-Ors a** I'M, \ s' MiPPe C; m,·, -4<θο composing to tty onto, whomin at toast 50% by weight of the tatty news cump~se ema0i-34&amp;tty aeldspsife, asters, or derivatives thereat whomfe to omogto fatty acid» comprise etosop^ntoenoiC add 5 ERA.; 020:5-oS). docosapantaanoic acid vDHA, 022fe;O .111.1 U.M'o^twxacrMiC' ,*ftnJ \DBA, 022 fed s whet am to rjfto of DHA to ERA (DMA:iRA) li to® fen 1:20, of DHA to Ma (DHArDPAl &amp; less torV2:;t, (0027] , ijt the compositions of the; at'·tea#''iO^:;dihe^3^lQ%:'ecjds, alternatively at least 5^¾ ottomoltvoly at toot iCI%;. pitornotivoty at leas! 65%. alternatively at least 70%, atoAitivo^ at ioatoi fSp. pemel#ly at least 80%, alternatively at feast 85%. aitoiftMtoly M least iSmyfesf preferably at least 90% omogto fatty acids of the total amount of fatty adds, [0028] In other embodiments. EPA and DPA am jointly present in the compositions of the present invention at between 55% and 100% of total fatty acids, altomaivejy between 00% and 100%. aiterrtovely between 65% and 100%, aStofefto^ between >'0% end 100%, anernaBivel/ between 75% and 100%, aitefefeAy bPtwdid: $0% and 100%, alternatively between 85% and 0®&amp;veeti SS:% add |7%s alftoitlto^ tot^^ altorrtovefy between 88% and #?%, alfimativity bfltotdn 00% and 95%, alternatively between 00% and 97%; df; fAe fetal atoeobt of fatly odldbv tfmi Thd: fitly Atofe such as ERA toil IPRA n^ay ftotobpl# ϊΠ ^ totiy acid, lotto, or φ.a-balL etob or dedyalyp. The fatty acnis are preferably composed sal tl^tywld^'en:eater:.|w!ish as an ethyl eelerj or free fatty add. Other forms of to; ony<fe fee * nm> i * m*mi μΙικιο^ν tto\ 0 an> typo an * ' di pr ttlliydondaa, ptfepWiptow$ny other form which can lead to metabofcahon of the fatty acto ($yoh 9* iPAiandfer DPA). or fe incorporation of to fatty adds touch as. EPA and/orDPA)i#b..ttofidlfe tissues or torg itnfe: p#3S| Qfega-3 fhiy acids may bo grouped by fe lpomitor of doobte bonds contained in. the fatty sod chain, for Ihstanop:, h^decafeoofe acid CHTAA alptej-jfetoto add {ALA) add: fecosfeenoic add {ΕΤΕ) art om^a-34fki0nic: adds; steartocoto acid (SOA| and ateosatotreenoic add ^ETA) are omega^aotraerinie acids: EPA, heneioosapenlaenw; add (ΗΡΑ), DPA and tofmcosapentaonpfe add 'φ&amp; fetmcos&amp;hexaenofe acid {THA) .w«':ei«»g^4^lw»noie.:sield^;. te-som® pmlmm4 embodiments, tba fern? omfga?i&amp; boeumnOio nuns will cater to a mixture of at feast boo omega-a pent&amp;enom adds m .¾ moo t-f at feast 1:26, more preferably' in a ratio of at tops·* 1 50, mora preferably In s ratio ol at least 1:75, more, preferably in a rate) of at least ISOO. more preferably ;n a nmo of at least 1:125, mote preferably In a ratio of at :east 1 150 more preferably m-a ratio of at least 1:200. In some embodiments, me mtlo refers to the mho of the leas* prevalent omegs»3 penpeenoic acid m the mixture to the rhbf? pr^v:alard dmpgay 7 penlaonosc acid m the mixture. $831} In some embodiments, the compoplortb of Ihe $$$$$' EPA, HPA. DPA and TPA alfbmstsvety PRA and /.DFA and ^Itemativaty iid wmposltioos of the propdht:lh#hipn r.omipsfe $832} In some embodiment, tba|ibmega'®£ the present invention comprise rip;jfiorie> than 0f\^( add. aifernmivbly ® mem tfnam 99%: pteb$dydfy A© feore than 9i..5%t alternatively. no mom: ten Si%:: alfernetlvoly no mem -fed®&amp;mativdfy no fern than 96%;: pStbmaflyily no more ten M%; affempiyely no mbrs ifiad: fM%: alternatively no more them 93%; :rt# more than 91 %, nttemotivety no rnore-ibar;. ^%^:.;stema8v@^ no met® ton 59¾ alternatively on more than 55% eftefftillvel;y^no mbM thah altemaSyfely rfe •nor® than 75%; alternatively r*o mare than 70%; at^??^iifef^'W''ih¥>r#:^n 55%: alternatively rm more than 60%, alternatively no mom tern 66%; altemafivstly no more dan 00% cfemnefeiA m mure tun tb > a fen fe me *vr -'-.'re term 40%, alternatively no mote than 30% $033] in some embodiments, the compositions of the present invention wherein at leaal 10% alternatively at least 20%, alternatively at learn 25*:=. alternatively at least 55%· -ittemabveiy at least 50'%. alternatively at least 60¾. altemallvely at least 95%, alternatively at least 70% alternatively at least 75%. by weight of the fatty acids comprise umeyafe-p-entaenostr acids. sails esters, or denvetsves iheteot {0034] In some embodiments, the compositions of the psesent IhvfeiiIson comprise el lead 0 0 1 % ΗΡΛ of tofef lady acids in the corn position. eitmoattyefy at feast O 05% HPA, alternatively at feast 0 U')% ΗΡΛ, alternatively at least 0.155¾ HPA, alternatively at least 0.2% HPA alternatively' at feast 0.31% HPA. aitercanvely at toast

0.4% HPA, alternatively at feast 0.5% HPA, alternatively at tees? 0 75¾¾. HPA .tewm.%vtey a t teas: 1% HPA alternatively at least 1.5¾ HP A. alternatively at least 6% HPA al§amatsx-i>->ly a? least 2.6% HiP.A.. alternatively at feast3¾ HPA, alternately at least 3 5% HPA, alternatively at least 4% HPA, alternatively at least 4.0% HPA, siterr;ahvety at. least 6% HPA, alternatively at. feast, i.1% HPA., alternatively at least ?% HPA, |#diffcf$V^i|f Ihe. compositions ot the present irweptfen· feast 9% HPA of total telly antes sn mo composition

In same embodiments: the compositions of ihe present invention comprise nos mot# teen 206¾ HPA of total tatty adds m the r;omposfeop, alternatively no more titan 15¾¾ HPA, alternatively m mere than 12% HPA, alternatively no mom teen 10S HPA, aitefoofiyety no tnore man S% HPA, alternatively-mp'-mwttt&amp;rs -7% HPA^ alfefOiiivdiy no mori liiart i% HPA, alternatively no more than g% HP^rattem^i% rid no more than 3% HPA, eifemathfely |h3&amp;:2$ HPA, alternatively no more than 1.6% HPA, aftemattvefy tite oompostfens of %m hMdgnf MV^ltbn comprise # least 1% HPAot fete! fatty adds te th@dsa^sltion< id s-vne embodiments, the compositions of the present feveotipP compose 1% te 20% of the total fatty adds In the composition.

[0035] in some embodiments, tea compositions of the present invention comprise n^·' 10%; pmegaASHallf^ adds teat are ate: omapate-peteasnote adds, afemallVdly no mpftilhan 9%, : -m m0$ " ^ aitef n' ivy y more te in a \ alternatively no -ποτ th in 6% dtemtetve γ no more than 4 5%, alternatively m 'dbrwior© than 3.5%¾ aiternsUvely no pom than 3% alternatively ® rooni fen 2,5%, altemativdfy no more item 2¾¾. alternatively no more then 1.561., alternatively no more than 1.25%.. alternatively no tepid than 1%. alternatively no more than 0.7511, atfemMiveiy no more than D:,S%:,;: aftedt^lyeiy no more than 0.4%, alter?«*bveiy O0\m<3#.:iH&amp;O 0.3%, a-tefnahvol·, m. mores than 0 2 5-., alternatively toe rxiropositionx of the peaent Invention copphee no '.mores than 0 1% ornega-3 ladyaads that ere^rtef optega-3-p^t.teteite ! *<. is |&amp;036| In tfei dPttedlPdftis of the prose r it AnventiOh, ifte :d6mpdSSfei^si^rfi^fe: EPA and DPA in an EBAtDPA ratio between 43-1 amj 1:00 £PA:DPA. afteotalfyoly botwaoo OQ; 1 and 1 ;l€^Semstivety bstwd&amp;h id:] and 1:#, 60; 1 arte 1:20, alternatively· between 6():1 and 1:4, eitematively t^^f^s:40;i;:-:Sdd. 1:20 alternativety botwoon 30J and 1:20, alternatively between 30:1 and 1:19.: alternatively between 63 1 and 1 5, alternatively between 40:1 and 1:4, alternately 30:1 and 1:4>: alternatively between 313:1 and 1:2. Memahyoly between 3Q::1 aod 1:1, Sd:1 ind 2 i'te&amp;iemaMy''fetter*-·&amp;fcf'aw&amp;fiit, alternatively: ij#twe«« 20:1 and * Jo alterrKjt.vi.-iy behveen 20:1 iddd 1:111 aitfcrnativeHy between 20:.1 and 1:5, nib»* naivety between 20:1 and v2, alternatively tetweso 20:1 and 1:1, atefialvdlf isteen 20:1 and 2:1, 20:1 and 3 1, alternatively between 20:1 and 10 1. alternatively between 20:1 ami 10:1, dlldfnMs^ly 6Ρ!ΐφοη 30:1 end 10:1:, iltemMnfdly Mtyaen iO:1 and 10:1, .fd^:Ntvve®r» 40:1 ma$ 1.0:¾ ^ne mntevJirowus, the take ot EP-\ 0P»\ i&amp; gr h an i:1, preferably greeter than 2*1, and mere preferably greater than 5:1. In dome embodiments, the ratio of ΕΡΛ:ΩΡΑ is t.1 to 2S:1, preferably vl in 1:0:1, mom prc!oraoiy BO to 15:1, even nrw^i^';Pi^eq^^3fF:^r^ 1.3l%*3.^(9^^e^-ir?^a^jpiiNs^ to preferably about 1 ():1, |003?J ip same embodiments of the present Invention, ex? compositions comprise hstweon 5o% and 95% relative to the total amooM of fatty φΐφ present So fbp composition, atternMtveiy faotweoo 60% «net 95%, afernaffety between 655¾ and 055¾. alternatively between 70% .and 06%, altemabvery between 76% and 9516, alternatively between 00% and §3%, alternatively between 801f and· 95%, alternatively between 90% and 95%, alternatively featwean 55% end 90%. alternatively between 60%: pnd 00%, alternatively between 86% ansi ipis aitomalively between 10% and 90%, alternatively betwven 755¾ and 90%, •^lem^ively··:.::het«en·. 80% end 90%, afernalivmy between 358'. and 00%. ali^f^iiyply 55% add 92%, alternatively between 60% and 92%, alternatively bPlwpep 66% end 92%, alferna?Ively between 70% arid 02%. alternatively ftetwpdb ?S% add 92%, alternatively between 60% 3 and 526¾. altemifiyily beiwenn :85%. end; 92%, alternatively between 55% and 95%, 'Sp^'#l^ty:5bwe^rt' #*tt 93%, altematively between 65% and 93%, al^npively beiwepn 7¾ and 93%, alternatively between ?S% end 93%. altepipslvely between 60% and,; :83%,, alternatiyplyl ibetwaen :66% and 9i%,eltemabveiy more tben 85%, dfanaitEvety mDn©: -than 65%, -dttmiativdy between ®6% end 0S% EFA rpiaflye tpibirfptal.-ifeity. ^ tes eomposteon. |6036| in: otber moibodiments of the prosont tevertenr?, th® compositions comprise OFA in m 1% end 99% relative to the total amount of tatty acids present in the composite. alternatively :¾ and 95%: bliemalivety 1% and 90%. alternatively ;alt©rnaiva^§al^^ 1% arki#6%, altemateiy between ill: and 80%,· aitemartey alsraalivdliffe^aen 1% and 75%i afenabveiy bnfwadd 1% and 70%. alternatively between t%· add 56%, "Mfeewr 1% and 50%, alternatively b®tmm 1% and 65%, alternately feetwfdd: 1%: and 60%, alternately between 1%, jactd 46%, attest tevnlv batwfeun 1% and 406¾. alternatively beteen 1%: land 36%·, alternately teteen 1% and 30%, alternately bteween 1% and 26%, alternatively between 1% and 2u% alternatively between i% and 16%, aR^rnntlvely daty^an 1% and 10%, alternately between 1¾ ami5%,tettemateiy bateau 2% and 09%,. alamatlvaiy bate^n 16¾ and:0S%> 2% and 90%, alternately between 2% and 66%. alternately Osteen 2% one 60% alternatively between 2% and 75%. alternatively between 2% ami 703$, alternatively batenn 2% and 05%, aiternativeiy befeween 2% and; 60%, alternatively between 26$ and 65%, alternately between 2% and 6031, aliematively between 2% and 45%, alternatively batman 2%· and 406% alternately between 2% and 30%. alternatively betwddp 2|$ and 303$, alternately beteao 23s and 26%, ditei;nilv^y ipteen 2% apd 20%, alternately bdteen 2% and 16%, alialnatefy b$mm 2% and 10%, alternately bstedd 23$ sod 6%, alternately beteen 3% and 0034, al^fdstely between 33a and 95%, alternately between 3% and 003$. alternatively between 3%: and 35%, ifomaitey between 3% and 60%, afemeSvely beteen 3%and and 70%, elleroetety between 3% and 55%, aEterddtely fedteen 3% iod 60%, ntenatety beteen 3% and SS%, allernalivaly latwen 36$ ood §0%, alternatively ba^ean 3% and .46%, alternatively feeteen 3% and 40%, alternatively betwaan 3% and 33%, alternatively beteen; 3% add 30%, alternatively b@tew 3% and 25%. :£ftgmaliyely\ Jbeiweeo ••'3%' and ;20%, alternatively babveen 3% and 15%, altarnativaly bol^dn 3% and 10%, alternatively between 3% and; ill, alfemaively belween 4% and 05%, altamaivaiy bei^een 4% iH*it|iaiv«iy;·and I5%r atfe^tvety btefap 4% and 80%, alfemativaly Oedvean 4% and 7563, alternatively· betead 433 and: ?ϋ%. alternatively ·between 4% and 653$, alternately between 4% end 603$. alternately between 4% and 55%, alternate! ·,> between 4% and 5033 alternatively 4% and 4$%, al*arnativ&amp;ly bb5vdbb 4% :en^ 40s%: alternatively between 4% and 35%, ;mn.ativ&amp;!y betM*#* 4% yWM 30%¾ alternatively between 4% and 25%, aiternetivaiy between 4% and 2Cl%, alternatively between· 4% and tb%, <.«ia'natlyv'y KtAvvn 4% ttnd 10%. alter natively between 4% and §%„ alter? «ativety between 5% and #114¾ between 5% and 95%, alternatively between 5% and 5014, alternatively between 5% and 85%s aitemalively between 5% and 80%. alternatively between S% wxj 75%, alternatively: between 5% and 70%, alternatively between $% and 01%, alternatively between 5% and 00°¾, alternatively between 0% and 04%. alternatively between 6'% and 50%, alternatively between 5% IJrftd 45%. alternatively between 5% and 40%., alternatively between S% and 35%, eltefbatively M*wcvn 5% and 30 to, alternatively bdf^dp §% add 26% alternatively between 5% and 30%., ««nmativety bdtwddn 1%; and 05% alternatively between .5%. and %%, s.nkvnatively bidwBen $% and 10?% alternatively: betweda 11% and 99%:. alternatively between 05¾ end 95%, alternatively betweea ttpd 99%. alternatively between 6% nan 6% ai^^^riil^^jvely between 6% and ^ 7054. dlidrnltti^ly: 1% and |5%, alternattediy between i% and §054 alternatively ddl#feii 051 and 55%, alternatively belwaen 6% and 50%. $)ie«rnaiMjt: t$eiftgM|&amp;- «nd 45%;!: allernativaty between 0% and 40% aitetnabvely between 634 and .544, alternatively between 534 and 30¾¾. alternatively between 0% and 25%, alternatively between 5% and 20%, alternatively oebvten 5"» and %% *%*' v i ".eΛ 5%. and 12%, alternatively between 6% and 11%. alternatively between 6% and 1:0% alternatively between 7% and 99%. alternatively Unween 7-¾ are 0S% alternatively between ?% and 90%. alternatively between 7% end 85-4, alternatively between 7% and 8089. alternatively between 7% and 75%. alternatively batweap ?% and ?0%. ellemetively between ?% and 5539. alternatively between 7% and 6084, t%': @sid S5p;j/alternatively between 7% 'and 150%, 0ftefft0P#|^ belwdee ?% and 45%, alternatively between 7% add 40%, iSiS^fv0^.'vbelw^d.. 7% and 35%. -alLematrvely between 7%: ddd I30%> alternatively bo»w>:n · 73¾ end 25%,. alternatively between 7% 5^028% '.-.ibietwiatil" ·?%· end 18% alternabvely between 7% v®d 12%¾ 7% dnd Vi lla : alternatively between 7% tend 10f% siimaiveiy 8¾¾ and ®i%, 8% ami 95%, alternatively

WwftM ami 90%, mid 85%, batw^» 8% and 88%, alternatively between 8% and 75%, alternatively between 8% and 70%, alternatively between 8% and 65%, alt&amp;rnatk^ly between 8% ami 60%, mmtm^rmmrn^ 8% and 5S%, afemsttoniy jbsfvwm 8% md ®0%v Setwe^rs 8% and 4S%. itirnailvdiy between 8% and 40%, mrnmMfy baiwrtt ;i% #M 85%. apntpvbly bpyppn i% add 30%, alternatively between 8% end 25%, aiema$|y@iy between 8% end 20%, afemaively bolwidn B%: end 16%, alternatively between? 8% and 12%, alternatively between m end and 95%7alMmativ^% between M; and #0%, alternately ba^ean #% and 15% alternatively between 0% and 80%. alternately between i% end 75%, aiternattvely between 9% and 70%·, alternatively between i% and 65%, alternatelyand 60%, alternately between 0% and 55%, altemaiwely between i% and 50%, alternatively betweed 1% and 45%, alternatively: between 9% and 40%. alternatively between 9% and 35%. alternatively between 9% and 30%, alternatively between 9% and 25%, alternatively between: 9%· ami '20%, alternatively between 9% and 16%, alternatively tw·tween 9% and 12%, relative to tbe total amount of lady beats present in the compos;horn [0039] in some embodiments, a relatively small amount of DHA as ocrouared to ERA is present. In some embodiments, the compositions of the present inveteion comprise no mote loan 1:5 of DHA· ERA. alternatively 1:0 of ΟΗΆΈΡΆ, alternatively no more than 1.7 of DHA;E.PA, alternatively no mere then 1:8 of PHAfEPA,: llfenmtivaiy f ΙΚϊΟΓίί iHs&amp;ifY ? . ίί ijf E RA*. m ΓΠ^·ϊί*": 1:10 Of DHA:EFA< aitemirtivseiy no mors (I» 1:12 Of DHA:ERA. ate^naflveiy no more Mm -1:15 of DHAiiFA. alternatively no mop tten 1:20 of PHAilFA, alternately no mop than 1'25 of ΟΗΑΈΡΑ, nitematbaiy no ntefe ttwn 1:.39 of OH ΑΈΡΑ, alternatively no more than 1,%} of OHA E-FA. alternately rsc more than 1:50 of DHAiEPA, alternately id1:76 of ΟΗΑΈΡΑ, temateiy no mono than 1:90 of ΟΗΑΈΡΑ, alternatively no more than 1.ΈΘ of OMArEPA. Aifbr!%ffe:iyy ,0HA may bo prosoot in the oomposteons of this ifiventiijn at a tete amount of ratio lass than 1% than the amount of ERA. Alternately, DHA may bo pmsonf to teewompoeisoos of bits iaveatioe at: a OHA:EFA raio of toss than 1:99. llWiJ: -fell amouritibi DBA retoffve to amount of fatty acsds present in the composition m present to soma embodiments, tAe iwspositipfss of the present; tnvonjte:. comprise he m&amp;re ten 20% DHA, Memativoly no mere nw* 1$% DBA, ''alternatively pd moire ‘ten 12% UHA, alternatively po more toad 10% DBA, alternatively AO more ten o% OH A. alternatively Ή© more thab 7% DBA,.: aiterestivaty οό: tharp ©% DBA, alternatively op more ihao 5% DBA, btfetoAlively no. mof# ίΑοη 4% DBA, alternatively·''·:^ more ten S% DBA, alternatively no more, ten 2% .DBA* alternatively no more than DBA relative to the total amount in the centellton, [0041j In same erefteltepts, the ratb of EPA:BPA B about iiOCfcf alternatively 10iK)"t to 50; 1, aitomativefy 800:1 toftol, alternatively S00:1to 6Q:1, alternatively 250:1 to 75:% pp altematiyef 1W:1 to In some pretend emteilmente, the reiso of ERA:BRA Is about 85::% Ιπ ια?» preferred nmlspdite^ mo ratio of ERA.HPA io nboaf 30:1. to some embctoimteB the ratio of DPAiHPA IB about 250: i to l. 1, alternatively 200.1 to 2:% altem^^y;:'1f^:#^1v:p^a^py' 100:1 to 4:1, alternatively SCM to 8,% alternatively 25-1 to 0% and alternatively 10.1 to /:1. In some preferred embodiments, the ratio of OF A: ΗΡΛ is about 8:% in some embed imeoto, : lie totie of SRA:BRA ls at>otl S:8, I&amp;042] in oter eotedltoehtai a relative! y small amount of DBA At tsmpared |p QPA is present, in these embodiments, the compositions of toe present invention compn.se >fi$ more thin 15:1 of DHA:DPA, alternatively no more ten 12:1: of 0HA:DPA., aitofpatovly ?to more than 10:1 of PBAtDRA* aftoresiivdty Oh more ten 8: i of DHAiDFA, aiu mebvely no mpre flap 1:1 of DHArOPA, aftomaihrety no more ten 8 1 of OBA.t'PA airemahvely no more than 2:1 of DHA;DPA. alternatively no more than Iff Of DBA:.DPA. alternatively no snore than 1:8 of OHA:DPA: ^Itontevely no nmre Ihap:1 8 of DH.A.DRA, alternatively no more .than %o of OHAtDPA, alterr^if^yy.-insf;' imare than 1:1 of DBA DPA* «flMHrMtfrelp-'ro recwvten ΊΒ0 of DMA DPAiAllatoahveiy no more Ihpa %15 of DHArDRA, Hlamati^^r :ftbi.rh0fb.:%®f1· 1 20 of DHAtPPA,: aitoreahvely po reori fbdO: 1:;2i of DBAtDRA, alternatively no Ptore: than life of DBA: DP A., reltoteiv^ly. no mere then 1:75of PHA:DPA;. alternatively 'no more fhah i.UQ of QNA..DPA, aitereatively on more ten 1:96 of DHA.DFA, aHerrktovfely oo mo-re than 1:10© of: OBAlDRA, to aprne embodiments, the ratio of DHA.DPA is preferably toss than 2:1 10043}·. ivohodlnrents, a relatively smal pnoynt W'P'NA'.'a'f:; e^lpaiisl to HP A >s pmsnhi In dieds embodiments, the eompesitionsief the. present invertor comprise rid more than 15:1 of OHA-.HPA„ afte:nnptivdy no mar$ than 1£:T pt DHA:HPA, altemahvely m more than 10:1 of DHA;HPA. alternatively no more than S:l of DKAHPA. alternatively no mors than 5:1 of DHArHPA* alternatively no more than 3 1 of OHAJiPA alum dkofy no morn fh m I I .* ΓΗΑΉ’Α aivnret'odv .Ό more mart' l:i1:of OHA.HPA, fjpft 1:t of :pHA;HRA:. ateroativeiy .W.viWfS-· ta* 1:3 ot ίΙΗΑιΗΡΑ,: afernaiyely o&amp; mare than 1:5 of DHA:MPA> alternatively no morn than 1*B altematsvely 00 more than 1:10: of DHA.HPA, alternatively n« more thin Iffi::Μ DHArHPA,· affbrepfydy no more 11® 1 «if1 of DHA.hpa, aitnmniivoly 12$ of :PtdA;H;PAs a|amat#!y op niore jflan 1:50 of D HA 1-1 PA, alternatively no more than 1:75 # IpAtllEA, alternatively no more than 1:90 Of DHAtHPA, alterrsgteg.m HSi of 0HA;HPAs oitornniivdy no more than 1:100 of ΟΗΆΉΡΑ.

[0044] In yet other embodiment!, tie compositions of the present mveniihn comprise no more than 10% omsga-li fatty aosts reiafee to sods. alternatively no more than 9%, alternatively no more than 81¾. alternatively no more than 1%, aliaresfivdy no more- .than eil.aiferrrativaly no more than 51% alternatively no more than: 45%, aftemdively. more than 3.5%. alteoialvely no <wn£:;#bh' 3%« Ppre Aan 2:5¾ alternatively no more than 2%, ailomotivaiy no more alternatively m more than i.5%, -than.41%.ΛηΛ# m tmm-.ttwn. 1%= aicemenvoly no more than 0 51¾ omega-9 fatty adds versos the total amrxmt of tatty adds composed: hy the compositions of the preseni lnvedifon. |QCt451 Om^sa fi * 1t> u ds nr ihii* ho ufe no* ! h %t to she eh" auh uA CU3 2 ore. n ertma-1 inclose ocsd ?GLA, CtAd-rdf ereosacheoou; οά-d (C20;2-n9>: dshomo-gammadlholefe hold (DOLA: €2θ:3-η5}; omohloohlo add fARA; and

Omega'-6 doopAppentenooic add (DPA; C:22:::5-n5)s fSiJAfI In fchhor «mbq^imenb, fhf: hempesfipne of the preeont Invehimi t^mphso: rM#m$MN4P 19% omeg;gu6 fatly acids releiva to ihe total ameynf of omsgsMSfatty epsdh: plhh omhga-S faiy.poiip- oltomallvely ;m> rodre than flip π 6%. alternatively no more than ?%, aferhhflyoly no mo^thab Aiereptiyoly m more than S14. alternatlvdv no more than 4:5%. nltemrtivnly no more than 4%, alternatively no morn than 3 5% alternatively no more than 39». aitematlvijy no than ns liissm: ilernMiyety ms mom than 1.7% oil amatively no more than 1 3%. aitemahvoly no mom moo 1.2Ί. nhomahvoiy no mom than 1% alternatively no more than 0 toy omKao iohy adds versos mo total amount of omooo-3 fatty acids plus om^-ga-d fntty acdo comprised by Hm L'om^ositkm of thepresent: rnmnUm. |t)047| In yef other embedments the compositions of the present invention comprise no room than amcddonic acid (ARA: €204-η$) relative to the total amount of omeg&amp;-3 fatly aails pfos ttmega-6 fatty odds, alternatively m more than 7%. alternatively no more than alternatively -no more than 6% alternatively no more than 4,5%, alternatively no more than 4%, ohemat-vely no fncsre than 3,5:4 aieroatlvefy no ofrwt than 3%r eltorhdllyofy no mom than 2.5%:: alternatively no mors masst '£%- $,;?% gffemativdv no. more than 1.5%, alternatively no mom thin 1 2%, atemativdy no mom then 1%·,. alternatively no more ihah E5% arasbtdonitt acid (ARA; C20:4‘fl8) versus the total amount of omoga-3 fatty acids plus omega-d fatty adds comprised by the compositions oF1ha present inveniKMSi |004$1' |ptj§®fni reldiy'#|y sfn#:A%H.!nt of omoga-E fttiy id; agg^stsi o#mr than EPA. ETA.; hipA idd ORA |il^nwfl¥tly Indicated as oon-EPA, noh-iTA, norvtiPA and noirfPA emegaoS IMty:; soids fo tblpl amditNi:; dfhlafiy :|iga# (he composition te proeedt> in eetne embodiments, the oompodtlomof the present invention c©mf>fi8«r ιφ ιήο^:^η;'·2Ι^ non-EPA, non-ETA, non-MPA and non-DPA omega-3 fatty ao&amp;, attemai»iy no mom ihao 1S% rsorc»£F4. norbETA, horvHPA and noo-DPA omega-3 fatty adds, aiamahvety no more than 1214 oorhiRA, non-ETA. non-HPA and oon-DPA omega-i fetiy acids. alternatively no more than lOS nomEPA, noo-Ef% non-HPA and nbtA OPA omega-3 fatty adds, alternatively oo more than 1% non-EPA, non-ETA, nom HPA «r$: fatty abide, aimnatively no mpr® ΟΡό-ETAy ned~HP%^ omoga-3 tatty aads, alternatively no mom than 6% πθό-EPA, nde-ETA, ndtAHPA add ebfhPPA bpip^3 fatty acids, alternatively no mofi-ttoi i%r«t>EPA, wrt'ETA, ooo-HPA and non-DPA omepi-B fatly adds, aftomnhvniy no more than 4% non-CPA, non--ETA oon-HPA and non-DPs omvga-A fatly adds, alternatively no more titan 3% non--€PA, non-ETA, noa-HpA and non-OPA ornoga-3 fatty acids, alternatively m more then 2% nomEPA, non-ETA, non-· HPA and nnn-PPA omega-3 fatty acids, alternatively no more than 1% non-EPA, and noivDPA fatly acids in aggregate relative to the toM amount: of fefty add^-pmsassiHo the eampa&amp;ifen, |O04i| !h some ;ifmbcxlim§nts, a reLativafy amount of the aum of ALA, SDA end DHA rotative to the to in I amount of fatty acids pfnoeni ai the composition in pres@«,A#lfe at th:0 same time largo amounts of the sum of ERA, OPAm3. MPA and ETA are present, la some embodiments, the u-rep^sstions of the oresens invention compose no mere than 20% of the sum of ALA, SDA and DHA. alternatively no mure thin 1$% of the sunt of ALA, SDA arid DHA, alternatively oe OW©Than 12% of the sum of At A, SDA and OH A, oitomohvety no more than 10% of the sum c/ ALA SDA OP# BtiA* dlematfvefy no more than 8¾ o* the sum of ALA, SDA and DHA, itemifkoiy no . mere than 7% of thi ioum of ADR SDA and DBA:,: afemaivefy m more than 6% of,AL% SDA end DiiA,:elt:enh8thrb!y pp the sum of ALA, no-ir^'i^n 4% of me sum of ALA, SDA apd. DHA, ^ moro tfiio,3% pi the sum pf ALA, SDA snd DHA, a Item jttvoV no sm *> dnn 7"$ oj tee sum of ALA, oDA < nd DBA, attemupvoly m. mom than 1% of the sum of ALA, SDAtand- .DH&amp;f ίΐ»Ι&amp;ΙΙ^···ΐ8 the tdiaife^uhtdi fatty. #HA:p?eient in the composition, while tfcsall 40%· ffatii sum of ERA, OPA^S, HR^ and ETA, aLemstBoly more thap 50% the sum of SRA* DPAn-A ΗΓΑ and ETA, , altefflatively more than 60% the sum'of ERA, OEAm-S, MPA and ETA, alternatively more than ?0% the man of EPA. OPAn-3. HPA and ETA, allemetiviiy mote then 75% the sum of ERA. QPAn-$. HPA and.ET%,i mom then 60% the aum of EPA, DPAo-3, HPA and ETA. alternatively more than 35¾ the sum of EPA. QFAn-% HPA and ETA alternatively more than 90% the sum of EPA DPAn-% HPA and ETA, alternatively more than 05¾¾ the sum of EPA, DP An-3, HPA and ETA, alternatively between 80% and 58% Re sum of ED* DPAn-3, HPA and ETA, alternatively between 80% and 965¾ She sum of EFA, DPAn-3, HPA Add ETA, Alternatively between 8S% and 88% the sum of EPA, DiPAfi-8, HPA and ETA, alternatively oetweeo 85% and 60% the sum of EPA, DP Am 3 HRA and ETA,:i«hrhattyely: beBta of SR% atemeivefy bdfpidn SQ% hoi :§?% yiie sum of EPAj /GRAmS, HPA and ETA,; :· #fP&amp;: .-arid:' ::ii§^·.·:·^: bom of EPA, Ρ;ΡΑι%3, HPA and ETA.: altemASveiy beteieh 99% and @S% fteAsiW :#f EPA, Df:jA?>3, HPA and ETA, eeyrpresehf in the composite! Is pmm$< [0050] in feohm mmlxxtonenH, the cmnymeUHons of the pmssm : vennon cu-i'npnse oc> morse than. 8% arachidowe sc id (ARA 020:4~n6) relaisvc to rhe mtal amount ef: M0\ add,', nils restively no more then 7¾. aM amative j no moo·; then 00,-.. alternatively m mom·, than 5% alternatively to more 'h m - ^ no mere1 than 4%, alter natively no more than 3.5%, aKernauvoly no more than 55¾. atehtiflyely no more than 2,5%, alternatively no more than 2%, affesmaiivaly no mdfe'tfton 1,7%, alternatively no more than 1 55¾. alternatively no mare Mian 1 2%, atemaively no mom than 1%, alternatively no more than 0.5¾ Abend onM (ARA; €20 4-n6l ielative the total ¢$$$( nereis composed by compo^hons of the present invention. {00S11 in other embodiments tte ^mp3ofttent of toe present feventfen oomprte hdmoto mm02:01¾^ no more then 0.4% osmAp-6-docosapentoeoofe add (OPA:; €22:5-¾) ami fed fetoro than 0,.25¾ gamm^lr^fe· acid (GLA; 013:3-ηβ): TOlative the fetal emPtfet oi lofty acids comprised fey the compositions of the present invention.. pcs52] Further' emixstimeots provide %uy add oampoRiticm?: od^p^^^::«o'':ino^' than 2.5%; machtdonie ooid (ARA: €20 4-¾ no moro tpin 0.3%; sefe tDPA. C22i%n5) and no p# than 0.1%^ pcld: Ct3LA:; C13 ;Αηό) relative the total tsmount of ^ tte of the present invention. |ft|§3J in yel nthor emotxfimenhr the active Ingredientdifhi to present Invention consists essentially shelly of the ERA arfe ORA or preeyrsere thereof (ethyl estei triglyceride. or any other pbarme^otictliy w derivative therool) In that case, oo large omoortfe feii ttian 15%, alternatively loss then 12¾¾. alternatively less than 1051, atemMl^y less than 9%. aimiTmhveiy less than #54, altemativety less than 7%, hKmafively teas than 6%, alternatively less than 5%, altomaliyely less then 4%, hlfemitl^ly toss than 3¾ aftomaSiveiy less than 2%, alternatively less than 1%, eltemfdsv^y tees than 0.5%, alternatively teas then 0.25%) of any other fety adds are present p054J In fmtw emhofemenls, the active Ingredient of fee formdatmns of the praedht loyenifen cunsisb essentially wholly of om©ga-3-pomaoTO*c actoe cr precursors thereof (ethyl ester, thglycehde , or any other |femi»ceytic^lty;ico^tshie salt or dorwative theriiot), la thet eeae, m terne amounte (preferably less than 1S%, i-temsm * 1y fern tone %%, alton\*hv*ly toss than KV* mtemuhveiy less than 9%. ίφβ. fest 11¾ 4%, atemaWy ¾ ' A^divB§f ']^;-$Μρβ 4%. altdrhpiyaty Jess than 4%tfeat than 3%, ate^a^veiy J®s# iNan 2%, aMematiyeiy less than i^i..#fl#Saiv<% ljes#::%a« 0.5%, gltamahvely less than 0.25%) of any aliftr falty ackia ar^ pnasani 1005¾ The fatty add percentage Is ie«wn«f an a 'wi^i^···^ chromatography ansa pomom basis relative s© a« tatty .aqife:7;'p^^r;|i)ivifta composition as determined by methods such as |^csln#y. la #>s liurdpapn: Ptmmm^psh·. monograph lor orrmga*3: Mi¥ acid eoRcsotrsfes, idmpean Fbprrnieopeia monograph for omena--3-aad ethyl esters 90%. of Eyropears Fbar^bpopfOa monograph method 2 4.29» USP monograph Μ te ai dietary supplements., US.P 55 oraeg&amp;*S-ac-id af^-iesters (LD^AIAiQ dtraoy eyppllatly equivalent metipdo: |#5p|dff :|y phrsmafoginiphy FPiCfp any other chromatographic method), [09S6] In some embodiments» the fa% aolel perooatapa la dPtasmlPod to! as a percentage of ail fatty acids present in the composition but as a specie syce of %Hy acid ethyl esters as percentage of all fatty acid ethyl esters pressm m the composition, thus excluding from the fatty aoki percentage determination such fatty acid? present ns tor instance; free fatty acids, rrrohCK dr. and trkjiyceodes, or fatty acids present in phospholipids (such as phosphaitdyiscmne or phosphatidylcholine) m poiyaofbates (such as Tween 80, Tween 20, or pojy&amp;qsfbate 40}.-IPiTl In other embodiments, the fatty add ·$£ φΙ^^^ΤιΜν^:;.^ percentage of all fatty aclds: present In the composition hut as a laity add as pm-oentage of el in the composition. thus excluding from the fatty acid percentage determination such fatty scads present as. lor msiance; fatly mM ethyl esters;: monoy dig amT or fatty adds present in phospholipids (such as phasphatidyisenne or phosphatidylcholine) or pelysorhal.es (such as Tween 80, Tween 20, or poiysorbste 40). |005l| Urn yet ott«M embodiments, the fatty add percentagers detemrlied not as a percentage of ai! fatty acids present in the composition but as a specific type of glycproS fetly aoid aftir as percentagedf:i|pybemt%1% acid present In the thus pkciudinq from di^mlnatloh suoh fatty aads present as, for instance, fatty add eihyi esters; free fatty acids, or fatty sods present in phospholipids (such as pbosphatidytsefine or phpsphatld^choisiie} or polysorhaida thsach as Tween 80, Tween 20. or potysorbafo 40). P«iS|; Ίο -fatter the doter^^l ri#i at a pleteebtege bl all telly atfcfe present ?n lh® : CSp«|»tltbn Itet as ::dh ar thd^fty eoM esters, wdb giyceml as percentage ul all glycerel do ana tnderiy· scsu esters f resent m the composition, thus oxelecdnn imrn the fatty acid pnroentage tloicrnxnotioe sunn fatty acids present at, for instance: g I yore o t-mo m>f a tty acid esrere tehy omo einy! esters, free fatty acids, or fatty acids present in phospttoiipias (seen as pfK-sphateiyteenne or phosphatidylcholine) or pel ysor hates (such as Tween $0, Bya#n tiT or pofyoorhota 40), ίΡδβΟ] In. yet other embodiments, the fatty acid peroenjage is determined not as a psroir®go of ill fatty aads present in the cemposlort but as a tri-fatty add esters Mill gfyeeroi as percentage of ah glycerol trMatty mM :\w$®m·· inetp composition, thus excluding from the fatty acid percentage defemMairon such fatty acids present as, for instance reortre arte dTfatiy aekl esters of gfyfcercte fpty seld ethyl esteret free teity vS«kf&amp; present te:· .^sp>h«.^^:{swPly ';de. pbosphatidytsorme or phosphatldy ichoti no} or polysoteates istfeh oa Tween 80, Tween 20, or potyserbate 40), p:pi1:| The-¾ ·Β)%: QP;% or emeia»3~penteoaefe adds.MPy^ho derived from any appfpprtete.source including plant ssed clls, microhm! oils fern terpo or idagai or narloe: oia torn fish: or ether marine animats, Certain species ,are^ o paitieular good source of ads containing DP4, lor example seal a;!. They may lx· nse-.i <n tee !omi of the natural oil if itut oh meets the required aunty requirement a at are pseseni invention, or may be purified to give- products containing the fatty acid composition of the present invention [0062] Tire compositions of the present invention may he produced through a range of the methods Such methods may include ddhtlebnn including shod path distillation, urea precipitation; ereymatic conversion concentration, conventional chromatography, HPUCfFPLC, supercritical carbendiorede extreetten: auporentleaii carbonteoxicte chromatography, simulated moving bed chromaiogrephy: superceded i'nitiundfcxide simulated moving bod ehromatogreohy or choose re convare^n methods such ai iodofictOoizatten. Sudh methods are gonoretly known to those skied lb tha wtof pyrffyteg and isolating prrtega-Ί)telly abide, [6063] Typically, the omega-3 fatty add corKteniraMoiv'purlticatlon process is iodeted by esteteysog tee fatty adds cornpharte by the marten oil raw material (such u undo ten re * rnte etha χ vb h'tts an; * ti >ι o * =, ~ i ., - te ;n *" ·$&amp; »Λρ^ bound together in the natural trigtycarndn molecules of th« source oil iebsequtrvily, the material may he d&amp;tll&amp;d once or several Pmes to achieve· emopP'S- aoid ef.hy1 ester concentrations above 60%-?0%. Alternatively. enzymatic concentration urea precipe a Pm or superconcaf #^|ractfnh may fee used atone or in fbvffcach cmega-3 levels above 7G%»9G%. ίο order to prepare a highly pore concentrate of a singlo omega-3 fatty aodt methods seed os chromatography, supercritical chromatography, simulated moving bad Gfcrwaatoiraphyj joparmtol eimuiafad moving bed: chromatography; or chemical conversion methods such as k>dciactoii?3tion are typically most prectibii to reach levels above S@fl* ASteirtttivety above 011%,: afemattveiy above 70%, attamafivoly above W%* -Altempbvety above aftemaivety above 95%; of :b ^ .-HPA* ΟΡΑ,ΤΡΑ, or DHA, [00841. Tlmso skied in the aA will bo able to dos^n pmceesot sulod hi prepaM a certain omega-3 fatty add composition as desired, based on the methods described above; Sucfe procassea are flexible ©hough fe> affect ftp relative propoAidhs between tfep teg chain 01%. C20. C21 and C22 i&amp;tly· saw aveilablb Isb ol raw moletiafs and other marine ols. it ppMdes not cmly for the cppceptrafep of his Ips -«Λ rern^iA.:ifi.ibin.',a patters of yedaiah caused by variations in nature. However, suitable methods ι umpensate f<*r sometimes extreme variations which may occur naturally. Thus for those skilled In the ad tl wtfitepomfele with a constant and predetermined composition. I&amp;Q65J EPA is relatively abundant in fish oils or otter manna relatively easy obtained through the application of osrmehfrafcn and piipficatigo teJteoiog*es from such fish or marine nits, DPA and HPA are present at much Ιον#?: concentrations in ordm to prepare the compositions of the present invention. ORA o' HPA may be cooceilreted and pushed front fish orto^sr .^cpnffeig to

thp rtiptfipde referred §:itsvi^ ©ithe1 aksne or DPA oorribirmd wifh ERA andfer HPA. Alemettyoiy. the DPA bf HPA may bte tfjNiffl&amp;ftty ^1%!* pftty ERA coneppirate by ^ioiiceflpfs </ the ΕΡΑ;ί!#Ι^ΑΜ.·'έΙ^Ιή: saturated carbons iC^^ongatten or €1'elongation) mtteoule dor instance with a nRethod itdtisir 'i© w *^'4ΐοΜώΚκ* results such as desedbed: by Kokiev SV and Smith Wi tn €bdm Pt^yis Uprds.. 2006; 144(2¾ pi-1 ??), in another alternative appmachsahfgh pomy EPA soncemmte may be partially oomniMito DPA (or HPA) using a mMh^:fc€24gbftiSi^:vCbf: Gi-elongation} of EPA similar to those described above, thus directly yielding compositions of the present ioventon or intennedraies therefore, [09^| Once the oils containing one or more of the dashed fatty accfs have been obtained, end purified as necessary, these oris may be blended to give the desirable relative arp&amp;unls of EPA, DPA. HPA, OHA, TPA, other ormyg#-3 fatty oHde onvi ornegava fatty acids to obtain fbe^mpoaiidhi of the present inmteon described in datali abovi:. |Qaa?j Eish oils may also contain hy-pmaeots end oontamioente sooN as pesttsides; ch#Sodfid or bmmiteted hydrodorpohi. tieavy metals, cholesterol and vitamins. During the pmbectigh of ·the conogntrati, the oonc^otfattems of ibetr^ are significantly rodeoed compared to untreated flab ofte Duoh ;redyclon la letereot duo to the nature of pudieailon methods and their ability to dormant rate of several or gpooiid loiegaAl fatty acids, thus rentoving other compounds, pQdSJ Triglycerides comprising more than: 60% of the om^a-3 Mty acids in tte composition may be produced from ethyl esters and glycerol by «II kfxmm, pupflsltod, or alterative chemlcat synthetic or eepyrnatie ptebeddres;: Ttefmo acld4 may be prodycedi tom ethyl «&amp;$rs,-: fey:.,pe.Mp0f^Pei#S3h'· procedures, htethods for ccrmsdiug ethyl esters to thgiycendes, free fatty acme, and otter molecular forms composing fatty acids, are generally known to those skilled si the art chemically or enzymatically converting omega-3 laity aeidaltedt pri# form to another:.

pifft] to some embodiments, fhe eompocfllgns of the present invention hate improved pitermacologlcrrl feomres as rirmsonsttiSfed by improved bioavnliahliiity IP a mammal of ΡΓΆ, DMA, ΕΡΑί-DHA, EFWt-DPA or EPAMHPATDiriA combined, totef ooteia^-pentaonpic acids, or of total omegas tetty acids; Kay pommetern ter tetemvns?*Q teouvaitehlay am muxmuv cor -om-.s. ,- * of a thorapootio cempound dr a rtetihdilte ttere^ Item idtefoiterpttpdi to maxiotum dOddOdl^iod (Trnaxt; and the areaundenfe lime (AUCf Such parameters may bo determined under stegie dose or mutepie dose administration regimens Methods to determine comparative teoavasfaMsiy in mammals or® generally known te those skilled In the art. When oompOhf^ TmteS Cmax, and: AUC for embodiments of the present invention to L.OVAZA€r and AMR101 throe gttout; this appcattorg such comparison will ts*3$f the baeto oftoo .e^ipdfeip·'©? 4 capsules si 1 gram eachfer each of these products, Ibm cosnpjS^Sivi^’i^^afm^^r!^ - Ν€>*»ϊϊβ%λ&amp;ιΤη, do apply la all essentially aqymaiaiitciaiaiisg :m©d#A comparing embodimento of the present invention to lOVAZAAX. IP^PVA*, and AMR101. 100701 Meal conditions nrnng administration k> a subject of omega-3 fatty acto cofBfJositiom·! or omega-3 fatly aerd formulations arc of speccsl sigtohoanco for :a&amp;s^ioit:aipd--lis^ilability#;0mw^ fe**y apMs, The r*w!'eanclii:io??sJ^«al^ considered are: fasting {no food at all prior for 5-12 flours prior to administration and 2*3 Poors post administration of Ihe treatment); a low to! moat fa meal typically aintMilhi loss than 25 gram of fat |3S0 -i0D Kcali consumed futo hefera or after The; administration of the treatment; typically wtlhsi a 15-30 minute range), or &amp; high tot meat {a meal containing 40 gram to 75 gram of tot [700*1000 Koto] consumed |usi 1#!·.« after the ..administration of the treatment; typMly #foto a 15-30 minute range). f0071J In seme embodiments of the pmseni fmmntton, compositions of toe present invention are more rapidly absented as measured by too time to reach the maximum concentration (Tmaxj tn blood, serum or plasma of EPA. QPA. DMAs EFAipPA, EPA+-OHA, totoi om0ipi3*p0htoohplc adidto, or totoi omegas Miy ao&amp;. In prefer* ed embodiments ©I the present invention, Trras, under high fat lima! administration conditions is less than 8 hours, aiternato-eh- toss than o hours alernatiyely: appmKitoaieiy 5 ttoUirsy altorrmlvely 4 hmm or toes, to otoer prefetrad embgdlfpepft: of tbe ipto^ppITpyphtten; Tmast .under ipto ifei. meal admimsiioiton IbAs tharr 8 hgufl, afteroafivhly less thap 16 hoorm hitemativtoy approximately S hours, altarnoitoeiy 4 hours or less· to vet other preferred embodiments of the' prePPnt invention. Tmax under tasNng admlrbstratloh conditions is less than 5 hoyr% bidmattvely less than 6 hoars, aftematfveiy approximately 5 imam, altooMtively 4 Pours or toss, to further embodiments d the present invention, t'mmw i»s Dfofo DHA ., EAtoDItoto E^RAtSHA, pr ©tot; eppat or less than than Tmax lor LOVAZA© tor ERA; Pf% DHA. > EPAdDPA,: EPA tDHA. or total omega-3 fatty amds under h»gh to! meat, tow fat meal, and fasting admtotsfratioa conditions, la other embodiments of the ptoaeM Irwentiarp TAtox far ERA, DPA. DHA , E PA* DP A* ERA*DHA, or total omega-3 tally atoste em leaa than

Tfffexfer LQ^EAiffcf EPA,/DPAS.. OfeilA: ,r;. e^A^PF^;;· felly agfes pnddr differ few fat meat, .festfeg:, or both [00T2J in yet other embodiments of the present invention. Tmex rot EPA. OPA, CSMA , £PA*OPA, EPA+DHA, or·total omeep-3fatty acids are equal or less than than Trnax for AMR1Q1 tor 8PAt DPA. DHA EPA^DPA, EPA* DHA. mife omega-3' perdaenole pads, or total omega-3 faity acids under high fat meat low fat meat and fasting administration conditions. finally:, in other embodiments of the present •invention,. Imax for EFA, QPA, £)BA , EPA^OPA, EPA^OhiA, or:total omega-3 4¾¾ AdisSA Afo tes fiih Tmax tor ΑΈΡΙΟΙ for EPAoDHAand to ERA, OPA. DMA , EPAaPFAvIFAAOHA, or tpfai omega-3 fatty: acids aoder either tow fat meal fasting, or both admfelsifeffee eorrtfem: fit?||: In other of fhe;;^r|sdht

Ihfelhfion are better absorbed than Ep\pZAif as measorfej: % file maximum ceboentretfen (Cmax) in blood, serem or plssmi of EPA, DPA, OihiA , EPA-^OPA, FFA+OHA, iri.it omrKKhd'pt ruinate acufe, 01 t >i », omeo 5-3 , thy near··

Pi?4| in preferred embodiments of the present inv^niK5ny;Cmfgsc-: 'for f3?A* DPA, DMA * ΕΡΑ^ΟΡΑΐ IBA^PMA, loin! omoga"3--p#ri^en^f aelds, or total omega'Efefiy aside under high M meal adsiAfesifallon oarfeifeos are preferably at feaal 1.-1 A (110¾ of) C«i^fc-:^p.:£8»A, DHA , EPArDPA. EPA+DHA, Mai Am^a# pentaenoio acids, df tolaf cintega-3 fafl|r ddids fer 10½¾¾¾ af faMt 1>I x (12A% of), alternatively at feast 1,3 x f13t)% of}, alpmabyely at feast11A x (140% gf), aiferprdively at least 1,5 x 1150% of) Gmax far ΕΡΑ, ί'ΙίΡΑ, "OHAg: EPA*DP%; iPA+DHA, total omaga-S-pantaenofe: fealda. of feti! otidia-S fit? aods fer LOVAZAa |0075J in other preferred embodiments of fee present rn-rennon, Cmax for EPA, DPA, DHA , EPA-rDPA EPA* DHA, total c>nrega~3-pϊ·iarox; aefes t-.r total om-rem i: fatty acids u:ndarfew fat meal adminmuatfen condfeons are preferably at fe^st 1,5 x CfifiC off emax &amp;r EPA, DPA, DHA , EPA+DPA, EPA+DHA<·· fetal omegs-3« pehtbhrfete ^cfei,of Ml 00¾¾¾¾¾¾ at feest 2 x PPQ% of)# alternatively at least :i x (300% of?^ alfemative^ at feast 4 x (400% of). ali^Alyely if feast 5 » {500% of), alfefhaflvaly m feast 6 x #0¾¾ of) DefeA fer E:P.AS: DPA, DHA , ERA* DP A. EPA^DHA, fetal orne^a-3-p« nSsc-axnc eeidsi or fetal omegfeh fatty acids· for LCA/aZA#^

In i'>Uw memrmi.' embodiments *,> - *he pmseoi m ,ert m. Cm,^ ί<>· s=RA DPA. DHA , £PA*OPA, EPA+-QMA loml omego-3'psht&amp;enoic acsda, or UI.U omaas-A fatty ..acids .under fasting administration conditions am r.=ret'er?·r:Ay at mast i 5 χ tlS0% of) Cmax for EPA, DP A, DHA . EPANDFA EPA+DHA t^tai emega-% psntasootc acids, or total oroecia-U fatty adds for LOVAZAIP alternatively at least 2 < (20i1ll of), taiternativety at least 3 x (300% o"\ alteroaiu^ty A seasv 4 < (400¾ OP afeTrtitlvOty a! feast 5 x (S00% of), aftemattvdy at feast 6 x ieQU% of), aitefnativeiy at feast T x <700% of) Cot for EPA, »%DHA / ERA+OPA. EPA+OMA, fofaf nmega~3-pentaono sc acids, or total omega-3 fatty acids for lOVAZA%\ pwif in other embodintema of the prosprstJP^pidft oHtm feifedd# fewrtsoLOUAZA#: as -mmm&amp; by the area under tie bfed4 sewm or plasms οίΕΡΑ,ΡΡΑ, DMA ,. o^oga-:3--pemaendfc acids, or total omego-Ά fatty aokfo-P073J lo protirrod present Inwodor?, AU€ for ERA, UFA. DNA) EPA+DPA, EPA+ONA,. total om®ga-3-ponti0noic add®, adds oodor high fat moat admintsPatlPd oorfeitfens m® ^rnkmUyt atfeast 1.1 x {110% pf) AUC fir EPA, :DPA;! Of IA , EPA-rBPA, EFA+DHA, fetai omogs-3-peofeeriosc sods, or total omega-3 fatty acids for LO^p^Aft,ti? x (123% of), attentively at feast 1,3 x (13D% of), t,4''-&amp;;f 140% of), alternatively at toast 1.5 x (130% of) AUC for EPA, ίΡΡΑ, ΟΒΑ:, EPA^DPA. EPA*DHA> fefei omega A'pootaonoic acids, or total ροΐΟ|ί*3 ftetly adds fgr LOVA2A*\ [0A7i| in other preferred embodiments of the presort inventfen, AUC for ERA, ORA, PHA), EPA+DPA. EPA+DHA, total omega-3-pentaenoic sods or total omega~3 fatty acids odder low fat meal administration conditions are preferably- at least 1.5 x {15*% of) AUC for EPA DPA, DHA , EPA+DPA, ΕΡΆ+DHA, total emega-3~ peritaenofc ados, or total orooga-3 fatty onrcis for ίΟνΑΖΑΦ, alfemaifeeiy at least 2 x ?2(ΧΓ i of), alternatively at feast 3 ;< (300% of) alternatively at feast 4 x 1400% of), mr a lively at lov^" *%> * of) ofexmcevvA at -Γ v tOGA &amp;*} r% ’ >r H G DPA, DNA , EPA+DPA EPA+DHAi of fetal ome|ep-pa;r!tAeoPfe APife: or total omega- .1 Fatty amdx foi LOVAZA®.

[0030] to other preferred embodiments of the present invention.. AUC-Afpr. EPA DPA, DHA , EPA+DPA, ΕΡΆ+DHA. total omega-Bfeerdaerfeic seEfe, or iofaf ordega- 3- fatty acids doder fasting adminsstrarion (x^nditions aro preferably at least 1.5 % 0δΟ% of) AUC for ERA, ORA, DHA ,: ERteDPA, EPteDHA, total omega-3* pentatete iadiis^. pr Iptsi omegte ftey acldAfor: LOVAEAfo, teemtetey at fotet 2 A f200*11: of|?: '&amp;i;t#teftefy at test :3 x (300%. .¾ tetetetey; at teat 4:A f400¾¾ pi), .Amatively at teas! 0 y tSUfte oh. <jiHornMK'C-ty at least 6 x (§00% of). atemotiyety at test Ψ x: (700% of) AUC for EPA, DPA. DBA , SPA* DPA. EPA-DNA, total omote-d-teoterseic adds, or total ente§&amp;»3 LOVAZA#. |O0S1) In other embotJjrtteras of the present invention, compositions of the present fri^ntte am tetter assorted than AMRtOl -m mmmrM the maximum cpm^irai^n {Cmax) w blood* serum or plasmaofERA, DPA:,^ I5HA>^ EPA^PI^:. EPAlDBAyiotai adds, or tofa!:omepa-3foliy adds, pcif^l It! ptofemd iteeotfem Cmax for EPA, ORA,

BiNA,. EFA^BPA, ΕΡΑΤΕΙΝΑJdt|i otteia^i^entaenoio adds, or told omepa-O fatty acids under high fat meal ..administration oonditona ait prteAshte AtBtedl 1.1 A {110% of) Cmax for ERA. DP A, DHA . EPA+DPA, EPAteHA tote omegote pentaenoic acids, or total omega-3 fatty adds for AMR101, atemteveiy at test 1.2 x (120% of), alternatively at teas! 1.3 x (130% of), alternately at !eagt;14^#^% of), alternatively at least 1.5 x (150% of) Cmax for EPA. DPA. DHA . £PA*DPA, EPMDHA* total omega-3-pertaenoio acids,; pr total omipte teffy adds for AMR101,

JiSiS) fh oilier prafoted tefoocfrments of the prose:nt irrrc:nt!00:; Cmax for ERA, DPA, PNA :i; EPA^OPA* BPA'rDHA, total omeiiteptetetetofo^ 3 fa% adds uteArtow fat maal administrator} oonditote a&amp;T:p8itai%:' atldaiii Jdt (150% of) Cmatefor EPA, DPA, DHA > CPA-HIPA, EPA+DHA, fofoi pem&amp;enoc acids, or total omega-3 fatty acids for AMR 101, alternatively at least 2 x (200% oft, alternatively at least 3 x (300% of). alternatively at teas! 4 x (400% of), alematlvely at least S x (SOO% of) alternatively M least 0 x (800% ei) ©mte; for EPA, DPA, DHA . &amp;PA*OPA, EPA+DHA. total oir^a-3^^[^fe :^ds4 or fatal ometp.-3 fatty acds lb5 AMR 101,

pS0)4jj In otter prefeonsd emtedimete bCtte pmtent teteterv ;Cfoax for DPA, DBA. ,. ΡΡΑ^ΟΡΑ. EFA+QHA. total r>mega-3-pentia^^e ai<i^,· er-t^at omega-fii: footing temtmstomen conditions -are poc0$fa|tyr- ^vM#.;1v5: A {150% of) Cmax for ERA, 'DPA, DHA , EPA* DPA, EPA+DHA. feta! omega-3-ponioendfo Odds, or total omega-S fatty "teds fo? AMP rQI. rutomfoitey at least 2 x 1200% of), atemteveiy at least 3 χ t30Q% of), a Star natively or ieast 4 >: (400% of). fotfornfoivefy at teas? 5 x (500% of), alferneimr-A at feast 6 < ^ r-r- Amovd \ Hy ····# test ? xittm, oijf Graac for ERA PPA, DKA . EPAH3PA ERA* PH A fohs! amefs-5 roniamviL.»» >ds, m iofot om 0d-3 fall·, .. % fnt *%1KUd' p01i| lit dfhererYibOdfments of Che pfgeen? invention, compositions of the present -feetlir&amp;bsori“fo than AMR101 measured by the ereacander the i%iha#htralioh dfryppvor t-roc fAUGfen blood, wum or plasms of ERA, pPAy PHA:, BPAaI|RA>::1RA-+PHA:, fofol Pm#gp-S^p#fllptPof€ adds, or total omegsfei in preferred embtAwnfs of.|h# jpreMnl fowntfom AUC for ERA, ΡΡΑ,-ΜΑ ·„ CV4+DP4 t PA*Ο ΊΑ mid on* ,κ .» nfoena r .. fos V n cpm--. info , ^ under high M mail rfomlhfolfotfcm oorvfttlon* are preferably at least 1.1 x (110% of) AUC for ERA, C>PA:i ©HA , EPA*0RA, EPMDHA. or tola! omega-3 tally adds fir ΑΛ10Ι, at felt: 1.2 x-112¾ .¾ alternatively at least. 1.3 &amp; (130% of), altemativil^.·'^.. lepet ?1.,4-:·Χ 1140% of), elfematrvely at least 1.5 x (150% oil AUC for ERA DBA, DBA * EPA+OPA, EPA+OHA, total omeoa-S-penfeemfo adds, or total omaga~3; i$|y :add$ for AMR 101...

[Q0B6] In other preferred embodiment of the present invention. AUC for ERA, DRA* DMA , EPAfPPA, EPAHDHA, total omega*3*pentaef«^? acids undwfoow fat meal administration conditions are preferably m least 1,§ x OPA. DHA „ EPA+DPA, iPA*U.HAs total omerpfo-pantaervoic acids, or total omega-3 fatty acids for AMRtQi, allernayveiy at least 2 x (200% of), alternatively at least 3 x (300% of), aftemstivdy at least 4 x (400% of), alfornattvely at feast 5 x (500% of), alternatively at feast 6 x $00% of) AUC for ERA, DP A,,DHA ,: EPA-rDPA, ERA* DHA* ipfof ,0$^ aotdm prifotal omega* : 31¾% acids for &amp;MR101 - fOPST] in other preferred embodiments of the present Invention, AUC for EPA, OPA, DHA , EPA*OPA, SPA* DHA. total omega-3-peafeenofo acids, or total omega-3 fatty edds under fasting admmfelr&amp;bon: o&amp;nditions ere preferably at feast 1.5 x (1505¾ of) AUC for ERA, OPA, SNA , ;ΕΡΑ*ΟΕΑ, ΓΕΡΑΑΡ|-ΙΑ: penfoenefo acfos, sr Wa! omef$a-3 fatty adds for^AIIPIDI , alfemallyeiy at least 2: % (200% of: aVmahvely at feast 5 x U)U0'\. >R) alfonxoiw^ άχ feast 1 \ fetfofo of* talte^^ly al^s^/Six: (M%;:bf). aiteroafMilY at feast 6 x {E00% at), alternatively dt-feast T x (300% ol) AUC for ERA DPA, DHA , ERA»ORA, ERAxDUA, fofo! smena-3-peninenoic acsds, or total omega-3 fatty acids for AMR101 pili] ip oiler ^rnbodteanls of thepfoseto invention. oomptosiiions of toepresent 'ire. feete" IPANGW® as measumd fe® maximum ΐ|Ι:' fetai, serum nr ptawwi of-.l£l*&amp;· EP^fDHA, total omega#g)entoenoic odds, or total omega# Jetty acids. pSiSJ to preferred rottoodlmento of the presen? *mmoifPhtv€max. for ERA, PPA, DHA ; ΕΓΆ + DPA, FPA+DHA into! omegj 3 jx ofoenoi*. erfes m tofol oa^xp-^ fatty adds unchar togh f;;.U mod administration conditions are preferably approximately 1.0 κ {100% of) Cniax (or wmsignifcant diffewca} for- SRApDPA, DBA t g;RAfP^As: EPAfDHA, total .#: total omega# toify adds tor E.PAN'OVAtH5 altomaiiveiy at least tm *. at feast 11 x MC > to aifem d,wt> d >sitt i 2 ^ toG0* ot; alternatively at':l^?1>$::*{l30% of) Cmax for ERA,. 0¾ OBA, i»«4 EPA+DHA. fot#am&amp;ga#^»tota adds, or tmd omega# fatty acrds tor EPAMOVA'^, 100981 In other preferred embodiments of the present kivenhon, Cmax tor 6PA? DP a. dha , EPA+DPA, EP.A-HDHA. total ornega-3-pentsenoic adds, or total omegs* 3 totty adota under \qw.. tot meal adrTxnisfmfkm corfoilions as protorabty approximately 1.0 x {100% of) Cm ax {or non-s<gnrfto&amp;nt difference) for ERA. DPA. DHA . EPA+DPA, EPA^DHAs ttg? acfes tor EPANOVAT% alfemaivety at te#1i)§ x ft05% of), stemately a! least 1.1 > (110% of). alternatively to least 1.2 x {120% of), alternatively at toast 13 x M'toto ¢3} Cmax tor ERA, DPAS DHA , EFAxDPA, EPAxDHA, total οΜΟξρ-Φ pertoiiiote acids, or tofat omega# Mty acids for IPANPiA {00911 in older preferred emtofornems of the present invention. Cma.x tor EPA*$3H%:i0t$. orrw^j'3»p0hl^#to^^. Add total omega# fatty Adda under i,csc^5€l|ttan&amp; are preferably^appmxlmtoety^1.0 x (100% of) Om« tor nontoignlltoirit . differences ? for ΕΡΑ,ΟΡΑ, PINA * EPAf'C^AliPA^ONA, tofai omege»3'pentaenotc oc?ds, or total omega# fatty acids t^r EPANOVA^h: alternatively at least 10¾ -< {105% of;, a l?of natively at toast 1.1 x (110% off, alfornaivofy al toast 1.2 x (120% to), tofeifelxtoy si toast 13 x (13δ% <# €ηιοχ tor ERA., DPA, DHA:, EPA+DPA, .MPAADMA* Mai dmega#toentoenefe acids, or total antoga#:toSy adds tor EPAN0%A—, |0092| In other embodiments of the present invention, compositions of the present invention are better ahsotoed than EPANOVA™ os measured Oy the area under tie concemmpon curve o\®riime(AUC% in blooAsmwi or ptasma of EPA;. DPA, OHA , EPA+OPA EPA*DMAS iotat omepN3 fdiyaeife. in prefeoed embodiments of the .present invention. AUC for EPA. DPA. DHA , EPA^D:PA, SW^DHA,: total omega-3··pentaenaic a-cxls, or foiaf oo^g^-A tofty ooirfs yoUer high tat moat aimfeisteian. sogdito.iss:;am:i.prdfe'mfely Appmxlmateiy 1:0 x (100% of) AUC (or npp-glgniipiAf iPomggil for ERA, ORA, OHA ; EPA-i-DPA, EPAxDHA, or total ooisga'S-poofaeoolc «Is, orlotei »megy% laity acids fer EFAN0W^ olfirnafi^lr at least 1.05 x (105% ofl alternatively at teastl,'! x (111» affor|)pfi«l%ai least 1 .2 x (120% bf| attem^v^fy #t l^st 1J x|136% of) AO0 Mr iPA( OP A, SNA , EPA^OPA, EPA*DHA: Wa!"omtga4“p®^r^ WM$, or fpiif omega-3 fatty acids for EPANOVA^ mm (a oftsr pfslarrs^ embrndirnortfs of its pre^ni Itxer^og, AiMi tor EBA, DPA„ DHA S: EPAtQPA, EPA^DHA. total omega-Siaentaenslo bdd% m total omega-3 fatly adds oader low fat meat admNstrai# ooadttiapi are prailMfely approximately 1.0 x {100% of) AUC for oon^igaiiiispi far ERA, DPA. DHA . EPA+DPA. EPA*DHA. total oategadB-peataeaoie aolda, or fetal omaga-3 fatty adds for EPANOVA™. alternatively at least 1.05 x (1053¾ of), alternatively at least U x (110% of), alternatively at lead I 2 x (120% oAs 0^0>alyaly at loan! 1#;x (130% of) AUC far EPA. DPA. DHA . ΕΡΑ-ΟΡΆ. pentaenolc adds, or total omega-3 fatty adds for EPA NOVA T% (0094) In other preferred embodiments of the present inventor*. .AUC for ERA, DPA. DHA . EP.A-t-DPA. EPAtDHA. totatomepa'-d'Dentaande acids, or tola! omega-3 fatty adds under iesbnq odmsnistfobon ccndlfloins bib pfeifefably op:pmHmafely 1.0 ' U00% otj AD‘ sOi "> π -ipruficunt UU mr ERA DPA DHA . EPA+DPA. EP^ADHA, or total omoga-3-pentaneoic acid#, or fbtai - |6g

SPANOVAf*\ alternately :U5 X (10514 pi|s afiemalNbty at leaif 1,1 X (110% cl), alternatively at least-^liamaMv at ieaet 1.3 x (130% of) AUC for EPA. DPA, DHA ,; EiBAlPPA, EPAtDHA, td%1 omega-3-nemasnde gcMSt. bffgMo^ p0i5| In some embodiments, lilt improved btDayiitabllly fabty me doepribed above 'rn® dpi# admmistmtiom wMlp ^ IPp improved bioaya liability features described above am appall after mnlfiple doio administration. <# -feNmuMiora- -itcwd-irtg to tho preset fovedfon eeveempomri to referenced comparator products above or substantial equivalent forms thereof pflij The compositions of the pro## idvAidr*$*(jy '.fee· ifeeif for the ttepment of pptrefk^:^^ amoont of cdeb .oompDlltfoiif Th a suh|elf lh need thereof,. such as 0 subieoi prone to or afflicted with a ilfsea^o or c^oitfen or ih need of treatment for a disease or condition. ‘The present fnv^ltoo pmyfdep methods of treating, preventing, and reding symptoms assoteated wfit a disease or condition comprise admtoplifatlpo of a Ιι00^ϋ cxemnfary diseases gr psmtffitom 1 include, but urn not limited to; hypprincjlyceridenraa (for oKampfe, lay- ttese ekifted in tha M typsoally esfiPifeNd % •massing faafmy tngiva'iide (TCd ievetei. hy^itrlgiyceodemm with TGd5ChQmg/dL fVHTGj; hypedrigtycendemia with TG 2&amp;Q-4S9m$8l*p imo^vmg/dL, white m statin treatment {HTGT; hyperrdffile^enoteotiai miml uysiipsdemia; coronary heart disease (OHO); vascular disease end related conditions·; heart tallure; cardiac amhyfhmias; blood eo&amp;gulatofy conditions associated with cardiac anrhytmtas, relM#d disorders, including post-surgical deep vein thrombosis or other high risk thromt^e conditions, oepteopaltw: kidney or urinary beet disease: reinopaity: eogntem psychiatric, neurological and other CMS disorders, trmidilfg hot it# tifcd to schizophrenia, depression, bipolar disorder and eny isfm ^ d«eni§ C^hd^g ischemic dementia and vascular dementia) autoanmyne diseases; Mammetdry diseases; asthma, COPO or other reipiitetery disease der'matologteai disease; roeteouk: syndrome, ombeies or other form?.- of mekmok (risenso: km diseases including fatty irver dicedidridisoaset affecting tea senses,, inetedmg those affecting \i . " sad hearing disease of the ynsh^nl· i! V tmot > .-sos * fir s* r fpmste .mpreddpiJye ;isysfppf ;or :te®|ed> lecortde ry sektiel:; organs;m tteiheer of. any %pee "ktclyiidg-.jyhipf'tpmeis^ myelomas: arid solid -tow^itBaihCTOt any infections rijsed η m e, l kUiiu'i hi pus Ο’Ά^ι x othc a-pams* The prasefe inverit^n also provkfe# $PT the .traafcrnerrt £»nd.'or prevention of cardiac eyerie arfefer cardsovrjsGular evopta and/pr vascular events and/or symptoms. The present tnyehiidn also· provides for the rixipdfiop of: norntjarmf Pbdhfpyente, ds well as a fedyolpp or aroeiiomtion of symptoms nssornfed tetih snob ewpite P0i?]i Cardiovasoolar and/or cardiac events may Joofeda,. :bpt JttiM-tcg myocanitef: iplpnaliorri ischemic cardiac attack, feobemic attack, acute angina, Tospftoitcohon doe to acute ongino, t'tnj-ke tmnstent ischemic 'Sprofsmi attack,, cardiac revascutenzstron, cardiac ^vascularization with stem pbremenr carotid ortey . rtvescufer^atkifi w© stent placement, peppherol: artery rseascufenzstferi, peripheral artary rsvascubrfeatba withsfeot ;pfe^fe«*t,. plague m$&amp;m« tfeit due to mi#tmtsufetr wpal, prd ho^tafesifer» :bteto^ eardkivaio^lar-pytat fferdipypsoefer aindlor cardies events may afeosmlmte in such catergory by those skilled In ife art:, [dtlftij The, present Invention provides ttfethods of tmatmppt Ibf h^ri#||ppFi^paili pper TGkSOBmg/dL TGOSOOmpaW TG>1Sempall, T8iQ0-4i9mgft|L, : m IG1SD4tSft^iL|y mbfed dysiipidemta, or ether ciseases nr mteieal conditions as ipppifted ebssfe, by dosing I» a suhja^ la aa0 itepbf enfegsfel docesapernaeteic; aeicl (DRA-nd) or lie glycerol or ethyl etdps, $och matted Pf Ipaateadipiavides: a dose ®i at feast §Qrei 0^-¾ :p^ day,: at least BOrng DFA-IM3 per day. affemptively at least §0m§ DF^#t3 par day, ttemittvely at least 12dm§ DPA-.N3 per Pay, alternately at feast ISOmg BRAd© per day, aiemaivaiy at least IPOmg DPA-N3 per day% altamaPvaly at least dSOrog DP.A'N3 per day, alternatively at feast 290mg DPA-N3 par day, alternatively at feast 250mg DPA-M3 per day, alternatively at least 39Qmg DPA-N3 per day, alternatively at feast 3S0mg BPA-MS par day, atiemphveiy M day. alternatively ai least SOOmg DPA-N3 per day, alternatively at feas* dP'lniQ DPA-b© per day, p^ir |S0S9] In seme embodiments, I the compositions..of the present Indention, which may compass sspnfecant amounts of omega-3 docoeapentaenolG add (BPAm3) or its fiipeml m ethyl :'rdaf Peatmen: ct hypeftrgiycenoemia (eteer

TGtebOmg/dl, TG2O0~#tegAJL 1J|mi|ldL|s tm0; .'#stpiaif»l4i* or any :^hpr diseases or medteet qpoditdm spaoifed above, Booh molted of treatment ptevldos fc a sybpct la need ttefeof a %ae:of etloaat: 2bmp DFA-N3 per day, alternatively at least 2Smg DiPA^;;f|®f'^ayi alternatively at least 3§mg DPA*N3 per day, aft®matrv»!y at least 40rhg DR&amp;-M3 per day, i;tt emotively at fees! Sdmg DRA^MS per d*«y tefemativeiy at feest Mmg OPA-N3 p^r day,: ?DniS :|ΪΡΑ-Μ3 per day, at !east:pprrif ;ΟΡΑ«; per day, oitbroaiviiy at :te^^:-'#Pn^pp^hi3:: ipCfeg KA-I^S oer day, alfemalveiy at at feast tSOmg DPA-M3 per boy, alternatively at feast 1C>Omg 0PA-N3 p#f #yy oitemahvely at feast I89mg 0PA-N3 per day. alternatively: M feeoiSbQmg DPAd© per day,: altprhsl¥eiy at feaft SiOmo Bffefet© per diyi: a!terniiyfety:al: :feost Sdipimg DPA'N3 day*, alternatively at least at least 4D0mg OPAH43 per clay, eitemohvely a I ' pa^^fey* -'aitam&amp;tiyeiy at least dOClrng DPA-M3 per day. alternatively aitemativelyal least dOOmg DPA-N3 or is glycercst or ethyl esters pec day. p&amp;l&amp;OJ In other ; embodiments, the eemposltlei^ of fe p^erh tn^^tbhyyyhleh m#y comprise signi^c^t emoeris of omerp^ dmwpehtapnoic add lOPAAii} dr it$ glyeero! or ethyl: eaters and which compose mletlyeiy small smomis p! graega-3 ^eaesahexaerroic: add {DHA-n3};, may te used fer the:; fmotmeii of ;Pii#r TGfcSOQmgfdL. TGaSDQhtgidLdlG^ISOmo/hL, TD20CA ASimp/dt. or 1fBli0M09mg/dL>, mixed dysllpldemlm or any other diseases or medical condition specified above. Such a syfcpd fe need thereof a ddie of si least 20mg DP A” N3 per day. attornadielyilleaet 2Sm@ DFA-M3 per day, afernatlveSy at least 30mg DPA-N3 per day, aiterhaiyeiy at least 4Dmg OPA-N3 per day, alternatively at least Sifhg'DPA-MO per ¢1¾ alternatively at least dOrng DPA-N3 per day. atfernahvely at least 80mg ©PAaN3 per day, alternatively at least 90rng OPA-N3 per day, alternatively at leastTlSmg DFA-N3 p*@$ day. alternatively at least ISOmg OPA-M3 per day, alternatively at least t60mg DFA-N3 per day. altethadvely at least ISOmg DPA-N3 day, aJtemapely at least 2O0mg DPA-N3 per day. alternatively al least 2S0mg DRA443 per dayyalterrMtlvaiy at least 30t)mg DPA-N3 per day, alternatively at least 3$0mg DPA-N3 per day. alternatively at least iQDmg: DPA«N3 per day,.fat# IlC^higyPPA^NS per day, alternatively at least GOOrng QPA-N3 per day. alternatively altemativelyaf Seast SShpd QPA-N3 or per day, white priwBtng fe% than loOOmg Of pHA, alternatively less thin i200mg of SNA,

IdOGmf of 0¾ siemaively less than BOOmg dRO^. 700mg of DHA, alternatively less than OClOrng of DHA. akemaovely loss than bOOrng Of DMA, e:tternat.ivel|c tees ftsirv ADiirrig of DHA, alternatively less than 3§0mg of OKA, atternailvety loss than: 3GCfrhp of DHA, alternatively loss fhpn 2§0hfp Of DMA, alternatively less than 200mg of DMA allarnativety less i^sn iPtig of DMA, alternatively less than i20mg of DMA. 100 mg of DMA, alternatively less than SO my of DHA, alternatively iess than GO mg of DHA. alternatively lees than 40 mg of DHA. alternativelyless then 30 mg of DHA, aftemabveiy less then ,2i rag of tes# ·8*»·20 mg of DHA or is glycerol or ethyl esiemperdey, |i1Sl| in fysther emtedimenG, the CMpodtiom of the pmssm toverdon:, which msf cer^phs^ sfgnffteahi amounts ofohiepmS: add fDl^hS^ w

iti.gipspfc! or ifiilrelatively small amounts of dmege-A doco&amp;i^exofc?noK' .vart fOHA t%3) way J)e used for the iroidmen! of 'hyperlrlgilpefkKi?rus feithei TG^SDOmQ/dL TGs^fJOmgidL, TG^eOrriQhlL, TG^O#4-499m§<pt,:, or TGioCMSCimg/dL? mwti dysHpkJemta, or any othar dSs#S*se&amp; # medfcpliepidiuon'? ap^oshc-d above. Such maihod of bestment provides to o subject 1h need thereof u dose of as least 30rt »y DPA-N3 per if ay.. alternatively at least 40mg ,DPArN3 per day alternatively at feast obmg DPA-N3 pe? day, sitomativoly at feast 6Qfng DPA*N3 per day, ilemdtdpfyAt feast 30mi ΡΡ.Α“Ν3 per day, «rtomaflvety &amp;t tab 90m$ DPA-N3 par day, i.sltari«ttefy al least 1Mmg DPAd® m® day, O' "oNi.1 a s. ist '*ό tig DPh-Ho ue* dav, jdnmd.vj: ·, at ^'t ' < , ΓΤΆ ,\ ,

per day, -.eiematively 5¾ toast ‘8Gmg DPA-N3 per day. e to ma lively at least doom,;:! DPA-N3 per day. alternatively at seast 250?ny DP.A-M3 per day. rftreroativeiy at feast 3G0mg DPATM3 per day, alternatively at least 3S0mg DPA-N3 per day. aferrialivefy at leaf! AQOmcj DPAdsii per day, attemetsvety at leaM SDCfmg DPAddd per day, sttematively at least 600mg DPA-N3 par day, DPA-M per day, alternatively al least lOOOmp OFA^ perf^ plerrmttyely al MatlMrng DPA*flf pAh dby::Altemafiyefy: at least iSDOmg ORALIS or stegiyeerot or ethyl osiers per day, while providing a relatively small amount of DHA-N3 such that the OHAtOPA dose ratio is to more than mere than 12:1 of' DBA; OP A, alternatively op more than 10:T of IlfdAfSPA, altemadvaly ho more than 8.1 of DHAiJPA. alternatively no more than 8.1 of DBA:DP.A, eitenatively no e^r®·. alternatively be more than 2:1 of DHA;DFA; .aifefflaiyeiy oo more than 1:1 of DHAcORA, a!temafi«iy 00 msrehtai· 1i2 of DBApBPA, alternatively no more than 1:3 of DHA:f)RAy sfemsatiwly fie more llifp 1.3 of DHAtOPA. alternatively p£> more than 1:8 of DtrfAtDFA* than 1;K) of DHA.OPA, alternshvety no more than T.tS of DHA:DPA. sdternotrvdy a relative dally dose of no more than 1 :¾¾ of DBA;BRA. f81.01J: The; present, iriventfon provides methods; of fedydhg O^lyoaddas AIM troatlng hypedddlyiiendemfa {either TGASdOmgfiL, l^A200m^dL, TGAliPmg/dl;:, T@2dO~4i#fhi|dL, or TGI50-ldimgfdQ, mtedd :d^ or medical oondltioos as specified above, by ddsfr^ te ® sob^ect in ooed thereof PiiiiaG dobh|apenfaeooic add |ΗΡΑ-·ο3) or its §^|||!'.;ir' '^t#rs. Snob : ftothod: of pr^\?Sdi|: a -Of at toot 10 n>g HRA-NS perdey. eltemiifi^ M ieegt IS mg .mg HP»VN3 per day,: alternatively si least 25 mg HPA-M3 per day. alternatively at least 30mg HPA'N3 par Pay, alternatively at tost 40mi HP^N3 par day, a$emativeiy at least SDmg; HPA-N ΐ p«r ttsyv alternatively at feast §0m§ -HPA-N3 par day, aiematively at to&amp; 70mg pardSy;, allirnali^ty at: liaal 8Gmg HPA-N3 par day, alternatively at: teas! #€$**$"HPA^rper day, alternatively gt IPaM lOOrng least 12C)mg ;HPleN3 per stay, difemafively at ;feto im®Q Mm« pf day, :a«sf?atwely at test 1€0mg ΗΡΛ-Μ3 per da/, altarnativ8ly; at :feapt 1»^ ΝΡΛ-Ν| par day, alternatively at feast 200mg HPA*N3 per-day. a!idfii§th*ety "M 1e££t1!!§0ni§ HPA-N3 par clay, alternatively at least 300mg HPA-N3 par day. aperaanvaiy at least 350mg ΗΡΆ-Ν3 per day, alternatively at least 40Gmg HPA-N3 per day. alternatively at tost 6¾¾ HFA-N3 per day, atemaMvdiy at tost SG&amp;mg HPAd© per day, :atiemalteiy:iat tost boOmci HFA^te orltpllypprpl or etftyi #!»- pipdiy,:: fttsat In seme embodiments, the oompbBlohP Of the present invention, which may compdie stgeiitcaiai an'iayets acid (ΗΡΆη$&amp;) or Its glydere! or ethyl esters, pay «ροϊ Ipr p#;. treatment (either TCB>2(l||mg|Slls of Tf ip- 1G3mirdLK ®κΙ ,iysliplderrtlp:i Mv any plhir dtooees or jmedlcal eondlws speeifed above. Such method of treatment; prpytoS: to o ptryeot In need th^maf i dose of at toast 10 mg HP^m per day, bitafhatiyply at HRA-N3 per day, alternatively at least 20 mg HPA-N3 per day, altemattoiy at least 25 mg HPrV N3 per day. alternatively at least 30 alternatively at least 40mg HPA-N3 per day, alternatively at tost 50nig HPA-N3 per nay attomahvoty at least SOm-g HP.A-N3 per day. alimnativdy at least 70mg HPA--N3 per day, alternatively at least 80mg HFA-N3 per day. alternatively el least 90s no HPA-N3 per day, alternatively at least 1U0mg HPA-N3 per day. alternatively at <east l20mg nPA-NS pgr cay. alternatively at least I60mg HPA-NB per day. aiLernahvely at least iSOmy. HPA-N3 per dev. alternatively at least 130mg HPA-Nd per clay, alm'-nstfvely at least ISOmi HPA-N3per clay,: ottemaiiveiy at least ?50mg MPA-M3 per nay. alternatively m tost 300mg ΗΡΑ-M3 per day. otonanveh d least Ί5(*ηο HPA-N3 "'nr clay, affaoiaivei at tost 4gomg HPA-N3 per day. alternatively at tost SOOtng HFA-N3 gear day: eternal!toy at least OOOrng HPA-N3 per day y atoned toy attemafivefyst least OOOrna ΗΡΑ- NO or its glyrorol nr ethyl esters per day. 3$I3$£ In otereteterifenbp Of 11¾^ |sn^s^nt fevsteorn widh tey o$$§i?fee significant vasfeeudife cf emdite aeid (HF^A-r-sSi or sit 0mmi. or ethyl asters and which pemphs© teaimiy small amounts of omega-3 docosahexaenosc acid |©HAm3), may he used ter ft# treatment #: hyportrigiycertemte CetterTe&amp;BOOmg/dL, TCIe20§mifdfe mfetitegtel, TG20i-mm$ML or TGtSCM^m^L). moted dyslpdemia, or any Ot medical conditions spsafcd ahovm Such method cd treatment provides ioasteect *n need thereof a dose* of of feast 20mg W>AdSI3 par day. alternatively at feast 2Smg HPA-N3 per day, alternatively at feast 30mg HPA-N3 per day, alternatively at feast 40mg HPA'N3 par day, a!ter«vd!y at feast least 60mp HPA-N3 per day. «Creatively at feast 7Qmg HP/VNd per day, alternatively at feast 80mg HPA-N3 per day, aHemaftively at feast 90mg HPA-N3 per ddy, alterristivoly at fed m lOOmg HPA-H3 per day, alfemadwly l2Wi§ HPA- -H3: par day,, aiwn»>*vNy H fete ttfemn ΗΗΛ m em a*v ntermrtvfcly at east 180mg HPA-N3 per day, alternatively aS feast 1600¾ per diy,;aifemativply at, feast 200mg HFA-M3 per-day, alternatively at least 250mg HNt« p^:dayy alternatively $$1. least feast 35©mg:HPAd^i: pdf day, isit«rn^yi@ily·^.^ί®#^·:· HPA-N3 per day. affemaiyaly at tepd «mg HP#H$ per day, aterpaivaly alfemepveiyai feast SOOrng HHA-N3 ortte prowling less than ISCtOrpg of DHA, alternatively less than lippmg of DH A, alternatively less than IdKtmg of DHA, alternatively lose: than 80¾¾ pt DHAf alternatively less than TOOmg of DHA, alternative lose them pOrdg # BHA, «Jferrfehvely fesi ihm 5CK>mg df SHA, alternative^ less ten WQm Of DHA. alternatively fees than 350rpg of OHA, aitemahvety less than 3G0my of DHA. alternatively less thee 250mg of DHA, alternatively less than 20(lmg of DHA or its glyedrel or ethyl esters per dey< ottemot5vely less than Alpteg of DHA, dffedfeively less than I20my of DHA, alternatively less than sf. ten 80mg of DHA, alferneflvely less ten S0mg of DHA, aiornedvOiy loss than 4%m| of DHA. alternatively fees ted-:30rrigtef'-pHAf-'';a^«reaiir^ tessthon 2Smg of DHA, dlfeffkSivoiv lavs !r\m ?0m,j of DHA m ,fe giyc^. -¾ λ fe; p oHote p" day Pf04] In further embodiments the compositions of the present Invention, which may comprise significant amounts of omega-d henofeosop-aniaenoic acid (HPAte) or its glycerol or ethyl esters end whrch comprise relatively emoN amounts of omega- 3 decosahexasnoie αοΡ fDfdAm3J, may? 1» y»b Ip tte tpatment df hypertriglyceridemia C either TfeSWra|iiL/TG^^f^gML, TOSQ©- 49«mg.'dL. or TG15<M99m&amp;*tfU mixed dysHpictemia. or any oiher diseases or medical conditions specified above. Such method of traalf^nt to a aebjeat in need femof a bate of at least 10mg HP&amp;4N3 §8*0 :ΙΜΡΆ«Ν3· per day, alternatively at least 20mg MPA-N3 par day.- atasefivoiy at least 2Smg HPA-N3 par day, atferrmiveiyat mast 3Pa>g HPA-H3 per day, atternativoty af least 40mg HPA-N3 par day:, sferrmtMy at·' .Jaeet ^Gmg· '':ΗΡΑ-Ν3ό|» day, atfemativeiy at least 60rog HPA*N3 per day, alternatively at least fOo^ HPA~N3 p^ day; eitarnaiivaty at taest ddmg HPA«N3 per day,^aiemefively at least ifptg HPA-® pw day, alternatively at least lOOmg HPA«N3 par day, elterrmi^ly At feasi^120mg HPA4I3 per day,; iltametivaly at least 150m§ HPA^Ml par day, otemativoly at least 160mg HPA-M3 par day, alternatively at:least 1S0mgΗΡΑ~Η3 per day, eterepiyeiy at fepst 2Mm§ HPA--N3 per day, elareativety et least iSOmi BPA-N3 per day, alternatively at least 3Q0mg HPA*N3 per day, alternatively at feast 35Defe HPA-dSf3 per day, alternatively at feast 4G0mg HPA443 per day. alfemaffvmyat feast StKtmg; HPA-N3 per day, alternatively at teas! BOOmg ΗΡΆ-Ν3 per day, alternatively at least BOOmg HPA'NB per day. alternatively at least mmm§ HPA-N3 per day, afferbaitvely at least I2()0mg HPA'N3 per day, aleoiadvefy at least 1 SOGfiflgn j^PA^3' W-M glycerol or ethyl esters per day, while providing a relatively small ampdet of DHAr® such that the OH ΑΉΡ A dose ratio is no more loan 15 1 of no mere than 12.1 of ΟΗΑΉΡΑ, rnMmmmfy m iOcfr^VDHAtHPA,· alternatively no mere thap: pf OHArHiPA,' dftf-5:1. et DHAiHPA, alternatively no more than 3-1 of DHAtHPA. alternatively no mere 3 " v<* DMA hHA. alternatives, no nvre ma n 1 ' o? DuAvnPA i to rmhv\ \ m mere than 1:2 of DHA.HPA, alternatively no more then 1:3 of ΡΗΑΉΡΑ. alfemadvmy no more then t A of OH A ΉΡΑ, alternatively to more man f. B of DHA.HPA. aimmatividv no mere then 1:10 of DHAHPA, alternatively no more than 1Αϊ> of DHAtHPA, alternatively a rslalve diiSy dope of ad :ppe ttad'1 :20 of ΡΗΑΉΡΑ, |Qlt35j The presam: feventioa, incorporates msfeods of trwfewt lor fiypirldilydoHdamla; fell# t^^CI0mg/dLs 'TtSal3®fe^fdLΑΤΒ2» AS^mpIL:,: dr TG130-lti9mgidU, mixed dyshpidemia. or any othpr: dfeeasas or Piedjcal conditions as,:Speoiiieb above* hycdoeing Id a edpieet Im aoad dieraof oot0aa^3''Ponlaenoic acids or their glycerol or ethyl esters, Theso methods provide to a subject te need thereof significate amounts of omega·-tepeniaensic acids or tesr glycerol or ethyl osiers arte white prnddhg only email amoyots of omega-3 -acid (PHAv«3) Such methods of tretemeotprgvietes !α &amp; ephfeot ?H odpd fhtedf a dose # at least 10t)mg omega-3' i^taendle. par day, idsorruitlv®i^''at'tea^t'2Cie.mg Omega-3'pent aeoofc adds per day, alternately M teas! adds par ildloaiiteiFMIdte .=·ί^^* alternately te adds per day, afan&amp;fively vat teas! &amp;©0mg-. adir par day* alternatively at teaat lOOGrrg omega«3-ptentaemte sods par day, alternately sf i«a$t ISOOm^ '^<^^i|ienteenoK·; aodi p®r day, sltesytetetely a! lead 1§8€Mng omap-i-pepteaapld ; aaldf ..par day, alternatively at teas! fODOrng ^.ef^S-ptntetddfe acids ,fter:ddyi:aitemtetesly at late 2SQ0mg omeped-panteened: adds per day, alternatively a! tead 290f)mg οΓη^ρ^ρ^οΜρρρΙο sis per day, alternatively a! least dOOQmg omeya-3-peotaeooiC aodc par day, alternatively at least 3500nig omege'S-pentaenoc acids per day, alternatively at least .dtiQCJmg oirsepa'd'pentaanoic acids per day, alternatively at feast 4tM3rng; nmegawh pentaoocic. adds per day, alternatively at least 4tG0mg omega-S-persteenote adds per day, alternatively at least 45d0mi :PPtd$\ ## day, alternatively at teas! iOOSmg omega-3-pentaeeolc adds per day, aiterri^fvaly at lean oSOOron oteega-d-pantaanese acids per day, alternatively at least 61tK)mg omeoa-3'pentaanorc adds per day or thei? glycerol W-p^-'^slerij,;tiMhlte'flte^^i' less than f900mn of DMA, alternatively less than 15®nig af 6HA „ altemattvely tess than i2iKhng of DMA, alternatively less tear* IQOOmg olpt#!,, osVmg ί>!' DMA nHornotedy tees than ?0Omy of DMA, alternatively teas tears GtKJmg / ! '* <-<, ,iten> 4i\ > V tesa tear m Omq of OH A altennte’lv loss trun ACRtrry re DHA, alternatively less than- 3i0teg of DHA, alternatively teas than 30Dmg of DHAv alternatively less tltert 2S0mg DHA, alternatively less idea 20Omg of DMA, afesti'aliveiv less te&amp;n tSOmg of QUA, alternatively teas teen f20mg of DHA, fiAd atiemeitive^ less than fdmg of DHA, elternaivefy fes Iter iOrng of SNA, aftemayvely tes® ten 40mg of OH% alternatively lass than 30mg of DHA, alternatively less than 25mg of DHA, afemtively less than 20oig of DMA or its glycerol or ethyl esters per day, P106J in other embodiments, tee mmpmtitesm of" the prnsonf foveolion vvtmte comprise significant amounts of omega~3“penteene!C acids nr their glycerol or ethyl estes and which comprise smalt of omegtef docetem^ aod (ΡΗΑ·η3), may he osed te mp TG>?ioteig^L. wmmm§m,* t^c^ita§fc m tgiso- 19fteg/dLK mixed dyslipdemtsg # ,;any other diseases # madcal conditions spddlfed- siteve, Spah. treatment: prevMeeto a ri^pd·: »: dose of at least lOumg omega-S-pentasnotc maG pa? day. akmTiammly at least Iflitilf idmoga'a-peniaenDtc adds per day,:0φ\Βί6Ν6φ':φ. 'J&amp;ast SOOmg oraega^ penteeooic omds per day. alternatively at teoet: SiK)m§ acids par day, alternatively at feast ?0fimg onmgoteperGenmc ados per day, alternatively "at feast QQtkftg omega^per^aen^i^i^v^r.^, altemiwly at feaet 1000ms omega-S-pentaenolc adds par day, sftematfvety at least fSQDmg omega'3-pcnmeooic adds par day, alternehveiy at least tQOOmg Qm«ga*3»pentae«Qic adds per day, alternatively at least 20D0m| #d1i|f-irp#ta^ete ^ per day* alternatively at least 2SOOmg omoga-3-pent aeooi s aete ae? day, alternatively at leas? 29Q0mg omeg?^3-pentaenofe acids par day, O'tsmatively at feast SOOtetg omega-G-pentaeoofc acids par day, alternatively it least 3§00mi «s^a^ penlaeeoic acids par day, alternatively at least ;¥MK)rog omega-S-perAaeneic adds par day. adds per day er their glycerol hr eibyleatem , wftlie provklieg a teatfveiy emal amoertf αΓ0ΗΛ-ΐΝ:3 aecit that me DHA:DPA ratio is no more tern 13:1 of OHAPPA. alternatively no more than 12:1 of DHA:DPA„ alternatively no mom than 10:1 of PHAiDF^ e^Pi^fiyely po momi^d S,1 of DHA:OPA., alternatively novmore.fcn: §ti.' no more than 3:1 gf DHA:DPAf altefr^aiyily » mar# than 2:1 of OHA.DPA, :^m^04r:^ fwr® mn 1:1 of PNIAQPA, alternatively rtemoiethan 1:2 of OHAtPPA, alternatively po mom INetT 1:3 # DHA:DPA, no mere than

1:5 of DHAtDPA, alternatively no more than 1.3 of DHA:DPA. alternatively no mom then 1:10 of DHA:DPA, atamahvefy no mom than 1:1 5·#0H&amp;O?^ ΙΝΗΜβββν#? &amp; relative amount of no more mao 1’20 of DHA:DPA |01&amp;T| In ott^er embodiments, the oompeieitioos of the present invention, which may comprise slgnifioaot Smoonts of omego-lhpefitierioto eoids or thei? glycerol oretltyt odpis and #mrh uvnenso eluhveiv email amounts of povga 3 doeoa,>He>,amte*c held C0HA-m3}, may he used for the redoohon of fr^tycetideS and treatment of: bypehr^lycerldemia (either TG^5CK)mg.'dL, TGaSOhmghtte T1PAl-$®mg&amp;tU IG2D0-· 43lkhqiii, or TG1hO"f§9me/dU, mixed dyshpfeemtfc Pi Afry spiffed above, Such ia#|hocl:0l a^p^eel iri n^ad fersal i dese of at least lOOrng omegaΌ pcoteenple adds per cfey, alternatively at least 200mo cmvegodvpmitaenoic acids per day, alternative!y at least tQOrng om^a^'pentaangic aecris per day. alternatively at teest SQOmg omega-3-pemoeneic ackla per day, alternatively at least ?OOmg omega-3-pentaenotc adds per day, alternatively at feast: 900sng dmeya~3-aeetaenc:c scads per day. alea^atively at least 1¾¾¾^ aesds per day. alternately at feast ISOOrng; ediaga-3-paataaddfe adds: per days altemaM^· *fc'1··** IfOSmti omega'3"pentaenok; acids pot day, alternative,^ m least 200° mg nmega-3-•paf|t^ofc ad<3e''.per «fay. alternatively at least 28Q0mg omegam-pemaenme acids pw day, alematlvdy at least 2900mg omaga-3-penteeeoie aads per day, ai^natiNly itlhhst per day, altarnaUvely at least 3600mg om^a-a-peritaenoie addi :p«r: :i^y¥ ittemmively aiMM 3§00mg; cipega^pentaeriold adds par day,· attamstfealy vfel fees! 400taq omaiadl* pt?ap - iS< ix a«. d* jn r d jv *.,> l'vn o v < rri oT ethyl rsta ^ λ ' lc provi »" v emotively arnefi amount of DHA-N3- such that t^esOHAi-NPA ratio is : eo more than 13:1 pf dtameliyely· ne mpFaihea :f2;4ailematicsiy no more than 1 0: 1 of OHA .HP A, alternatively rfe mora imrt irl pf DHAtHRA, aiemattvefe no mere than Gti of DHArNPA, afemabvely m moMihaa 3:1 afenofively no more than 2:1 of DHA.HPA. alternatively ne more than t;1 of ΟΗΆΉΡΑ, altemafivaly m rrthri: than 1:2Aof BHAtBRA, alternatively ·#0· mitm. IlMtt ifS'fef. ORAIHRA, attemaiMy m more than 1:S of DHAiHPA. altemhttvely « mora then 1:8 of DHA:HPA, alternatively no mom than 1:10 of DHA:BPA. alfehietlvoly no more than 1,15 of DH.A:HP,A. alternatively a relative amount of no more than 1Ή- of DBA: H PA, Ι010S] to further embodiments the compositions of the present invention, vvtvch may comprise Significant amounts of omega-3-pentaenoiC acids or mesr glycerol or ethyl asters and which compose relatively small amounts of omega™3 docasaliexaenoie acsd rOHA-n3i may be peed for me redeohpn of ingiyoendes aed ieiimehf of bypedrtgiyrmddemis farther TG>SOCimgAt.,: TO>2t)0mg/dt, TG 3 1 SOmgAlL, TOJiG^ieigMLy er 1A»1bO-i99mgfdL}? ml»d dysgptdefdia:, or any othef diseases a* medical conditions specified dlbVAi provides to a subject m mood thereof a gjjjMt! ΦΜ acids per day, alter natively at least 200m<j oh^s^xf»enf8iwfe''':SP0id»·' iw· 4sys after.caiivoly a? toasr 300mg omegs-3-pentsermjc acids per pay, alternatively el feast pentaeooic acids pfr % least SOOmg adds p# altomitfveiy at leas! lOOPmg {):ras;:ga-3^aalaaaQte adds per diy, teesF'l SDDmg omega-3--pootPop0io acMs par :dP$ aftornetiveiy it : tiCMIrPi csaiaga^-pa^asaaife adds par day, allamalivaly at lead, 2i£lbiM| Daiegs-S-pentaenoin accis per clay, adamativety at least 250Qmg omecpKh .^ntaerteid.aeids per day, alterpaiyely it least 23Q0mg omefa^pPrdaii^p eel# per day, alternatively at ted-^toeOifle imaga^3^perteenale adds per day, alternatively at; least 3S0tMg omega~3-pontPonpId^:^ m: least 3t>00mg efa^a-S-periiaerkaie adds per clay, attpmiivMylet l^ast 4pOdmp ;&amp;met|a-3-pentaenole adds per day, altemaively at lead AIQQmg apipgavS-piPtpepdM acds per day. 4900^ pm^a-3^pntaei#ip aelda per dii ilternalivety at :.'^©©Ortip.: :mM&amp; -/.pm days attematwly at least SSOOmg enippa-^ppntappid adds per day, ittemaSvaty a| least aooomg omsga-S-peaiaenoic adds per day or-their glycere! dr ethyl PStant, white providing a. relatively small arnoam aF OHMN3 #rt^irapire#^ # omega-3-pentaeooio adds (H3-6eaoicFA) soch that the DHA;H3-5em>;€:FA ratio is dp more than tS:l of DHA:hl3-5anotoF^:itt©maively m more thin.

SepoicFA alternatively no more than ItM of OM^iNiMapateF^': mere than 8:1 of DHA N3-«5enoicFA:, alimaiyely Ms more than $:1 of DHA;M3-ienolcFA, alternativaty m ftem Sfid 3:1 af DHA’^Sanilc^A, aKrrta^ly do more than 2:1 of DBA:N3-bonoicFA, alternatively no more than 1.1 of DHA N3-SeomcFA, aiiematlvely oo mpini iiah 1:2 of OHA.:N3-ieael€fA, altematively bp more than 1:3 of ®tA:AI3“i®npfPFA, aiwnatiwiy oe mom than 1:$ of DfiA:N3^adoicFA, itemaively nomomthim.1-:8 of DHA:NI3-SonpIoFA, attemattvoly op mom fen 1:10 of DMAtCFSenosoFA. allernahvely do more than 1Ί5 of alternatively a relative amount of oo more than 1'20 of DHAiNS-iaholPFAi |Qt#i| to some embodiments, the improved profile of the eempodtidds of ti# present Irwentloo may dp |pmppsfrited ypon tremment of a aohjoet fey diilereMtatly ifePdi flw ratiorrand fragments tdomoi Jalao tnowh as pIMoW midropaMoJoil: Seed fragments may fee:oyaliafidmivi whole or ipmlopd and described as ffaqmvd eur>-w.b.ifiortes |P110j to other embodimaats. the improved pmhlo of the compositions of the present invention may ho demoostmtbd upon treatment of a subject by dffemotsaity -dte'mo h, ~>ad ke cc ,.i. ] * < bk«->d | pc k is- and s ^mtms thereof e-hvr sn mating ateto inon-activotad platelets) or activated;#;^:,: pill] l«- "yet. other embodiments treatmsri ol a sdi^abt or patient with compositions of the present seventeen affect ft# coagytefory cascade and dsfierectiall^ alter eoarjulation or blending fimeo or piofeioi aipsgaian dmas md:. demsrty.

[01 1 2f In fijrther embed imenfs, WalMrt with cote|teslt|@r?s;df tlte present Invented; rrriprords Ida vascular heaini; process In response te aifeitpsnle disease, SuA healing may he demonstrated by reduced stenosis andter restenosis over tme% oydttddd Pf lasser increase in rnfema-medta artedai wati, larger lumen -size andior larger vascular diameter at vsssuiar sites with stenosis or clot bdllhppr.»vdelarmtefd' -fey;.r^;.'lii%tr^ya^ey^r «Itrasoyed fiVIJS}, radtegraphite ytiras»ur$d;, tomography, teigrtette h&amp;^rteooa Interterdoop '0$$% dr aii#r addpptehie methods, in heafeg may to 1vm n nod hv n\ vasua.a wmf wiposrtbv»» λκ h as a T*soyc©d foam bill : pmsence - or f ibtei atod feuo In the vassal wal in yet such

Impsoyed vascular healing is demonstrated by improved inflammatory meteors In the vascular wall |0113] The improved profile msuling? tern IfSAstertt- with :9m: present mverteon may also be demonstrated by a differentiated impact on blood/somm/pjasma lipid and apoprotein tevals in a fnamriii^ltt^a· MoNte, but iti not limited to; Triglycerides -: TG). total<;hotesteroi ebri-Mfcctetesteml LDL-chcieslemh VXQL-cholesterol. apoispoprotein1¾ ippllpopmtete^Acageflpoprotein €h id HDl-cho%stemc and Lp-PLA2 The compositions of the pmasini! Invention may' also be used to provide a beneficial impact on the one or mar# of the following; ape lipoprotein ΑΊ (apo Ad) apoiipoprotem B (opo B}; 'apg lipopsOleinfa) (Lplaj), lipoproteiivassoeiated phospholipase A2 (b.p-FbA2^ low density lipoprotein ?LOi) particle nutobei and sore, o<id*2e4t£3L* ;CRP:·. high sensmvhy C-feactive protein (HSCRP1. sotraPaliyiar adhesion rnotecyte · 1 (IC.AM-H E-selechh, P-seiecbn, vascular coll adhesion molecule 1 (VCAIv't-l} or cipstgr of differnhat-un 106 (00106). interteteukm Ί&amp; (IL-Ίβ). idtedpytenhi:flc-2), inierteukirHS (11.-6)- interleukin-·* (11.-8), interleukin-· 10 (IL-IQ). )nterfoutete12 (11.-12¾ intariepkin'15 ht-ib) teterteukm't<8 (11--18¾ turoor neorom teotohalpha (J!#Bo:)s tiimbf rteoDam foettedtete (ϊΝΡ·8,\ plasminogen activator inhibitor-1 fFAl-1)» SI (TXSi| thrombo^aiw A2 (TX,A2):. 2>dirter it. tree tatty acids {FFAi serum amyloid A1: :iE«yfcid A2,:; ©©rum amyloid A3, serum amyloid A4. thiobarbituric acid fTBA} reacting material, arilponecfio (®ΒΡ·*2θΚ P©mo§lobid Ale (MhAlc }. macixiphas*·; colorty stimulating·. factor (P-OSFI pandigrAid; maumptego · ootety stimulating feeter: |.®MhCSF|j, fllddogAd,: Fbrin D-dimer, platelet φΡ^^^Ρ^^ΙδίρΙ,. Plpn :^^.^y:^fum©:;··:' :(MFV|, platelet aubpoputattons, head rate, systolic and diabolic blood pressure r^l#pr4a«^iQf-l^pp4i9N*©WP cmhance? of activated B cells tNr-Kpl adenc^vv diphosphate induced platelet aggregation platelet ondotheiusi cell adhesion molecule ,(PEjDAM-tt vlfoodPid fdbeplor itej*}, &amp;r*d glycoprotein ilbiflta fgpilt>/lifa|, Ttif «empes.iti€ms of the present iaywslipa ./:im&amp;i$·· ato |?g in methods of ffMtong, prevehitog, and reducing symptoms associated with conditions associated with the above. pil4J yetbods io determine comparative bJood^rum/piasmp· IpM -and itpopreieiit levels and therapeutic effects on these levels in mammals- are generally teow fe those efelfed In the art and are typically based on fasting lipid and lipoprotein tevels. Differences of active treatment versus placebo era aeooraity assessed on o group of subjects verses another group of subjects basis, with significant changes noted If the pwaiue lor the appropriate statistical oom^^h':lsi::P4|i# isWtess tte 1)..05. P-values larger than It 05 but equal to or lass man 0,10 may be considered berdaline significant ies). P-vaiuns lasger than 0 10 are generally considered not ei^r art fN5u In o Ne enhod rn^ \ h e d frem with tte < pcs tense* be < < _ i invention is mom f. oteni then ->thw ^nega Λ cnmp'eih"v Kurwvn m mcir to

(such as LGVAZMB, ΕΡΑΝΟ VAm or APR1011 Iri reducing ae OPfifpiiil to placebo or baseline- TG Iwate, TotattoMusteroi Iwsltp psrvHDL^hotesterot love's, VUQt.-phbiostemi r.hotesterni levels, apolipoprototo B teveis, apoiipuptefete CF lit tevele, tp-FLAI levels,, or any combmakons thorenf. in other emfcodimwdtss, such more potent : effects in reducing thane para re meters are achieved in pslients with baseline T®. pypr In :petibnte on eighh-trealment with baseline TO in the

200-4119 mg/dL range* In patteris. net on statin tmafm&amp;nt wrlh baseline LDL-chbldstefpt of: lib: -jpg/dL or higher and with TG in the 0DD--7OO mg/dt rsrvgo. in patients npf pdetatte treatment with baseline LDL-chalssterol of IDO mrj/dL or higher and with TO In the 3S0--7OG mg/dL range, in patten?» not on statin Iroatmont tote Pastorne L DL-ohotesterol of 190 mg;dL or higher and vtoh TG in the 390-750 rocpdL rang», m patients not on statin treatment with baseline LDL'-cholesie-oi; of T<0 siipdL or higher and with ?G i the 050--> OCi nupdo acs. or so gahenrs oor όο storm >*" 't ο o hs v^mo πμ n KDt -t > 1 ’-dmo! of Λ'ύ n ' 0 " ohe1 an 4 TG in thf 3pfr?d0: higlli: 'irdrtge, *.'·> in pm <. Hs not on tat n Tonic >·ν+ w t oase i j rw:-HDL-wbotesteml of 200 mqML or higher and with TG In ts« 350-700 mg/dt range: ., or m pabenG not on dahn m-Mment With baseline non-KDL-oholesh-mi of 200 mgfdL or higher arid wih TO to fie tango .. or In parents not: dh statin trihtfaani with baseline: pprhHDL'Choiestetoi of J»K) rg^l or hj v* and wrtn TG m the 350--750 rog/dl range.

JtITSi irt. a fydtw erphedirhahh ;ffghfrnhhb with the &amp;:Qm. -0fl$fci£r ihvenihh fogeiw with : Main therapf la: mo^v pslpnt than other amyga·# compositions known in thi phht:art tsfbh.f s LQVASft hr AltilR101} lb reducing as compared to pIa®ho » »eeirne: TG thtfetsdTotehDMeateral tevelh noe.HDL-chniestafti tevflih VLQL-ohotesteml tevalM :LOL<hofeatMei ievei^apotipoprotein B tevols, npotrpopfwtein C-lll fevMs* Lp-FLM Ifevefep nr any combinations thereof, in other emb^smentB, syoh more potent efests In mdyping these pararemefers ore achieved in patients with basehne TG over SOD mg/dl, in parents on statin, treatftift wPi-fcipalr» TG in the 2111-4¾ not on baseline statin teatWRthsiih baseline rfigl’dL of higher and With TG In the 2i0~70i; raghtL range, In treatment with baseline ;# '^^.:'^t'^®i:|h: Hi# 350- 700 mgtdl range, 10 patlaats not oholosterot of 150 mg/nt. or higher apd with T® In the ^h-TSfl rnghlt tangth In patients not on baseline stafen fmatment with baseline tpL^MleslWt of 190 ntgMh or higher and with TG in the 350-750 rng/dL range, or in pihphts mt on bas#tlha statin beatmoni with baseline nonTlOL-choteMero! of 20Q mgrdt or higher and with TG in the 300-700 mg/dL range , or in patients not or? baseline statin imatfnent with baseline non-HPL-cihofesterol of 200 mg/dl. or higher end with TG In the 3S0-700 mg/dl range , or In patter#:.:r#ipi baseline static teatrnert with baseline non-HOP dtotesferP of 2C© mg/dl or. higher end with TG in the 300-7SO mg/dL range, oral iddWlfP not: on baaeiine sfatirt Iff effhant. with ha#tne ffbrh!®^^ mg/dL or higher and with TG In the 350-751} mg/dt, mf>ga„ [0118] The present Invention also provides πηΐΙΡηςίκ of nxiacing rnglycoridpa levels id a sataeet. wherein the non-HOL cholesterol levels sooh as LD; -ccolmaanpi lewis, of thesyfefaet are y.--¾^¾¾.. =fαr^4¾^rϊ:>#ies. levels t»<afor^..tiK^^trtmr^ti:·: 1^:. trealmeef the compositions, of too present invonhon results so u iwnor peas then 10¾ change from baseline, alttmetlvo!^ feat titan 5%} and/or nonsignificant change to hi»H£3L rtoetoaferdi levels fsueh m. L0L-qtefesfe^i:::feti^ii· as eompamd to piaeifeo\|&amp;ΐρβκΑι, v^th baseline TG levels altoi^iOer in a toriher ^ the eampdsiitons of toe present tnythttoh msufts In levels a# compared: to plaeefoo In^ paianite with haeeiioe 1¾ Ito^Is above J5C10 mgfdL to some grohodlttiento, the methods Involve ooadmtoish^eh Cf a stain.

In another embodiment, treatment with live composlttone ef toe present Invenlito ap compared to placebo does not increase LDL-cholestorol levels In patients with of 20to4Si:mgtoL:^ statin therapy.

[011?] In yet another ernbcdlment treatment with the composliona of toe present invention as compared to placebo results In significant reductions in LDL-ehelesteroi levels <n patients with baseline TG levels of 200-409 mg/dL white m statin therapy. [0118J In a further embodiment Itee oempDeitions of the present invention as compared to placebo result in significant redactions to LDLchotasteroi to veto In patients not on statin treatment with LDt-chelesteml of l§0 mg/dL or higher and wilt TG in toe 300-700 mg/dt range, to patients rt#.: oi;' -photo stem! of 190 mg/dL or higher and with ?β. in' '?£(&amp;£' :to .paieilfsrrtdfc-wisfaih with LDL"Cholo§te>l TG In the 300-750 mgtol range, or in patients not on statin treatment with: LDL-: naiesterp! of 190 rng/dl or higher and with TG in the 360-750 mgtoL fahp: Finally, another embedimom. the compositions of the pteseto -invention m pampered to pjacebP msyi In significant reductions in LDL-cteiesptol ieveis In patients not ρη non-HDL-ohotestoroi of 200 rngtdLbr higher and with TGInthe 300-700 rngodL. range, in patents not no state treatment with tVo?>HDbcholetueroi of 200 mg/dl or higher and with TG to the 3S0-700 mg/dL range, in patients not on statin treatoiant; with nen-HOi-mholestero! of 200· mg/dL or Ng|tor arto with TG in the 300-755 tngtt: range, dr to patients not on statto tr^ito^ with ohi>iesten>i of 200 mg/dt or higher and wih Τβ in the :350-700 mgrdL range.

[0119¾ m another embodiment, treatment with the composlttons at the present invention tpgpther; with etatto Tbempy rpsylts m significant reduettone to tpt- cholesterol levels as compared to placed in patienm n,n on static treatment at :-.£meiiheswitb' I DL-chofete&amp;l of 190 mg/dt or higher and with TG in the , , ' «> mg d n v,t m mMus not Oh Ki''*! r*^ ϊΐ, +ιΌεκιΙ r^* Ot- cboiosieroi of 190 mg;di or higher .wd w?fch TG in the 350-700 mg/dL range, in pntihats not on teioltesfafe ireaimorst with baseline LDL-cholesterol of 190 mg/dtv ' T&amp;iSj' tte;;a^0r7iD mgdt -ήΐηρη of fo ^treats not on basalt: stife treatment with ba^eiloe LBlrOhofestorbi^of 1:90 ipg&amp;fL or higher and with TG Id the 350-750 wg/dL range, 10120} .Finally, another embodiment, treatment with the compositions of the present Inyeptteh tPgether with statin therapy tegrifel· reductions in hOi- cholesterol: Istmte as oernparect to piaehho tp i^ehte not an treatment with haseilhtnop-^ mg/dl or higher end wib?C7 in the 300-700 mgfdL raiip, in patients net with bssefi» namHDL-diolestere! at 200 mpfdt or TGdn the 360-700 Pifdl range, to patients not pp haaalln# statin treatment wlh peielpe noreMOL-ehoIesterpi of 200 rogAJL or higher and with TG m the 300-730 mghfL range, or in patients net an baseline statin treatment with bpseine <rf or higher end wtth T© in the 350-730: mgfdL range. J0121| in anotherembodiment, the cornpoeSsona of the preseat lrweribn are there potent than other omega-3 compositions known in the prior art (such as i.OVAZA-d, £RANGV'A5K< or AMR101) in increasing as compared to placebo or baseline HOL-choiastere! levels, apohpoprotem-A levels, ora combination thereof, :fp;l^i}; !h leFahpthnr embodiment, the compositions of the presedt:vlhwhibjb··^ more potent than other omega-3 compositions Known in ;fbe poor id Csyphv-ns EPANOYVVM or A.MR101) in decreasing as ,:si»Ri^t:ed· ;:to·. jtopb© M (ApoB) lewis, Apallpopmtslh-Gltl Jtpfs, tp-Pl.A2 levels or ap|i: pomblhatibn themcC: fbl2B} In further omk<>\n'enN s,hv compositions di: tea preseat invention as

apmpathh to placebo m basilme are more potent than other oaιβί^τδ(bomposstsorts koowni ta. the :pflor ah tench as LOVAZA#, EPANOVA^ or AMRIOi) in reducing TG

mershpe in LOL-abgieetem!:, a falser nonmigniiiand increase In: LDL-chotsstsml. no increase in LDL cholestore! ar all, ora mom potoof reduction in LDL-ohOtestarol at in patterns with baseline TG tevois above-506 rnghliL P124] in some enfoodiments the use of the compositions of the ptesent rnvemioit may alter for a reduction in foe dgae of fie testin mooted ifi sbift. P# Otemple, The «administrate of foe «mposiion of the p®$mi Inytntfon la a subject receiving statin therapy may alow for foe reduction of the dose of foe stem wopomd fo sobfte not bifog pdsibmfoitered a composition cf foe prosoot invention: In some embodiffsents, foe dose of the statin may be reduced by at test ip%i alternatively at teas! 21:%* alternatively at test vipp, or alternatively al least 7$%, filial: in sonm enfoodfmerte the use of tie eorapostens of fifopboent teerteh may reduce the lime needed for a subject to macb the recooimcndod teod levels.: Per example*th^ administration of compositions of foe pteasoi fnwfotno may allow a subject to roach goal lipid levels, for example, those described m the NCEP ATP iff Gfodeifoes, or any levels moommended by a heStfotere pmotitfotm fo some emfoodimoolB* foe redoefioo of time is greater foen :5¾^altemattely greafoc Ihan 15%,. alternatively greater foam 25%, altematrvety greater than 60%, and alternatively gtetorfopri 7S%, lAif Ttetemppslfons of foe present inventfon a# otso hei;d::dteiffo (CHO). vasemfor liilso* ifotrotplpfofb dfobaa# or relote Tbs compositions of the present invention may ate fe&amp;ifcfgfe for Ib'e and/or prevention and/or reduction of cardiac events and/or cardiovascular events ano.-nr vascular events and/or symptoms. Determination of soph curdiovascuiar dteesos/conditions and prevention of evoris/sympfoms In niarnmals and methods to determine treatment and preventahvebhempeutfc effects therefore are generate know to those ek.Pted in the an, f§127jj The present Invention nfoo folete fo Imetment pi seef oenf tens In vdfo ddn«foitant tdetfoodtl regimes or combination products with other active pfomecoyfioa! foifodtefov Such concomitant or foted .rfffy include a state, an aoilooaibteif Couch:, m fospldn or cfoptdogreip m anahyperlesslvf isute as a diuretic, betmblocker, calcium channel blocker. ACE* mb! bite; .11 l.m^pir£3r anfogohfpfl, Or Other treatment for cordsuyaeogte^

The present mw-mhon also includes pharmaceutical compositions, for example, a enfoteeaqei comprising one dr more HMG"CoA rddoefoie inhihlfofo |''teifooG and; the fatty acid opfBposItion of foe pmseot fovooloh, Tffo pmseot ioverten may mm feibwn or lulore statthi; la an amount generally recce vs cod os safes Them are currently seven statins 5hat ae wsjmv avomhie. ais'jfv.-'hvtatsn, mouviistHto, ilnvush-mn, knustuhrt guineas woo roro-colcOn, rod siOKotedn An regM slatm cenvustutin, is as been οοονον inco the; U S market at a a.·.: fme of too wnboq However it e, com'eivabto u> one skilled m liar? art tom ehhvagfatih may b® u&amp;%1 in eonjumtbon with soma emtjoekrrwnis of the present Inxantiqa if cehvasfaiin Is ultimately dolftnasnao Ic Do safe ami effective in certsm tmatawii mgifMiaa. Such stados are typically ι&amp;ίχΙ at I hair common daily doses which include bui we not limited to lov'astabrt IQmo 2Unvg. dOmg; p-ruvastalw 101119. kOn-d dOmq. hOmct. shnvastatiP 5 my, iCJmg, 20mg. 4C)rnd SDron; ffewwtatfe lODmep 4dw-y. eOmq alorvasinlin tOmcg 20mg 40mg, drtwy; rosovustafin 5mg. lOmgt. fejmcj, 4 it γγ;γ|, ,-j n<j pitnvnsfahn 1mq, It mg 4rog> dmg. (01281 Generally, the effect of sfabns -s dose dependeno ; a the higher the decs the greater the iheiageutfe effect However, the effect of each states a a re rent a ad therefore the lever of therapeutic effect of case statin can oat ha acaasaana no directly correlated tu the level of therapeutic effects of other statins For a core·pic bo availability vanes widely among the statins. Specriicaifyc it has been spawn that simvastatin !e feaa than S% bjoavaifebte, whslh ffeyaststirt is appipxfiwttily 24% absorbed at rates ranging from about 30% with iovastatln to 98%. with fluvsstatin. Pimbpess metabolism occurs In ail statins accept pravastatin Pravastatin is also the least pmterh-bound of the statins (about ίϋ%). compared with the others. which are more than 90% protein-bound Accordingly the stakes possess distinct properties from ope:pinother. The oomfenafine products of this mv#htsort involving each statin ora plorelfty of efaties are also -distinct, Ϊ01291 The present, inveptioh also Includes methods of trsaimeoh eomprirtirig Posing id' one or more atutins and die ernegmh fully acid compdsijior of she present snviu’ikon, rather as cormorndaet therapy or in a liked dose oombmotbn prodfew composing both a claim and die compoehon of the present jnvwife.im This method pi teatraeet eothbihes the adhtlnlstreiPrt pi: pm or mtp epmmbti doed or an silemaive Ρφφ. with Itie cdmpgaltlori of the present invertttoa |&amp;13-01 to · the compositions of the preeortt. fnvemtoe which:

comprise significant amounts at oruegow drioosaperhaerioic add iQp.Aw3) or its uivcxnol or ethyl o^turs. together wth 0 common or stt«ffi£itive statm dose, may no used for the treuimer'il of nyperinglycendemia (either TGhP00mg.!dt. TG svOOmgA'jL ':;ΪΊ3^;ΐTCS: IG 1iO-1 ilm|^d:L), -^b^dysiipifemfei or any ottSfcr diseases or fried ifei eonciitfens spetfted- Above: Sootr methods of irgsimfet provide to a subject in. need Ihereot a dose of si feast 3D mg DP A· N3 per -lays ePo;: :,dlveiy at feast 40mg DPA-N3 per bey utter njrrveiv s< least bOmg DpPvHd per da¥, atte^^ivsly at teaet bOmg DPA-N3 per day, alfenfeivvdy at feast fOmg DPA-N3 per day, ultemabvdy at least BOmg OPA443 per day, oifernnUvely at feast RQmg DPA4M3 per day, feitemaiivfety at least 100mg DFA-N3 per day, altemMiveiy at lafet 12Dmg DPAsHl per day, aSteFnattvaly at leagt 150mg DPA-NS per day, alfernafety ;j$-fe0i£ 1'SQfeilg f^ojitay. attamativaiy M i#a^ 180mg DPA-N3 pfr fey, ittAraalvaty at |aast ^SCIaig DPA'-Na per day, altpin^iityely at feast g50mgDPA'N3 par day; ateMfiyaly at iaa®t 3®mg D^Mttf^rfey, attemaMy.at laast 350mg i($PA^j^ tigy,. alternatively at feast SOOmg DPA-N3 per day, alternatively at feast 8GGmg QPA-P ΐ per day,. afemshvefy at feast 0O£img DPA-N3 cm its glycerol or ethyl esters per clay together vv-fe a common or alternative statin dose. In some embodiments the coni positions c? the present inventory whioh compose significant amounts of omega-3 docosaponfilpife add <HPA*n3) §r is gtycferot or ifhyt safes, together with a common or attfeilm ffein i&amp;m, may te used for the treatment of hypeingtyeaddimia feifw TQ^StongfcIL» llSAldOmgML, IBSffe 4§0mgAtW or t^0»idfillpidamta, or any oiw diseases or medical conditions specified above, Such rpfeitoefefe^

In need thereof a dose of at feast 10mg ΗΡΑ-ϋ3 p#rfe&amp;. ISmg

BPA*Hi porday, alfenratdeiy sffea0f2Pmg HFA-BS per day, alternatively at feast Mmg HFA4P ife doypaifomaiyAly li feast SCImg HPA-443 par day, aifemahvoiy at least 40mg HPA-N3 par fey, aitenativaly at least 50mg HRA-143 per day. a ittarna lively at feast fi€ mg HPA-M3 per day. atfematlveSy at least BOmg HP A-N3 per day, aifemfevdly at lfefe@f)mg HPA-N3 par day, ojtamattvafy at ifest 12f)mg HpA-N3 per day, aifernabvely at least 150mg HPA-N3 par fey*-.-nMemtivefy; at feast ISmg HPA-M3 per fey. alternatively af feastAfemfBRA-M3 per day, alternatively, at feast JSOmg HEA-N3 par fey, aitamatMy at feaat 2S6mg HPA»M3 per day, alternatively at. feast SCImg PRAfeiiypfr day, iligrtMt^ HFA-feO per day, ilfematlfeiy a! fefe4€!§m§: BpAs® par day, felfefeaifety at least SOOmg HPA"N3 per day: alfemaifeoly af teal-iSC)tf^iNFA-N3v,ip^::feyi:--alta'rr^ti«ly· at least :f;pmy ΗΡΆ-Ν3 or -dr :dthyi Mini:'p^ ftg# ί^φφϊ a :p:mte;n or alternative statin dose, :|Ι1Μ| the compositions, of the present invention, vmich i^mprtso: aigntiasnt amodhte. of ontega-3 docosapentaenote add (DPA-nGo or is fftoarot or ethyl .pompdse relative srnaii amooms of omegas dodoaahexaenoso add (EMA-mB), together with a rmsmdrt oln^mpve «tatm dose., may lit ipt for the tmahneri! of hy^®rfef^yooridomi¥ TG^OOmyAiL, TGitlSOmgKiL* FG 20iM<>Smm'dL, or TG 1SQH9SmgAiia nuxod :tlyal|pld#mla, « any other diseases or medical mnddihmf Ipdetfh# abdm Sydh me^^:^ffreafrnent provides to a subject In need d>emoi a OdOpKm or glomitivo stafe dose together with a dose of at least 3Qmg DPA44S per day, alemadvety at least 40mg DPA443 per day. alternatively at least Simp pdf day,: alternately at least 0€mg DPA-N3 per day. aitwsafcvsly afjteaaf -day, alternatively at least ODmg ΟΡΑΊΊΒ per day. alternatively at foes! IlCImg DPAr N3 per day. alternatively at least 1S0mg OFA-N3 per iSOmg DPA-N3 per day. alternatively at least ISOmg DPA-N3 pM day, eitOBiattvaty at least 20Gmg DPA-N3 per day, alternatively at least 2§0mg ΡΡΆ-Ν3 per day, allnmaljvefy at least 300mg DPA-M3 per day, a^^ativelyi|if;^M:3§^^P^W^ per day, alternatively a! least 400mg DPA-N3 per day. alt@mat»!y of feast §Q0mg DPA-M3 per day, alternatively at least 600mg DPA-N3 per day. alternatively at least SOOmg DPA"N3 or its glycerol or ethyl esters par oay. vd^!!# pmvppg Ipsa than 2000ntg of DHA, alternatively less than lOOOmo of DHA, : altproaflwdy fssf: tliPP ISOCmg Of DHA, alternatively less than iBiOroq of DMA,

1000mg of PHA,;; tests than SOOmg of 0ΗΑ*. flW TOOoig of pHA,: Altimatiyefy: less than 6€0mg of DHA, oi DHA, aiietnatnedy lesttfsah 400my of DHA, alternatsvsly;teasPHAj alternatively less I hart: 3CKJfhp of DHA, alternatively loss· -::9>irt· $50ί|φ Of ΟΜΑν otte* natively less than 200mg of DHA, ' l®m. $Prt 461¾¾ of OHA, than I20mg of :DHA:i alternately foes than iOOmg of OHA, idfefTtttiy^iy iasp than 80tng of DHA,, alternatively lass tteo dirng of DHA, allfrnadvdly lap than Sdrrtg of C1HA* alternately laid tiirt:'·. rtf SNA. adamaflvdly teas than 3tog of DHA, altemadveiy le# t#t df DHA, atemadvely teso then 20mg of DHA or Me glyoorel or ethyl astern per day. pi:12j Irs other the cempeslhhins till pi|#S wlich connpns© significant amounts'·^ ornege-S dcx.x»sapenfaenote acsd {.HPA-ri3} or tis glycerol or ethyl «$tor$ end yvhfch comprise relatively small amounts of omsQa-3 donosahsxasowc acid iDBA-nS), together with a common or alternative statin, dose, may be used for 1½ tmtrnent of hypertngfycorid^mia (either TGP6CK)rng/dL TG^20€rn.q/dl,: T^aliOmgfdL T(S 2G0^fl9mg/dL or TO l$0499rng/dl); mixed rfystipidomig, or any other diseases or modteat conditions Snoh methpo of treatment provides to a subject in need thereof a common or afemnTive sfehn dnse together with a dose of at least iQmg HPA-N3 per day. alternatively at inaot 15-rog HPA-H3 per day, alternatively a? teasi 20mg ΗΡΆ-Ν3 per day., alternatively at least 25mg BPA-N3 per day, alternatively et Hast Ik rep ΗΗΑΉρ per day, alternatively at least 49mg HPA-M3 per day, alternately at least SOmg HP A Ay 3 par day, alternatively a! least 6Qmg HPA«M3 per day, alternatively at least aOmg HPO-3J3 p^r dev, HtemaavHv at least CHlmg HPA-N3 oar soy elfernahvely at least 12Qmc| HPA-N3 par clay, alternatively at least t50mg HPA-H3 per day. ailernatively least 160mg HFA-N3 par clay, alternatively at least tdOmg NPA-N3: per day, aimmahv'ety at least 200reg MPA-N3 per day alternately at feast 2S0rng HPA-B3 per day, alternatively at least 3D0mg HPA-N3 per day, alternatively at least pOmg HFA-N3 per day, alternatively at least 400mg HPA-N3 per day, afernattvely at teaaf 5D0mg HPA-N3 per day, alternatively at least eODmg HPA-N3 per de^ iltemaively at least 800mg HPA-N3 or 4s glycerol or ethyl esters per day, v#tttepmvMipg f« ?hsn 2000mg of DHA, altomahvaly lees than 19Q0mg of OHA, aitemaflvely fees than 1 §pmg; of DHA, ; iltefnefiyity: leit: tipi 12iDm| of OHA. alternatively less then 1{K)0mg of DHA, alternatively lair than §$pm0; #,¾¾ lead tltep TOOmg of DHA, alternatively te#i tW 80fcg At of DHA, alternatively less than 4CH')mg of DHA, aftepalively less then SSpmg pf DHA, eltarnativoty tees than 3CAtmg; of OHA, aiternatwly tees then ShOmg at SHA, aftetnteiveiy less than 200mg of OHA, alternatively less than IfcOmy of DHA, iltem^fiypiy less then i29mi if DHA, mftematteaiy less Ihip iOCfei df OHA, alternatively less titan BCtmi of DBA, aitefflalivety less li^ ^ DBA, alternatively tees than i«| i OHA, aiemehv&amp;ry tess then Aarnn rjf DHA, ahorravvHy less than 30mg of DHA alternatively less than 23mg ot OHA. aHematfv^ty tees than 20mg of OHA or Its gtyseost or wtere per d P133] in further embodiments. the compositions of the present invention. which domplsa a^d .(DPA-«3) or te ^iycrnot or oihyi esters and which comprise relatively smrPI umowtto. of omogna ttec^sahexaerigie idd |DH<ifen% together with a eommeti cr alternative sfshn dose, moy he used ter the touiiiM^:3Cii nypermoiyoehdemla (either T'G^SOOmgML, TO\'^o no d ?PhR50rngmt, TG 2 X* -h^rna ml * FG .......smed dlsi^'ioeoiie, λρ any other or medical oondiboni Specified above Such ::jpett'<xi of treatment provider fern aaPiect in need aldwtaiveh: siafln dose together with a dose of at least 30mg per day, alternatively at teas! 40rng OPA-N3 per day, alternatively at teesl QPA-N3 pec day,

PlfMhatfveiy at teaM 6-Omg DPA-N3 per day. alternatively at least ?0mg DPA-N3 per day, alternatively ai least SQmg DPA-N3 per day, alternatively at least ohmg DPA-N3 per day, alternatively at least lOOmg DPA-M3 per day. ekomativety v toast 120nip DPA-N3 per day. alternatively at least tSQmg DPA-N3 per day. alternatively ~Λ least 160nig DPA--M3 par day. alternatively at least IdOmg DPA-N3 per cay, alternatively at least 2O0mg DPA»fX3 par day, gltapativety er fee^ I5fe| DPA-N3 per day; alternatively at least 300rn§ QPAA53 per day, alternatively at least SSOmg DPA-H3 per day, alternatively # ^e^vfOiprriip ISfAAv-NB alternatively at toast SOOrrig OFA-N3 per day, SOdmp ORA-NI3 per

8Q0mg DP.A-M3 per day, alternatively at least itHHfeng ΟΡΑΉ3 per day, alternatively at least 1200ta| BFA~^3 pdf alternatively at; feast I500mo ORA-M3 or its •gipMotor wMe providing a relaWy small amount: MOHA-NS secti ihtethe OHAiOPA itoan mid is od iw than 1$:l of OHA:QPA, attemativeiy m df;OHA;DPA, alternatively no mote then 1%1·; i^ftemaissgfe- W'nwra/tfian / 8:1 of DHA-DPA, aftemetiyaly no -DHA'DP A, alternatively no more than 3.1 of D HA. DP A, alternatively no man? than Jrl of DNAiDPA,. alamaivaly no more than 1:1 of PHA.DPA, atemaivaty ho mote than 1:2 of DHA: D FA, aiterrteivoty no more than 1:3 of pHA'DRA, ^orrpivety no mote fiahi 1 of DH A· DPA, ottemahveiy no morn than 1 3 of DHA DR A. alternatively no morar than til 0 of DHAiPRA, tesamahvely os more fen lets of DHA. DP A. alternatively a relative daily dose of no morn than 1.20 of DHA DP A. |^134| in further embodiments, fie compositions of ftp p$p#t th'te«^0i eempnso significant amounts of emega-S dooosopentaonolB acid (:ΗΡΑη3| or its giyoemi or ethyl astern and which comprise mfa^yefy saiall amounfs of omega>3 aci-j or 1¾ ¾¾ may te u»cf for toe treoteoni of hypoflflriipiOridooii^ (either TGslOOmg/dL, TGs;150rn#iL, T# »-499^11, or TG 150-i99mgfeU mixed dyslipiderrsa* or any other disease# 'pr mertteal conditions specified; above. -Sued method of treatment provides to :a-:syb|&amp;et-te'heed thereof a TOmmpn or atfemTOye statin doee together with a doss of at feast Ibmg H^4fS pdf day, alternatively at feast ISmg HPA-N3 per day. alternatively at least 20mg HPA-M3 par day, aiterTOfiTOly at least 25mg ΗΡΆ-Ν3 per day. ottemauveiy at least 30nig HPA*M3 per day, attemaPveiy at feast 40rno HPA-N3 per day. a^emativefy a- toast SOrng HPA-N3· per day, Plfpmatiwiy at least 60mg HPA-N3 pet day. alternatively at least HFA-N3 per day. alternatively at least SOmg HPA'N3 per dayy:&amp;tlerait!vety:ailegisfc 90mo HPA-N3 pet day, alternatively at least lOOmg HPA-N3 per day. alternatively af least t^Cpi^pHPAW per day, attifflaiyely at feast ISOmg HPA-N3 per day, altemailveiy st least taOmg HPA-N3 per day, HFAt4s33 per- day, alternatively at feast 2Q0mg HPA-N3 per day. alternatively art least 25Gmg H PA-MS per day, altematjy^iy M least 30Qmg HPA-m per day, aHernsflvely at feast 350m$ HPAHSfe per day, alternatively at feast 400mo HPA-N3 per day, alternatively at; leap! S00rp§ HPArNS day. alternatively at feast 60Qrpg lHm--tv3 per day, HRA-B3per day, altemativel? et Itesf 1O00mg HPA-M3 pm dpyif 10¾ 1200¾ ;HPA*Ht :pif day, gtiema^fy: if. feast 1.500mg HPA-N3 or glycerol or ethyl asters par day, while providing a reiativeiy smell amount of DHA-N3 such that the DHA:HPA dose raTO fe no more than 1S::1 of DHA:HPA,. alternatively 00 .more than 12Ί ot DHA.HPA. alternately no mom than 10Ί of DHA.HPA. alternatively no n»p than 8-1 of ΌΗΑΉΡΑ, alternatively no more than 5:1 of DHAtHPA, alternatively no mom than 3 t of DHAtHPA, alternatively no ppri than 2 1 of BHAtHPA, alternatively m more than trl ef DHA -HPA, altarnaiyaly to mom than 1¾ of BHA:HF'.A:. alternatively no more thin 1>3 M pHAtHBA, aitemafifeiy op motfe: Itao 1:5 of ΟΗΑΉΡΑ, alternatively to mw.ttevM of OtdAiiPA, 1:10 of DHA:HPA. r#v8^;ihah: 1:15 of DHArNPAfeaitito^iyeiy a TOaifee daifedose Pi no more than 1:29 of OHA:MPA.

[0135] In yet other embodiments, the compositions or the ipmsPdt Ibygnlkm. which cempdee fegoitlTOei amounts of emoge-3”pool.aerrofe aoltfe or ttiOir gtyceml or ethyl esters and wfe*.h compose retetwnly "mall aiTOum of --m hfe-: non mmaxoeTOr aod (DHA*n3), locker with a common or ailemahve statin dose, may 1¾ ufe$*if-the treatment tf h^rlhgiyoeir^^hl^' feiHer TQ^OOmg^dL, TQ&amp;ISOmg/dL, T€ 2G0«499m9&amp;L, mW· i SCI-1 or ioy othor diseases or medkte conditions #.*<vifk>»t above* tteeh methods d treatment povy^s Iss a suhpetmooed thereof witra ^sommoeforatterhative statin ddsa mod a dose of at least lOOmg omegaetepeoiaenciic aods par day. alternatively at least Mm§ par day, attemsUvely at lea# S$0mg omega-S- p^oteartete aofcte par day,: altern^teely .at teast;SC^^: :om®p^^Shl§«^slo· aekte per day, alternatively at teas! TOteg per day, aiyrnaliveiy at SOOmo pai^ipd-pPPlaePoiP aetes per day. ptorpayvoly at tea# IGGOmp pmaia-^^taaaofe adds per

|edfaeasts: aoted per lay, aifdmtitvely at tea# t9D0mg aoiaga-S-ppatepaote adds per day, itiemativaiy at tout-ψΜ®$· 'WR$ 'M alternatively at tea# 2500mg omaia“8-p^Paaoote adds ;^r day, PteriMlyeiy at least aOOOrng omoga-S-pontsanate adds per day. alternatively at least 3000mg orrcaad-Dedaenoso adds per day. alternatively at least SSOOmg gentsenoiC acids per day, altematsvety at least SSOOmg op^i^pt^fetemistKidd^ per day,;: alternatively at least 4®0m| omega mpeotaeooto Spiels per day, aiemafeiy at least 41 «3mf| a;meia-S»ppntepnate aetde per day, ettematPtely at teas! 4$00mg amega-3'penteioote aotes par day. aitpriiPtiy^y omega-3-peataenoic adds per day atternativesy pentoenok; acids par lay, altemahvelv at least d00Qmg omepe-3-p^teeaote aside per day or their glyi^rfl' dr ethyl osteis white providing !#*&amp; than IS^mg of DHA, aisernalively toss loan tSOOmg of DHA , aiternnW#y less than 120Dmg of DHA.. aitomaiiveiy less than HXlOmp ot DhA, alternative ly toss than S^mg of DHAv alternatively less ihad TCJOmg ».4 DHA. alternatively less thao dCIPpig; df DHA,: alternatively less thad 600mg of DMA, alternatively loss ttwt .4(¾¾¾¾ t$4Ay alternatively teas thw| 3S0ma of DMA. alternatively less than PCtfeg of DHA, fed 230mg of DHA, #temalvety tees than DOCtrog of DHA, iftefp^lvgly lilP than loOnig of DHA, atteroaivoly toss than 12 bmp of Did A, afldmeftyefyi tess than fOOmg of DHA, alterrsattvgly less than M3mg of DHA, alternatively laps thao Idmp of DHA, glternglr^y Is fifl Ifei, f PHA> aftemaivdy tees fhao ddmg of DHA, altemativote teas ihan 30mg of DHA, toss than 2Smg of DfiC altomaivcfy less than 20mg si DMA or sis giptotol or ethyl osiers per day. ftilltl ip glhar praipciimaritSi the oompo&amp;itiorto of ilia preipoi comprise significant amounts of Dmegn^potoaoneto ends inctodtog DPA or their giperol or etiiyi; efthm aocl which comprise tftltfMy - small ;mmmU· of docosehexaenoto acid tDHA»«3}, together With a common or alternative ststm dose, may be u^d Isr llif tmitment of hypehr^peridemla i#tier TG^SOOrng/dLs IG^mrn^m^: TO 2m4mtt\04L, m TQ «MMmptoL}. mitod dyafpdemto. or any other diseases or medical conditions specified above·. Such methods of treatment provides to a subject tn need thereof with a common or atemaive stole dpse and: a dose of at toast IDSfhg pmefa^pefttepoto ao&amp; per day. alternatively at toast 290mg ornepa-S-perttaaitofeTicirto per day, altefttattyely at least 300mg. omega <1-pentoenotc adds per day. alternatively at. least 500m$ omega-

3-pentaeooio acids per day. alternatively at least ?0Omg aaiega23.-peirttoanpte acids per day. aitemahveiy at toast 9S0mg omega-3-peniaenorc; actos par day. alternatively at toast IdOOnig optoi^i"P®htaenoto mM$; gtr dify alternatively at toast 1500mg omeg^i^laiiigWp :Mfe-fftt?- aitofflaivaly at least tSBQfng omega-3-pentaeooic auoa per day, alternatively at toast; lOOStog omdia~3-pehtaenoic adds per day. alternatively at tests! 23CMjrog omega''3-pentaibd^:;^.tpt par day, altamsllvely ai teas! SAQOmg omepS'd'penlaeno^c octet . per day, aitemahveiy at least 3000(¾¾ omega-3-peotoenoic aeios per day, attorns n*ely at toast 3S00mg dmeqa-3-pentaenold acids per clsty, altomaOvely at least 3900mg omogm3*peotoen<\i·' acids ' p|r day. alternatively·' '0 least 4i>00mg omega-S-pentaenoto 0M0p0'4k% iltep&amp;tlvefy at least 411100¾ oi^eg.s-3-'pedaenaic adds pier : dayy aferriatiyeiy at toait: dSOCimg omeie^^ipeoiaeoeto aeidt- per dayy dtteAl^ljvely at less? SiKtomg omega- 3-r*eotaet>oc acids fv. day, altemaUvely Pt: Iplet 360Omg oovKjo-3-pentaeooi<, nods p*r day, alternatively at least dOuOmg pmega^-poetaorioto adds pprday or their: pipemi of: ethyl estoto ¥ ^vto pmvidtog a rehmvely soul? amount u OHA-Nn such Hut Hu DRADPo ratio $ no mouv than 15:t of DHArSPA. alternatively he more than 12:1 of :OHA©PA. alternatively no motto tharf 10:1 of DHA:D:PAf: alternatively no more then: 1:1 of PHA:PPA> attomtotlvely no more than 1:1 of DMA. DPA. aitomatively no mom then 3;? nf OMAOFA,· alternatively ste more then 2:1 of OHArDPAf eiterhtottefsy m more than 1:1 of OHA:DPA, aiternutivoly no more then 1:2 of OHA:OPA< alernaivoiy no more than 1:3 of DBA;DPA, alfefiialrvo^ no mssi than i::$ of DNAiDPA, alternatively no *ΜΓ6 than 1 5 of DHA.DPA, alternatively no mohs fflan T:fd of OKA:0FA< alternatively no moffc than 1:1$ of DHA;DPA, Jsfforrmfiwiy a rdaive si^^nt: of no more than 1:20 of DHA.DPA |013·'?] in yet other embodiments the ''oppositions of the present i?iv^rsti'^-.whi6h ComprHse significant afiouots of omega^pertfaerioic sods inckeffeng NF.4 or their glycerol or ethyl ©stem and which comprise relatively small amoonfo of omepAS dooosahexaefioic add |DHAmSi together with a oomhlPhfOf· lfc&amp;rnefi¥i&amp; statin dose, Pt^y te :pied for the treatment of hypoAflgiycendemts (either TQsSOOmg/dt. T9*2flGrtj#^. TOfctSOmgAJL, TG aiCHM^mgAfl., # W 15CA1iSripli;|, mixp m diseases or medical coodiens .$pecii^.:^m Such methods of treatment provides to a subject in need thereof wih a ^fomon: or atemative statin dose and a dose of at least lOttmg j»^a-S-penteenoio adds par day, .alternatively ef lead 2€0mg emega^'-peotaeoote aolds peF day, alternatively at least 3t)0rog omega ·3· pentoenoic adds per day, alternatively at least SDOmg omega-3-peniaeooic adds per day, alternatively ei least 70Omg omega-3-pentaenolc acds per day, gjtemativdy gf tpast 900m§: omeii-0-pePtaem»o selds per day, aJlemafDdly pf iasi 1 ί|3δόιρ omego^-pentaenoio adbsper day. alternatively at fsaal 11031¾ fc^/jper aitsmaflv^y at lias! fiCMAttf . day, pfemaftWy a! least icpomg omeg.a~3~ pentaervmc adds per day. afteroabveiy at least 2DX ry omega- 3-pantsoncac acids per day, ailimatively at least :23331¾ omega G~pent«io$o adds per biy, eltemeilyaiiy :dt: adds par days etitemaiyeiy ,at :tpdst iSOCfoiq urnog:#g,pent^pnalc apldd pfr day, eilimidyely tome·.!3'3'ponKHoiloie \aud« per day, alternatively at least 4®dfo@ Mnep§*3e peiitaenoic adds par day, alternatively at least dtOQmg prneQa-G-peotaenoio· adds per dey,: atternativaiy el least 4600rng ornooe-D-peotaeooip adds per day,, aftOfnatSyely et ioeat SQWmg omeg.a--3-pentaeno?c adds per day, atematlvely at keel $$'Aln,'U omega- 1-pedaeoosc no ids per day alternatively m least tSQC%rn§ omego-e-pentaenoic: acids per day or thoir glycerol or ethyl osiers ,. while f^vMldg a roiadvaly small amopot p! ®A*$f3 sqph that theDblAtWA ratio le op more than 15:1 of DHAiHPA, alternatively no more than 12;1 of DHAiHPA, attemabydy no morn than 10:1 of DHA:HPA:( attasmativoiy no more man Set a? DHA:HPA, alternatively no more than 5:1 of DHA:HPA, alternatively no more than 3:1 of :·|3Η&amp;Η|%:·$ iMh ffet pf f>*> more tteri ,: 1:1 «I BNAjNPA. alternatively no moro th&amp;n 1:2 of OHAi-HPA. alternatively no· more mm 1:3 of ΟΜΑ,ΗΡΑ, eltem&amp;tlveiy m more than 1:.§ of DjHA:HPA: aBemailvoiy no frxae than 1 &amp; of DHAiHPA, alternatively no room than 1:10 of QHA:.HF:A;. alternatively no more than 1; 1S of DHA.HPA, alternatively s relative amount of no more tharM :20 of DHA.HFA so further embodiments the compositions of the· present inversion, which comprise significant. amounts of om®ga-S*pervtaeriolc acids or their §fp®i or ethyl esters and which comprise relatively small amounts of omega-3 docosahexaeooic acsci (DMA-no}, together with a common or alternative statin dose, may he used lor the treatment of hypertriglyceridemia feither TGeoOOrng/dL TG&amp;200mg/dL TG^1SCm*'dL T'G 2Pa49dmg>'dG or TG 150-13£mgfdl), mixed rhoVipklemia, or any other diseases or medical cannibans cpomhed above. Such methods of treatment provides to a subject sn need thereat vote a common or alternative siohn doaa and: a rfPsd of At least IDQmg omega-G-pemaonore acids per djy. alternatively at least 200mg om^ga-3-piahtaertoic adds per day, .*!tui natively at t$$$t 3#0mg -omeg-a^pentseTiotc acids per day, alternatively at least oDtoig otiiefp-3^pentaehoic adds par day,, alternatively at feast TOGmfeemega-iper day} atfernativoiy at Ifefei ppfd$: fmapnl-piPflfete :^s per day, aMfnafiveiy at: toast lOOOmg ompga-S-pantaamic acids per dayAatternafivety if lei|t liCtShii omega G-pafeaghbio acids per day, alternatively pi least IfeKfmg c?megjhVpontaer>o!n acids per day, sltemativeiy at least 2GD0mg oniegav&amp;· pemaenotc aqids per day altemativmy at least 250§tf^t omegS'-S-perttaeftofe acids per day, aifernahvely at teast 29GGrog onega-S-pentaenotc; acids per day* alternatively at least dOOilmg arnega-3-txmtaenoic acids per day, alternatively at least 3500mn omega-3-penta«no«c aads per day, atemaiveiy at least 39¾¾¾ omega-3-pentaenei€ adds per day, alternatively vp feaet. AOQQmg omegfefe pemtaenoic adds par day, alternatively at least per day, oilnmafe/ety at lasst ?f500mg otaega^-petitaerioig acids per day, alternatively if least SGOOrng ipptip-S-Pentaehptc acids^ per diy, afiemattveiy at least ssoomg pmog?^3-pen*aer*oi€ adds per day. aiierTiatively st least 600€%hf| umega ^ i ^Gocrvio m G’- ou ! w ui th ! olvm k>' >-’ c syl «-Gem wrs omv:: im·.^ ,> mlaffvely small amount of DHA-N3 as compared to fee amoifei of pfeepefe pentaenofp acids tNCAienoscFAt such that the DHA:^3-$odofc FA mltf la m> more than 16 1 ot DBAtAGGemmcFA ,Stern deelv nn rr-'m tear» 12 t of DHA'N3-5anete FA; alternatively no more than 10:1 <yf OHA'N3-5eunte FA. allemaiively no more than 8:1 ·ύΙ pNA:Nl«Sthpfe^.. pftemafevely no emm %® S:;t of DHA»ihmie FA. alternatively no more than F1 ¢0 OHA N3-denote FA. alternatively no more than 2.1 si OBA:N;P5»io FA, alternatively no mom thoh 1;1 pf DHArN3«5anote FA, alternatively so more than 1 2 of Oil A 143-SenmcFA, aitomubvely no fTu>m: than 1.3 of DHA:N3-5enok; FA. alternatively no store than 1.5 of DHA.teCFSenojc FA, "dUemahvely no m&amp;ns than i ;8 of OHA:M3'5«nok5 FA, diemittvbiy ® mom thisA 1:,10 DA A fj.N teynmc FA altenvmvniy no room than 1 15 of pHA N3temni>c FA, alternatively a toiati® amount of no more than 1.,20 Of FA, p13B|; In some the-composition φ . |;0hfpf|sef :TPA::^t::'^F.P®F;^^F of a* toast 0 0S% in «Dmn omhDdtntame, the TPA: concentrabon.ljs about 0.01% lh about S%, uiibrnbttveiy ahsul 0M%t9 ghp®2«s alternatively shout 0.1% to About 1%, alternatively about 0.2% to about 0.3%, alternatively about 0.45¾ to about 0 6'%, alternatively about 0 ΰ%.

[Θ139] The compositions of the present invention stay ale© be taken as a genetol rrutotmns* supplement |0140] On a EPA dally dose basis the compositions of the present invention am prelbfably provided m a dose of betoken 100 mg and 1E0P mgAtoy;, ol^maffvely bethiedh 200 Pi and δ,000 mpAfey;, aftemgthraiy betoken 300 mg·.·· and OlOOP mg/dey, alternatively between 400 0%¾¾ ·,δίί^Ιί^^.·ί#®6η;.|Ρ$ mo and 4,000 mti/day.

[0141] On a EPA^DPA daily dose baste, pr^seht:ih%#®Ph arb preferabiy ^rnyiidd inddh Abla bf between 100 mu and 10,100 mg/day, atematively between 200 0¾ and i, 100 mglday, alemaiveiy betr^en 300 mg and i:ip me/day, . pfenldflvaly bitwabp 400 rng and 5.100 mg/dayt aiferriativdly between 500 snq and 4,100 mg/d% [0142] On a EPA^HPAdDPA dally d©ae baite, tha a?mpustteg of the pmeent invention urn preferably provided rn a dose of between 100>ng and-.10,100 mg/rley, 8,100 mg and 0,100 mgfdayt alternatively bmrnm^MQ SAID mg^ay, aitomatively between 500 mg end 4,100 mg/efay..

[0143] Open: daily dose basis, the dm^Osibns of ifm present Inventten are preferably provyad in a rtose of between 1¾ m§ and 10,1® mg/d&amp;y, alternatively between 200 tog and 8,100 mgidaf, aitemptlvbly between 300 mg and 6,100 ragtoay, aitnmatwely between 400 mg ami 5,100 rog/dyy, alternatively ;:be^en'6Cte mg and A J00 mgteiay, fiWl The termyfotion ntey fe a single daffy dose In boo dose the above stakes, or may be m convenient divided doses, for example, a dafiy doso formed' of two fo Joyr jolt golatio or other doaago form^ 300-111)0 pig of frni: flftyiFA, EPA*DPA**JPA:,.Qt omoga-BdiornoorMJie aeida fo any form emhodted in the present fevtoioo. 10145J foavourarits or emulsifiers may be included, for instance. to make the preparation palafaisfe venilonal difoadts eld ^pdofi- miy fop present The preparation ter Ingestion muy bo in foe term of a capsule, a dry powder a tablet a solution, an oil on emulsion ot any older appropriate form The foppaglgS: may Ite tiard or sod gelatin: capsules, agar capsutefo or any other appropriate capsule.

[0146! Use of the formuistsons of the invention in the manufacture of a medicament for tne treatment or prevention o! any disease or disorder. Including those mentioned above, is tedyded in the present invention 10147] The omega-3 fatly aaid coaipdsttlpn optionally loclubgs afuniiidaf antloxidaritjy Aadb as alpha teoopheroi, which am administered la pyre term for suapsrteed Ja a vegetable ail, mm oft |0146] Tile blended fatty acid compositions may then be incorporated into any appmpdate dbeaie temi for oral, eniaral, pamefomt mctei, ^gfbabderma! or olftef route af admfnlgttetten, Soft or bard peSsln capsules, favoured oft bfends, emolsitiefs of other liquid forms, and micrt^L-apsufeste powders or other dry toon vehicles are-alt appropriate ways of admihisteribg the products. 191411! irrn! drug product jootelhteg the omega# felly apfo tpmitesifiop may be admWstored te a mpmteif: or patent in need fhefteaf m a oapsylte a tablet, a powder th-M oaa fee dtepemei In a bayer^e-or am)teeraoiM #Mi dosage term, a liquid, a Soft gel oupsuie or other convenient dosage term Such: as oral liquid in a capsule, aa known in tee art., la soma afobadim^rite, tie capsule com pPaeS: a hard gelatin. The eombigatteb pod^mayr^iso be obtained; in a liquid suifabte lot inieuifen gr infusion.

[0160-] Example pharmaceutical grade ttetehad doeagb terms: (a) Sod or hard gelatin ©apsuies each eomtening §00 mg or 1000 mg of a mix cQ pasts of SPA *te &amp; free fatty acid in i parts of DP A as a free taffy acid: (b) As m ip? put whom the EFA end DPA free fatly acids are replaced vnfh the fatty amds r- ,-m other upwopnafo fyessttfelialife form such as foe efoyf astern; foil As in (a Mb) hut wham fo# mafomti is in the form of a mcroencagsufoled powder which can be used as a pewddr nr comprised into tehfots. Such powders may be prepared fo t ®ri«ty i fehnologies la«n fo those skilled m foe art: id) As in taHb) but where the fofmulfofog §·· # l|uid nr emulsion, appropriately flavoured for palatable oral administrabon; fo) As m ίβ)*Φ) but where the material is fommlafod Info a ph»adefofoa% adeepfottte wfocfo appropriate for fopM soott as a cream or ointment, [01511 The omega-3 compositions of the present inwoitfon: may aisp ffo admmistered with a cambinahon of one or mere .'..ptefr^cnytfo^ irrgredtenls (also known generally herein as ’’excipients") Non-active erpredfents, for example* pfhfo fo iioiytilltp, emulsify, stabilise* pmaerve. protect* eofen lavoo an$ tfasfeito. -ΪΝ*;*ββΜ* inpmdfonfo folo an appioabte and efficacious preparation dial is safo, convergent, and oihervase acceptable far use Thusy foe ηαη-aotive ingredients may indude «ofltt&amp;lsiftfeQ factor monohydrafo, tecHhfa, microarystaflfoe ppifofoso, polyvinyl aM soeifom Ipyryf spffofo* sodforn -sfearff lyptarafo, talc, hfonfom dfoxide and xanihuot §um, [015¾ The term Hnh.armeceuhcahY a« coptabfe vehicle," asused horfon, inclotfoi any of the following 3 eolation whom tori first ΑΙ*|#$· era? wholly dissolved r. a aokfoiteer te g , a prwmiosuftsaify acceptable ooSvoht or mixture of solvents), wherein Use solution remains In cfoa- rgufo form at about room temperature: a suspension, on or), or a semj-soucL wherem the first API and optionally other ingredients are dissolved w-truliy or partially fo a solubilizer φη emulsion, cream, etc ) 101533 A foharmaceuhc&amp;i grade finished dosage form*' as used hCifolh.-:^y:-::b^ ponatruod as a unit dose form suitable for administration to. for exampffo human tw anmai subjects, and 'having content uniformity acwmfofoe to ;agufatorv aothontws. For example, under the USP requirements for cement uniformity, a phamtaoautmal grade finished doouye form should fwv·.; an amount ol API withwtfoe range: of 18¾ Id 113% of the desired dosage end an R3D less then or equal to 6,.03i. tn arlditfon. .a pharmaceutical gwfoe finished form most ho srafcfe {[.¾ , t^wxt 0 fohoff !ifo<’| tor 0 oh,v no· > m c Pi,' \a * osahfo >\>mi un of tim t i vfo alfo at least am months.. aiternabyeiy ^ teas? one year.nr at least two years, when stored at room temper elute Cahoot S3 bogra^ Ootefos to 27 degree Cetdus , preferably about 2S degra^ C^fcius) and 60% relative humidity. Typically, stability ?s determined by physical appearance aniicr pbemiclil mc^ification.^f^-ibjp^li^vtri.'^cairclarice with standards wgfr fcnewm m the pharmaceutical arts, efcbirsi ttest docrw»ted In ICH gordelnes. P1§#1 fflrt omega-3 forty add dosage form optionally includes chemical ache^diaiis; sddh as alpha tocopherol, pits, 0¾¾ :¾ soybean ell^ hhrt: partially hyJ?mjissy viable oil and \ubficmU ^ m Mhirt aftd a rhlxtyii ti fid same. EKMiPies (01SS] [0158] A composition according to the prooen! prevemkrn ;s preparncl yy noon·;; and honing ηπ;Z!π-y ;n a raho of SS 2 hie shtemiedraies 0.1 EGAPE>i 1::90(^001::E (BC% EPA ethyl osier,) and MAMQIIEQA DPASS FFA :(¾¾% PRAspiheoc iaby odd pn.xhx.ed from EPA ethyl ester concentrate i converted to ethyl estne respect? why. These intermediates wore prepared pod oommer-cia% otic-red for pate hy Chomped Kama %1Τ% AT%>h and Ερορίος Ltd from Scotland. UK RAAXQMEQA) The reiahvo amounts of fatty aods present in the stoning intermediates sod is; the ms; iking now) composition are listed in Table 1 below. The resuthmt novel eemposttieo comprises 89 1()¾ EPA. 1.95% DPA 0.19% HPA 01.241¾ amega^-pardaenoic adds lees than 0.01% DHA, 01.24% omega %mentaooQic acids. 03.00% total omega-d fatty acids. 3 15% APA and 3. 57% omega-6 fatty acids mil Are§%): ϊ-*'* ' Kitty ^ek^pov.t»o«jVc*H<»f imrnwrt^arMJpcve' vsmposiewacamimgisgssampi® 1 9&amp;p&amp; £«®* ............................................................... I i M -,( N MvVVb-i KxUi.'-'S·' κ K Κί'ν-' X np * iii'» c 14:0 &amp;OK 0 dS:.t^ a.os δ a 0® c&amp;ie? a.o? &amp; 0« sis^svg ao* 0 $0ί eHk3r6 afio; &amp; ϋΜ «»** &amp;m * am ¢:10:¾ QA2 P 0^i (:i$-A*it 00? ¢. 00'·? ί,2ί>:ΐί :|) Ο '&amp;G0- :$. t $09' -:20:¾ φ.· $ &amp;%;

::20¾ >$ &amp; i-P «20^5 ixll: ί> ^ t203r!§ &amp; o casi tS>&amp;A n.n ¢: ms ¢21:0 0 f &amp;O0

C20t4n§ 3,23, '0: MS ¢203^3. t? 0 <300 sJ0:4fti 1.44 „0 1.41 «HbSfll $a$U 0: ^.22:¾ as t 02$

«221»Π 0.0? € OM

-::22. 3r<'> 0.30 0 O.IS ¢22-¾ 0.19 0 0.1$

¢21:¾ 4l§ 0 0.B

at-Mt 0 0 0-M «»:5«3 0 m:!? 135 £22:6»3 0 0 0-S0· ¢:24:0 0 0¾ a® ρΤφΙΗp4|M_2,42............. _______________________________________________________________________________________·$Μ 10$ _______________1½ W157] iLeoifei |ίΡΐSiS| Λ acoar^in^ %s \n »- raid of'-iS-:4:fh#itemi^dlafe0 ME GAPE X E.90D0DEE (90% EM AIM ) Md MAKQMB^A 0^1$ f FA (¾¾¾% PFA syrslbiiic tatty a<M pTOOyeed

IrM EPA 0thyl cmicxmtrete}. ^dyiiMd to ethyl estep respectively, TAese Ini sm Kdtai&amp;s wore propel ed and. ooeitwrolblf yaliened fo.r toe by Cbampofl Korea fbtES^PE,X| and Rquateq Uo' from Scottami UK (MAXOMBGAp This relatly® arRPOnli bf tAd\ Asi'iiJ:· p«^ent in the 'starting int#n"toato end in Ote iasyiiting novel: composition :s hsM sn Table 2 below Tbe resmbnQ rvcto ocmonroHc-n comprises· 808% ERA, 8.89% BP A, 0 18% HPA, 91.35% omaqs-^penteinosc acuity U»s •.than 0 01% DHA. 93.175s tola! amega-3 fatty acids and 3.49% omnga-6 fatty scsd?· latiArwii),

Tisfets L Fatty asii.d CodipoViti®ri fftree 4i| of ΐni ejwsedSaifcgs aratf sow:! E&amp;fTipc-stitos aeea^tii;la Examfiie· £ ............................... 550% %0% %%______________________tOT>ottet:........................OPASSf*a =>> ^ ............SI%iS9iEESE%. <200 0.¾¾ o. ats : 15.:: :, :1 0.0ft 0 SS- m-An? f!<® ξί .0,02. £t&amp;?.8§ 0¾ 0 5C1 c.to:%S a,% 0 9.92 ¢-.^:%¾ tint g 9% ¢23:4% 043: 4¾ &amp;« -:22.4% &amp;§? a as·? £20:(}. a 9 500

rio-lsjl' § Ο AM c20:i% it S nm :.20:1% 0 0 0,00 ¢20:2% 9 25 D 524 £00::3% 0 g 551:

£00::3% C15 5 &amp;M £0 i 5 5 it J ¢0 £0:0:4% 3.21 0 3.05 %05% 0 5 500 *254-5 544 0 :1...90

¢20:511¾ 3592 ϋ %? M «2233 53 Π 5.24 < 22 J:':1J. 007 0 503 <>21:^ aia 0 O i? £52::283 519 0 0,.% <52-:%3 5 59 0 0,13 £22:580 O 0 0,00 £32:583 0 87 ft:· 7 ft* £22:5:3 0 0 0,122 ¢.:% :5 0 032 0.01 oosn..........342. 2-4.........2 ft______ _________|5§_____________iee...........ΐ»_____________ (0159] Example '8 |0f β0| Λ composition according to tho prwwp^on >'&amp; prepared by mixing and

Oomogen%ng sn a ratio of 94.8 the sntommllaies WESAPEX EyQDOOEE {9052 ERA iefiyi estaru and MAX^I^O^piPASS FFA fa$5%';DPA syetb®fc:fatty add :fem SPA ethyl ^$te-.coRO«itmte) eow^rted to ethyi ®mr·, fmp&amp;dmfy.· Thasa imerai^oedes we ay peepered and commercially offered for sate by Chs report Korea (ME6APEX) arid Equaieq Lid from Scotland; UK {MAXOMEGA}. The relative amoyafs of laity aolcfs present® the starting intermediates and m the msuiiing nave! com position are fisted in fable 3 below; The msallng ©emprises EPA, |J4% DP A, ΒΛ$% HPA. 91,46% ome^a-3-pentaendle «Ms·, less than ο 01¾ DhA 93 20% total omarm-d laity mxIs 3 (T% ARA* and$ Ji£% orwq»-6 fatty acids (all Area%). .................................... mm’.......... .....................§m ____________ £?.«i______________ £^QQix;€E___^^'ii^ai'cyAgSf^A^^ ....... Navel

= *S.O ecs ' 0 ' ” ' MB

< 10 >0 CUB 0 (i-M am o Me o.at a mb •me β·ι mas 0 e.et

si89r.< iBB 0 MB <&amp;.*'·* &amp;Λ&amp; 0 &amp;n <1S foi 0.0? 0 o.or •v-o ο o aoo O/OiOti ip o g £X> c-io.i-iO a 0 a® : ¢2^ AO; :.d a a® ¢:20:10-0 $$!&amp; 0 024 hM2.n§ 0 θ £i.® :.1#:%Κ 130 O 014 v2.t;d 6 A O ® <2&amp;4«4 X2t a 1 u? ipAiaii o a a®

:.;-:'>4i:11 i.44 0 i.B <Kt5n3 90.52 a sa ¢22-0 103 0 a 28 cmSMl aif α 0..00 :¾¾ 033 0 0.17 DXtr? &amp;:|0 0:1 010

£21:¾¾¾ 0.:B 0 MS ¢92:548 1:0 0 000

£22:543 0 ¢7.1:7 -;,.B ί:22:®·> 0 0 0:..00 ¢-24:0 Ο 0-B 0.07 ;0|Α|Α„............................................ >.42 2,4; 2:42 lie 1® ΪΜ- ^ssssss^vvv\vvvvvvvoo^vvv.\\\\\\\\vvvvv\\v^.v.vo.v.\v^vv.v.v.v.v.v.v.v.\vv\vwv«v«w^^^ WU'Bgiiii [81621 AiOSimpoAMi:· acciofdiri^ to tte present :pmpared by mixing and

Ponmgppiprjg: MEGAMK K9pP0i>EE (90% EPA ^.^r.i|'a.r^; MA^Q^EGAIJPAiS piFA (a$5% DPA syri^^tslty .acid product fom iPA «fayf wrier eonGorifite conyaded to ethyl estor, wpeeth^y. These irtlemiecNates were prepared and commercially offered lor sate by ChefDpoit Korea (MEGAFEX) and Equateq Lid from Scotland, UK {MAXOMEGA^ The relative aoiOMOls M fatty acids present In the sfarinp lolacrdadiafes .eMf Ip the iresoiting no¥el: ooaipoilfcd le llatad In tdpe ;l:te!ow,. Tfie: resoling: de%% 68.10% EPA, 24.32% DPA, 0.19¾¾ HP A, 92.65% omega^#fSdf^pote: acide, less then 0.01% DHAS 94.0?% total omega-S fatty aads. 2 41% ARA and 2.73¾¾ omega-S fatty adds fait Area As),

labile: 4 tArea$»J _____________________________________________________________________IIM.. 2&amp;P*

Pul? Acci_____________£43000¾¾ D^ASWA *> ££ fiimd Cem^osttseei ztB® am D 0.04 <S8:1*J ύΜ 0 Om O&amp;US 0,0¾ 0 00? ejsisg- mi.\ a G01 ci&amp;3s6. 002 a ail a*:.a? 002 a as: (.«Ail 0.42 0 a 52 («-s=ii o,a? a aos <700 a a o.ao OQMt o a ·άϋΰ· am. ix® a a aoo (Mi*? a a a« as a. 23 a ail

t30.*f*§ a 0 0,M (1¾¾¾ a. 13 0 ail cSi; 1 o 000 <204^ aii: 0 >.42 <20 3*3 ii 0 Ο.ΟΘ <20s4ft3 144 ΰ 108 ¢20:341 OO.IQ 0 0010 <22 a 0.3 o a.a sa-irdi 00? 1:: 0.03 <μ·ι*9 0.13 a tm cZfcta» 019 a 0;14 c21:5eJI 019 a a 14 c^:S*6 0 0 000 0&amp;$*$ 0 9·,· :.;;· 24.32 <22 0*3 0 0 0.00 :14 0 0 ϋ.Ι'ΐ 0.08 ΰΙΗ£0 .................................... 2,4.¾ ._______ 1.5 2.42.......... icq rn -SO0 10Ί63] Examl§..:§ |0f 64| A composition according to the ρ$$$φ&amp; pravomion isprapasied by mixing#^. aorm>geao:mg so a ratio of SO,40 the mtormeiliaies KP-PharmaKO-PUR 900EE end #A^piE0A 0PAip:. .^;:.;.:#ftVf^ 'tl;..»thyl ester, faspeciivety.. Tidse Irteitladptea wsre loghimditslaliy dtfar#il fer sale Pa KD-Pbarma

Germany fKD'Phsrmis) and Eouateq Ltd from Scotland. UK (MAXOMEGA) relative amounts of fatty adds prefect jrl the stsr8o<j ^ and Id result lag aaiisi eompdeffion la itsled la tabte S tjetom. iTHe^sessAtg aimposllon: cptiiptfses 55 74% ERM» 3¾¾% D;PA. 2.,39% HPA:. 97.44% ¾^^% pehlaenofe:adds, and 98.0657 total omago-Sfatty acids (a4 A:rae%).

Tafeie 5k fatty sd<$ Composition {Ar*a %] of mtsrrnsdiates, astdl oovsl canspesstisis aceoiding:to Example 5 S£MM .¾¾%

FsM^ Aeid KP»Paf %DC€i: Mjic-ois^s DS>auSKA -*£ξ No-fit €oiRfjat.it*«-n &amp;m- 6 9 0.D0 ¢12¾¾ 0 9 0.00 '$ 0 0,00 /ni> 0 9 0.00

SiliJiA 0 0 9 00

cIS :9:3 S 0 0 GO

ClS-An-i 9 9 009 9 0 O0<:

4.:91:0 0 0 0GO c:0:1:0.1 0 9 0 09 4:/0:¾¾ 0 Ο 0 ΐΧ- ¢: 30 :1.% 0 9 : : 00 ¢:309:00 &amp; 0 0,99

OlAa/l 0 0 9.90 ψ 0 9:.09 elm 0 0 0.09 ¢90:400 0 0 0.09. ¢24:300 Ο 0 9:99 ¢24:3¾ 0 9;93 ¢20:00¾ 42. 99 0 30,22 ¢22:0 0 0 009 ¢29:1011 9 9 2.09 ¢32:1¾ 9 9 9. €11 ¢3.2::1¾ 9 9 0.01 ¢31:5¾ $Μ 9 2,10 ¢22:000 9 9 0.01 αΖΛηΖ 9;Sa 97.27 39.2$

¢2/.9ns 9 9 9.GO ¢21.9 0 9.31 912 £0 00......... 1.41 /.9 1 31 __________________________________________________________moo_____________________________________________________________too________________________________mo&amp;__ piiSl -liiffirifel [6166] A composition according to thy present provennon la prepared by mlAog and homooeniziog m a ratio of 96 4 ?he intermediates KQ-PUE 200EE KD-Fdnarroe sod M'AXOMEGA DPA95 FF.A converted to ethyl eater, respectively, These intermediates v/ere prepared and commercially nbered for sale by KD-Phanea Germany (KD-Pharnin) and Bquateq Ud frnm Sorted, {ΜΑΚΟΜΕΟΑ}.- Tb4: felatlve fatty acids present in tte sladba iniarrnadialns and in ill# r«s;u!t:nq novel composition is listed In tefeln § bpbw. Tb#;···^^ί^^!ρν··:ή·ον^^ c-.*m»wton coinpfbae ERA, 4,45% DPAt ::3¾¾% HRA; 3Γ.54%: onwgi^ pefjtaenOic acids, and 3% 54% iota? omega'3 fatty ackls (all A%a%5,

Tahte §, Salty adit €»napo**tfan (Area %} -raf· sssl:«irm®iiiaiex and ttoaef mrap&amp;g&amp;tQ® ap3p^^^;i^amci|!^.cj$' 4.0&amp; fatty Add Κθ%.)%%ΕΤ «>it N&amp;vd v •<3&amp;&amp; a. 6 0:.06 ¢:10:.1% !> 8 il.CS) ¢:18:1% 8; $ 0.% cl^ftS a 8 0.% 0 8 0% <483% t 8 0.%

Cl8.«fi3 0 a 0,% ¢18:.^1 0 8 0,% 0¾% 0 8 0,% 0 8 0,% c2Qr*n5 0 . O ' 0.% £B&amp;sM? 0 0 0.% ά&amp;Μ 0 0 0.%

c3CBi*> 0 0 OM c2&amp;3nS 0 0 8.% £2i;0 0 0 0.% c%:4n-S 0 0 0% s%'%3 fi 0. 0.% S%l4i':S :1,% % i.i® cio-sna siss o &amp;o.2): ¢:2):0 0 0 0,% ¢:1):01:11 ί 0 0.% %0;1% 0: 8 ::0¾% %) ::10) % 0 0.% <Al;Sn$ 3:% 0 3.82 <%<3% :0;: 8 9::% <ZHM1 02 37 4.45 <%%2 0 8 8.% <248 0 843: 8.81 _______________ l±l____________________ 2.4_________________ 1.45-__ ...................................................................i«m» 1% ~i%%.................. I^i ill iitmiltl [0168| The ethyl ester composition of Example 4 may pi converted mto afnsa fatty add oo-mposKion with esssmiiatly iht; same fatty acid coimoaoitimi according to Xonverasoo Method EE to P FA' below Tbs method b adlscmronaie with re so eel to tof salusatiors sr topi's si faiptoP if p>ertorm©d tor an adequate ;dttKtttnt rffsto y defer to ctodHtiM rtoy§I©?to

Con version Method EE to FFA P fAtar (FAEE GMP, apprmoSmpm^«# to -brm^ghttt&amp;# ctosfx* heatwt/QQ'tfad reaction stmmber iiipi φτφ$0ϊρ fprpfwmbiy wihirpmmum cmimil mMdmptediP ^dkius pmkr stirring,· 2 2M NaOH > Hi <hop >n water ;<· added under itrm sbrmg to ensure phase mixing (ost. 2-3 x ^ΒΒ·^^)β^:^·Μί0.^··0ί^ mteris

2-4 hrs), Test atk$-m$m·. ptmmm:^^<ao&amp;$^npF®mm·· wife Wt%'' ύ;4)\·}φά with EP CSC d^toeto to »fe? maoMon ttsnpMion uncko GMP 3. Under cooling (keep mixtuta h&amp;low ?§ degree Ceichsl mid §M MGi m water (tot <f hr) imbi sightly adi# .ξ**ρΗ&amp;4}, M may be necessary to control prasmmHM .pmymi emeeaim to&amp;mfeg. T&amp;ari :φ&amp; time to let phases separate, ami mmom wa0P 0dmMm bottom (lieφ oit protested to? oxygen, apply mtf^^PH0^pphmm:^h^i)t·· 4. Ado dmimaraiiiad water (esi. 2-3 x FAEE wiw) and mmh mi Nad and ethanol horn oil under firm #11-1¾. gtos itoto to tot toaa<ea ££>£?«vafe, and femme water phase from bottom (keep oil protected Pom oxygen apply mirages * atmosphere btehk&amp;$

5. Rof«\P Stop 4 \pvt\l-:u' t;mt\- (~3x) to remove effem's; and NaO 0> Remove wales ami remaining alburns! (d00pfbe· topstoctost £6yfep#| cmfimsmder CMP with U$P msiduoi whmitdmiiM' {tergeb-criftmtpf 3 ">Opoon b\ tov>a oh sWvt or-oGmg vnvonm *0-50 mt*a ato o-Avont tmppmd heat oh (70--80 degree ceidus) i#if - wat^btb4^c^^tiM:'hmt {Pet 2-4 hrsp F. Add anti-oxidants ge alpha D'tocoptoaf. USP> mng&amp;f 4 mg/g} other axdpt&amp;PiL· ·. i. AM:reag&amp;Pia and excipients PSPgifep, pi?®| The ethyl aster composition of Example 3 is ainverlsd imo a tsa fetly asfd composition *$h essenhally the same; folly odd composition Id "Conversion Method EE to FFA" above. Tills method is indisoro?tf*#e to the fype(;: degree of ssfutiffee or length of fatty add I perfetinod fer on adeguale amount of time under the described conditions. p1?1] Example 9 [0172] The ethyl ester composition of Example 6 is converted Into a free fatty add composition with essentially the same toty ##d composite amending to “Conversion Method EE. to FFA" above. This m$m$. to thef^ length of faty acid If fmi-fomied lor an adeguafe mmM: of flrne under the described conditions.

[0173J ExameieJO |Θ174] The eempesiian of Example 4 ts fcrmolafed Irtm· a soft gelein ^psofe. Frier to encapsulation, an anti-oxidant preparation (composed of 400Ct mg atpha-p-tocopherol in one liter of corn oil, com p is a thglycer^ omegaaS} liadded fo ::tte.':Oampositk3n of Example 4V by mixing and hompgeriking l-OOmi of this snfh oxidant preparation cv.o 1D0 liters of the oil composition of Example 4 followed by thorough homogenizahon. The recoiling pre-oncapsulahan fpmiytatdd nil oodiplos approximately dnig/Qtvsni alnhe-D-tecopheroio iyhsepeenfJyv the fenmiafed oil fe encapsulated info·' deft gelatin capsules wih fphntdcl; toga methods typically used dy iAdCddaph in Can^f.t^'::P.h' <#$ Of h|? any Wm. docurnented and operational eacipsptaflen method- The: St rnasenf the oil cisrry&amp;apsulu. providing a dose of approximately lOOOmg omegmSm^nloenpic-'acids ethyl aetem: per capsule. Finally, the capsules are botded In 'HOPE bottles with induction s®at nod ctvid mspnaol ο&amp;ρν! P»l Eawatell JOiM) fomsalaW into:s»Be^Mn capable. Prior to encapsulation, an antioxidant preparation {composed of 4000 mg pIpha-O* toooptierot frvono-titer of corn-oil; •com-oifie a triglyceride lew in omega-S) is added to the oomposilion of Example <-$, by mixing and homogenizing ICO ml. of this and- jwW'|pi 100 Item of f>p:W eomposlon 4; f^flov^O: 0¾ fbdroygh - te^^riWti^: .1¾ respiting;ipim-enoapsylatt&amp;h ©If t»nt#ih&amp; approximately 4mgfg?&amp;m nlpHa-Qdoeopheral Subsequently, the formulas·.? oil m encapsulated into soft gelatin capsules with pnmed logo accord-eg to general methods typically used by Saraner in High Point,. N€, fer fish oils m by any ether documented and operaaona! encapsulation method. The till mass of the oil is 1,09 gram-'capsula, providing a dose-of approximately lOCtOmg omege-^p^h^erqlC'ac^tf pcs capsule. Finally, the capsules ate bolded In MOPE bottles with Induction sea! and cl^Sd resistant cap, PITS! The;dprnphslloo of Example 5 ^formul^ciinto a stoft geiatin capluie. Poor to icnpapsyiafinn, an anli-oxidant preparation· ^rojxxsed of 4000 mg elphi^ lociqpberot Ip.-orpifterpt com oil oom oi Is a trlglpedda low in orooga^l io addod to the reposition of Example 4, by mixing and homogenizing lOOmt of this antioxidant pmppmtlop Into ii)b I4nrs of the oil compdotion of Example 4 IbiiowOd by fhproygh hoo®idb®Stteh- Thh lasollni: pp-g«capso^tloo Mmofatod oil contains di^pixsximitaly 4mifgrani alphp-DddObpftgrol, Sybcegucofly, the formofated o| is Opoapsulaled into cod goiahn capsules won printed logo nccording fef: gonoMi methods fymnnily user? by Gatakvnt »n S? PatmsonrQ. Ft, «or fish oils or py any gfho? documented and npootioiVil encapsulation method. The fiN mass of me oil Ik 1.05 qramfcapsute. providing a dose of approximately lOOOmg ornegodlpentaenoicmoids ethyl actors per capsule, Finally, the capsules am hohieu in HOPE bottles with induction seal and child resistant cap, [0179) Example fo [0180] The composition of Example 9 jsjbfrouiated into a soft gomun capsule Poor in encapsulation, an ants-oxidant preparation [composed of 4000 mg alpha 43-tc eoohnmi »n oca liter of <mm or corn o>3 is a trylym no a low ία on fme-3> s aoued to fhe compoilfibh oTixhmpig 4S by mixing and homogenizing IdOmL of this antioxidant pfopdfaidrr Into 100 fiers of me oil composition of Example 4 fQfiovwed by thorough homogenization.. The resulting pre»encapsuiauon ferroulPied oil oomairts Oipproximatoly 4mg/gram alghe-DdOcopnerol 3yhseqi*en%. the formulated oil is encapsulated into soft gdlifb:-pepsylai:, wifh printed lego according to general methods typically used by ii^grIP Tigh Point NC, for 1¾ ois or by my other god ogjergfemat encapsulation m#5®&amp;> The fit! maaa of fh<a oil is I 06 gram/capsulg, pnovkllog :¾ dose of approximately itlOOmg omega-a^pantacmoic acids ppr Rnaliy, tbs capsules are bottled «π HOPE homes vmh induct <on sesai and dsii reafeiaoi sap,

101813 giiilliM

[0182] A pa&amp;nt: Is; ΜρμμβνΤ hypS!rt%iporfiJ«ipli: pQA§OOm|i^l,):

Thereupon. im patient may be initiated en- Jttly, treatment wttih one of itie encapsulated compositions according to Examples ID, 11. 12 or 13, Foot capsules per coy are administered to this patient (4g/d). E01S3J Eilttl [0184J. A patiani li ttaatpd as pw Example i l, 'The trealmeol msute ip aiini&amp;anf rrxiuv'Uoa of TG as wall au imu-ΗΓΗ and VlDL-ohoiesteroi levels wftite fte U3L- insignificantly* pi 8i| A patient is boated as per Example 14, The |matfO®nt msujlM te significant radiycidn Of TG as wetas nomHDL^ LDL-· aod VLOL-choloslaml lewis, [01873 Example 17 [018¾] A patient already yaclarpiPi treotmenl t&amp;Ib a statin is dtepbsed: witptllgh: triglycerides (TG between 20D add SCIOmg/dL). Thereupon, the Of? dmiy treatment with one oi IPe anoapsulaled compositions aecotdiof to feampies 10. Π.12 or 13 Four capsules per day are administered to this patient (4 g/d).

|01β9] Exot#jJ

[0190] A patient te · 11^1 ThpTmatppIt pfylts in s^nlidadf ;radocfipP:Of TG as well ,as pdd-H:P^p\fL:E3i^ ;:and LPE^Ilolsstppi je«la,

(¢1¾^' %;::^Ι^η^δ^'''·^ίί'Η·'·^ί(^Ι dyshprdemla (TG Peiwseo 200 and "TOO η n dL and 1 PI cholostmol above GXI mi>‘dt i ·* the pot ent s in*' eve m : dalf treatment with asfain aodone of §m ermspsylaisd eomposGons ac«0idM§ to Examples 10, 11, 12 or tii Foor oapsafes per day are admNstered to tdls patient (4 g/d).

[0194| A patient is treated 0¾ per Example 1S Ids treatment feswtte in significant reduction of TCI as well as and LOL'Cbolssloroi lewis, iwsj IMiiteti PIMl A patient isdiaiaosed Mid mixed dystpdemla (TB detweso 200 and TOO: mg/dL and ooo-HPLs3te!0Sfero| above 200 mgML). Itweypm lte :peferd is initialed on nononmitant datty treatment with a statin and one of the encapsulated eomposrtJORS:-acoordi09 to Example?! m 11s 12 or 13.: Foar ipr ddir dm administered to this patient p o/dp

Pt97| Example 2f [Oita] A patient is treated as per Example 21. Tim tmetrspo! resyflsln a^nlcaot reduction of TG as wet! as non-HDL-. VtDL· and LDL-cholesteml levels |020Dj A patient is diagnosed to bo at significant risk for a oartfevascoler event according to toe NCEP guidelines and has TG ievtils ibove ISfhnpfdta Tberntpoo, the patient is initiated on daily treatment with asdbrdid§; fd:f 5pmpfte;10, 1 13: Four dipatlds per day sm acfmintsiered to this pafert P2(n] ExampleJ4 $1202] A patient is heated as per £*νηρ*α 23 Td# Ireefmdni msoits iisdlpiifteani: mdyotipe of TG as well as non HDU VLDU and Ll^.. 10244] A patient diagnosed as pet Example 1A u Ip ;·ι a 2d ,- mnted wU 3 eapeetes per dey liesmadrof 4} of one aoooming to

Examples TOp I t, 12 or 13 The treatment resets In slgntiisaiti iφ TG as woi. as noii-'HDL·' pno VL. DLedwlaafpret te«k filial; ixempfeii -At ^ΐίβΝ(ΐί:ί!!3.ί^ρί,ί^ϊ®^:^^;·|^^ 1^: ^ .21 or 23 is treated with 3 capsules pet day {instead of 4) of one of the encapsulated compe^cene according to Examples 10. 11, 1/ oj 1 t The treatment result? ?n terte'vmt h-m.tei "> ,u TG ,e, vrell as; nendlDG. VLDL' mm mmmrr |02QSj A patient diagnosed as per Example 14. 17. 19. 21 or 23 is treated witn 2 capsules per day (Instead df 3 ir 4| of one of the encapsulated compositions according to Examples 10, 1l> 12 or 13; The treatment results la significant redacUon of TG os wel as ηοη-HDL» and VtDLsteolestmol levels. P2®1 iMElleii [0210] A patient diagnosed es per Example 14, 17. 19. 21 or 23 ss healed with 2 capsules per day {instead of 3 or 4} of one of die encapsulated %mpoeiiohp; according to Examples 10, it, 12 or 13. The treatment resote Id sSpiItcani reduction of TG as wefi as non-HDL-. VLDL- and LDLchoiesterol levels, ptiij P212J The following is an exampte of a preferred emhodiment of the present invention.

In CfyPOSITIPN 1 tffe EPA;HRA IS andm ?im EPA:OPA rafe

Is- Baril 1¾ the MPAtDPA- and 1, the DPA^HA mife? more than 2,4, preferably more than 4, more preferably mom than 8. most preferably rntfie than 10.. and the EPAiDHA ratio more than 32, preferably mom than 38. more preferably more than SO, most preferably more than Ob. Tht EPA, HPA:? OPAand DHArnay be composed as a glycfende (such &amp;s trigl^Hdte},. ester), or a freo fatly add.

P£i3J EMarhPfe lO pllij The following te an pKompfe of a preferred embodiment of fee present invention

2, the 1¾ between 0.2¾ and 12, the DPAtEPA ratfe is between 13 and S3, the DPArHPA ration between 13 and 130. the DPAOHA ratio mere then 32. preferably more than 38. more preferably more than 30 most preferably more than 98, and tne hPArOHA ratio more than 00 6 preferably more tban i .5, more preferably morn then 2 4, most preferably more then 6 The EPA, HP A DPA and DHA may be composed os a glyceride much as fegfermndeh an ester •such as ethyl ester), of a free fatty add. P218| The feltowinq·: $s an example of an ernPociirs-sfinf of the present .rvvenfioo.

Tte 111¾ ie as a giyeehde fsaefi as Mgipasldai, an es» (suefem ethyl ester), or a free fatty add. mm mmmm |921 §) A mixture of OP A and ERA was prepared by combining 1g DP A Ethyl Ester {8EM33d!l} with 1Gg ERA Ethyl Ester. 914 mgrg (KD Phamia -FM130011 in IStetl bf 95% ethane!,«water containing 35ml of 2M sodium hydroxide. Thss reason mixture was stirred overnight art ambient temperature, lie analysis showed complete cefiversion of the ethyl estera to the corresponding adds. The madton mh&amp;re was cooted in an ice hath, acidified with ON hydrochloric acid and o»cehbated on a rotavap under reduced pressure.. Water and ethyl acetate were iddeb* the phased separated and tte atp^bus residue exacted vwth ethyl scetoto. The ^thyt «state extracts we^ chnihlnddydaed over sodium suftat* orc.lt retavep under reduced pressure Yield: . converted ίο thefee fatty acids as described In examplt ?.

[f211] A'"representative samplefIfeyl ester oompoMhors was pnaly^t using split ίφοί fey capillary gas ch;rpmfip|ra;pihy by a 3D meter x 0.25 mm Restek Stabs! wax coiymo using temperature phsirarfernihg. 10220] EamfeJ3 [0221] The following describes studies (Study hi and Study 02} to determine the affect of compositions of the present Invention [0222] STUDY m-Zmkertm

Male, eight to nine week eld noredladefie locker rats are used, with eight rats in-3) per group. Examples of compositions of ten present invenne-n tha? are evaluated noiudtd COMPOSITION 1 of Example 29 anc COMPOSITION 3 of Example 51 "> addmon to exemplary compositions of the present indention, v'ASCcRA^ .,ϋ c - x-wfitv! ethyl, mug yxier of eioosapentoereoic a· *d? on-- atorvoMs-nn Jr·' men as mint once compounds.: Vegetable ell is used as a diluent, «md to prepare the itfebtosletie for dostog. A separate gfOdptor bnlhialstmdeiyidf y^gteble eiliafeheiife: ο?*, t -a animated rontml gnx ^ ^pn.is cc\»· \* v 1--- 4 ^oiaHoni 'by ^rai iaviigiei The sly% Is oo^iyel^d m 2 phases:. 1¾ the first phwse, COMPOSITION 1 COMPOSITION a and VASCEPA^ are adm^i&amp;temd m300 and 10OP pigiki>: a<Jdktoasii SO mg/kg dose group Is foufoded: for If» «NritaHtfewi of-HilT 8003 pslsne^ Anteak « spsM daily for 14 dap: : CQB|POSITICfN 1 arid COMPOSITION 3 are «sad in their free odd forms. Thi pfias^: op t#; wild lie grnups mgeivlhg ffom»ifeon 1 and

Formutpipn 3 :nnd VAiCEPAsi el doses of 400 ms?kg feeing oo*admfniaiefed: atomastatia Another group receiving atorvastatin ;s indLKfed as a reference control This second: pg&amp;su pormfeted of 14 dap of daily, em:: $κ| ministration. Pidsma fogiyoarides ..tNJlStfoiT m #y 0, 1 end Ifogm! for those groups included In the second phase on dap 11 sod 28, In addition, total cholesterol, LDL. HDL, VI Di. and ME PA {non-esten!ed tree fatty sc ids) are quantified or epfeuloind as secondary lipid parameters, along with mtses-miem of glucose. ALT and AST concentre dons, ah tesfrg ;s geriVme-ii osmu standard techniques on a chomfstry analyzer. 10223] STUDY#2 -Homans

The overall phoriiiaooltt0i|es Of dll df ODI^POSiTlON 4, :'Z or 3 and evaluated versus a: under fePog or fed condtions m norm»!. mostly healthy volunteers In a standard, 4-wdy orodippr idal design format VA3CEPA!) is used as a mferende dompound:. A fetof af 4iluhp|ls: are separated into 2 groups of 84, ieob mfofeot serws as his or her owti Memai control for comparison purposes under this 4-way crossover design, indoskm include volunteers heiweeh egos 18-li, with a SMI of 30-35 (alternatively a Bfeli of 2?'3$) and triglyceride levels less- ifssfj-::35&amp; who densu^ 1 ish meatppr week; and- who afo phafmadmfheiapy for lowering tngfycarfoes,: loolt.fomg hut not limited fo ffomfesy gfofopdp agents, and nfecm. Volunteers on stable anihhypoouriissvp, antifoiabetlc and Ihytoid therapy Atalfowed for csnsideraiim Any person on stable sfotlh therapy conslddrod i ihefoty ycedbe fevats are fesrlhan 3§§ mgML However,; the total composition of subjects In the study with this particular profile is limited to no mom

It224] Volunteers omega# nomprescripfion dietary' supplements atobSired to ;^a. 2 weeks pppr to the initiation of the study untit study comp to? ton B2mi Ε^μξ^9^^^£Μ0ϊΜΜ§μΜ: :p2il| The effect :gf :eii0ijy^imlhl®|raltori of tlm hompggndi tesfed m:tNp .tou# &amp; eyfcfN or^el^r·: contains, in onti®r ip determine drug pharmecokfoatfoth m:mtl y^a^PMama tbe eff^Gte. of food on drug pdaffhaeokinotico, COtoFOSfitQht 1 or VASGERAi; are dosed at 4.0amstosy in

The morning by ndmihistratlort of 4 eapsoies copfalntog 1 pfdm of agbh compound Several days prior to phomsaooktoetfe evalyafens, voiuntoere are hoy sod at the testing facility in order to ensure wdlreontroltod eKpedmetoa! oobdttiono. |0227] Compounds are given to volunteers following an overnight fast, with plasma aampteo nbtainad prior to dosing and at mrioos time points after day 1 aod dey 14 dosing. Volunteers are allowed access to water, and well-defined meals at certain times. Afterwards, compound administration is stopped for a 2-4 week washout pebod, and the groups are Globed with respect to^tob compound they would rocotve. manning that ili group toitially fecei^ving Q<^iPC^fT10^ i- |i switphod to reddlypi V^SCfiP^ and vice versa. Facing pharmacokinetics are determined yafrtg the pmm^um dsdobbed ahoyo, Mtowtog eompteiloa of fcsesond 14-day dosing cycle, compound dosing is stopped for a 2-4-toaek Wailto:ui period prforfo lid: initiation of the a similar cycle as above, nowWith ©OPPOSITION 1 Ahd VASGEPAfo administered together with a meat |®2|i| Plasma levels of omega-3 fatty acids fftdiy :ar&amp; detofmtned utiisdng ah analytic·^ LC/MS tochnHfoe ypferSLF laboratory sdndifods to: pdldr to determine €todik,;:Tm®;apd AUG for the orrrogatolatty acids of interest, including EPA, DPAcHiPAvpHA, and other omega# fatty adds. mm B§mik i00010]The results of tlMf study show that 1 has a bettor bioavotobility (as meoadretl by AUC ar$‘t&amp;ug&amp;;$grt Vl^sepli* This aim: if d&amp;tof under fasting and/or fad adniofetralkm iwiiitoos:: (00011] In an alternate study design, this Study 42 is conducted with a certain dose fetof of COMPOS IT ION 2 OR CGMFOStTION 3 ipstoad 4 GpMFOSt TtON· 1, mm I™pto34 glflf l$TUt)Y #3) TO dolt mini; M effect of r^mpoeliona of the p^ontlo^onlteo, [0102.] A Mu Hi- C Fla^efeeii ·:$1ΐη$*

Study to Evaluate the Efficacy and Safely of COMPOSITION 1 2 nr 2 m Patents With Fasting Trigtycende levels 2SCX? mgfdL and :S2iXi0 regtdL; f0103| This Phaae 3, multi-center iWy #nsits of a S- !b 8Avbak •f^srfing.'wa^Huut .ρΛ$! |I0: diet add #api®fion pododjv whthh foefyde^ a losing tagiyeeridt <?pflty‘ng peiad ofl^S weeks, fdt!owod:fey a 12h yyioi dGMbte-Uind treatment, period. f%ieris; on elabn therapy (with m without e«iimibe) at scroeoidg spo oyalydlid by the Ib&amp;ttMfgfef could be safely discontinued at screening, m if ft &amp; to bo continued. Patients on any other dysfipfdemia therapy need fo diapondnao those m o^dor m onayfy· for thestudy. If sfaffts therapy {with bo buntieesd, doaoia| muii: 0a stable for 04 weeks prior to die fasting TO baseline :^piips§ fir randomization. The screening visit is to occur at either δ weeks before Mficibmtiation for parents not on Sipid^tterfng therapy m ipmemng or #r paionti who do not need to discontinue their current dyOipalernm therapy, or at 8 weeks before ratKJpditkalion for paberUtrwho rdcpfri; fhorapy af adteenlhg:, pi04] Thi',|^Pl^Pibr this study is men end wdhiah ;a· body mass index tBMt) £45 kg/m2, Patients on lipkbiowehng therapy and patients not on iipkMowanng therapy are eligible to enroll in the study.· Patterns bad to have an average TO level £500 mg/dL. and dSQCpmg/dk. daring th« ccranning parted to be eligible for raodonuzaiion.

[0105] After confirmation of :gual%lpg;:feetlhi TB v®tee!: .eligible paiehts wit. enter: 112 v,i'vk insorrwo'p duuNr M,ml :u m no*'* »<. A. V'V’X 0 p <ht* Ta writ be rmndomly assigned to 1 of the fefkm'mg treafimant groups; COMPOSITION 1;(t g daily), COMPOSITION 1 (3 g daily). COMPOSITION 1 (4 g daily). <* placebo The ^ ::^ΒβΜΓ3-· p«tr- day. 80 patterte per treatment group will b#jmmtemizdd lb tfe Stratification will be by baseline fasting TO levs! {^750 mgkfl drWSO pgdJL, gender, and the use M .statin therapy at rar^InmOatiera Ow^^r.-te^o-ybld-bllrd:'. return to the site at Week 4. Wwk It:Wddk:12tfdf safety ^uptefepic

Ii10?| Tli; petodfy: adjective Pi fte Atdiy is to determine the efficacy or COMPOSITION 1 at a 2 g dmiy dose, 3 g daily dose ami 4 g daily deem compared to placebo, In towering feslng TO levelsm pnttents with lasting TO levels ;aS0i mgtol add 420€0 h^idL pisa| The nf the study picij; 1, To duterHane the :safety asdtotemhsMy of COMPOSITION 1 2 f daily. 3 g dii^idddidally: pidd|: &amp;i&amp;< ^mrn m e#e&amp; of composition· i m ^;pmm ^r#l CfCy h-dansity lipoprotein ^oioftorof (nip* H0OC:) few-density lipoprotein cholesterol teDteO), higtedensity lipoprotein chotedMd (IHjDL-C), and very foehdenilty (VIPL-C); .0111] 3. To datermVmlhs cited of ΟΟΜΡ·0$ΓΠΟΝ 1 on apoiteoproteih A-f CapoA-i), spalipoprotein B |ρ|ϊό B), epo . A-l/apo B: .ratto, f|>dproteinM) {Lpl#,. -;<$d Ilpopmtpip-e^sootetad phoepbollpaso A2 fl,p-PlA2}:; p112|: t ;p#i3Ct of COMPOSITION i on tow-donsity lipoprotein toy pnritte number Wfifeo. on oxidizedtP!~ And on Odetctfva pmtefn (CBPT [8113] 5. To dotermi» fM effect of COMPOSITION 1 on Idtraoeilular adtmeioo ffidecufe--1 (ICAM-1) vascular call adhesion fhofecule 1 (VCAMC% Interfeieolgd OS $11-18), interieykin*2 (11.-2), irdodoukid-i (fcd), itedeuJdfHi.(IL-S))lnted^ti?s-l:£l (M 10). interleukin* Ί2 (1012), inteheuteml5 til-15). intorieyNn~f8 {!L-ti)s tumor neaests factor-alpha (TNF-u), tumor necrosis factor-beta tTNF-S) and plasminogen activator inhibitor-1 (RAM);; [0114] 6. To determine the effects of COMPOSITION t on nuclear factor kappa* tighf-chain-enheace? of activated i cells (fplB), widhecin raptor (oepd), glycopmifein ilh/iJto (gpllbfllla and ether pafelet and thmfflpDgetic factors:.

[0115) 7. To determine ten effects of COMPOSITION 1 en E-setectse, P-setecfen.

Itoto&amp;yttelrte,:^^ thromboxane Bi fTXBiT ihrembcxst® A2 (T4W2), Iteonteoxarm B23 0m%. A3 fXXAy,2,3-dtnor thromfemmrte 82, free fatty adds (FFA or ΝΕΡΑ), serum amyloid At i.nmrn amyloid A2, serum arriviste A3 serum amyl,μ! A4, thtobarferturte acid (TBA) reacting rnatertei, adtpenacdrj (GBP-28), hernogtobin Ate [HbAflc. k facing to&amp;ulin, fesltog glecegor?, lasting plasma glucose, testing plasms ;'0^€φρίΝ^·'. iimofsini : fid# ;«nf) paayigcyte eittaapfaw^^ ySMC&amp;fc pi ti! fj To determine she effects; ff ipy POSITION -:i(· - :|Ρΐ dlaior/ derived -nwoparttel^· -mean pfsfekrt wrlomp Pictet subpopuidso^ platelet ptetelet «hdoteeii^b# «$$$$ nmidbbfe ξ00Μ^% M$t wtf*.:«*$. blood pressure, |0117] 9. To tevostliate. mlgiloogtilp MwembCttef^P&amp;'· ia IMy add eoocon irntions (including B*&amp;>. OIM ' aad DPA] la plastea aad rad blood coil nrombfane» ondido totiaj 10. To: laiioaliiolo the relationship betwoea ohaages la fa% aofcf eoncentraffons ftraskidtog EPA> DHA and ORA) ip plasma end apt blood coil m^mbmaas and the rodbchan in teabag TO levoiiu |0119] The primer/ efficacy variable for the doable-blind treatmem period is percent change in tasting TG from baseline to the Week 12 endpoint.

[£H20jj Tine' -secondary' efficacy variable for the doyhle-bllad Irassfamnt period1 includes the following: Percent changes in fasting iiklomldtii^G, LDheO, MOt-CT Lp-PLAS, and apo B from baseitae to Weak 12 eadpdlat;, [0121] Statistical methods for efficacy ovoluatioas will he conducted oa the ioteab te-beat {ITT): add on the pepprctecol popyfetten. OeecripliW :$tef£sfifcs tor the basoHno end poobhaseiino measurements* theptepintobteilete or ehahge« tern baseiiae are to bt presented by treatment group aad byefelfor al effeacf sdablos. [012Ξ] The primary and secondary efficacy analyses will be ptidormed edng an CAMCOVA) mc#§l Jmppimi gemfe sod lho os# al statin ^Ti^iomtfaUan as factors · and toseine !astla§ TO vatee as * novariaie [0123] io on aifernate sb.idy desrcpn. ttes-Study A3 1' e love c < rOMPOSI f < Ή 2 t IR O nsmed * COWOSd i ON 1 piail pi|if The following deoenbos a study {STUDY #4) to determine the effect of compositions oi the present --rs eon lion ptfij A MuHFCdinter, FlaGebO'-CoeirolfecI, Ra^domjz©d,Ocsyb:te“ BiimX 6- to 12-Wd#k· Stfee^-W fSffkxscy and Safety'fef GO^^SrOQ^-fj. · 1¾- 3 tns Sfatimlrsafod Fafiohts %lli H|gh Fasting Toplyoefeie Levels 1¾¾) mgML sad ^4¾ mg/dt, ]&amp;127] This muffeoenter study m .period (to Include a diet and lifestyle stabilization period, and to wash-out any non-stabwezetknkw dyskpidemis medications), which also mdudos a 2-3 week fasting idgiycebda (TG) leyel qualifying period, fofe^Wdl-:l>y ra, AS?®^·doyfefebUnd treatment penod. Patients on stafiin therapy {mh w without ezehmlba) at screening dfe eyetuatad by the invealgeter as to whether thle th^py does maintain tew-ddMly llpopfdtelh IhOL) ievats of a 40 mgldl and M semedfrsg, statin therapy (wAh or without ezebmibo) ;s to be initiated, in those parents who am not on statin therapy in order to achieve IOL levels oi a40 mgMfand «100 mg/bl. Dhse|s) of statin therapy must be stable lor >4 weeks prior loefeta. ^Μφ&amp;··φκβ#φ measurements for randomization. |S128| The population for this study is men and women >18 year's of ig# wp a body mass Index {BMI) d4S fegM, Μ$φφ:Μ· jii^Nwer^ thm^py and patted: not on iipid-lowering bid te haw on average fasting TG Sdvel ^2^ mplL and 04$®·period to be eligible for randomization Ϊ0129] After confirmation of qualifying fasting T@ piuei, dltifhf® t^I dhtw a i- to: 12«eek randomlied, ^Λτ^ίΙίρ^ίοά· l&amp;iante will be randomly assigned to one oi the following treatment groups·. COMPOSITION 1 at ΦΛ. a^upmmon 1 at a 3 gram daily -dose, CfOMFOtmON l ot a 4 grsm dally dose, or placebo. The da% dose may tefafcgm m eimdfeso or distributed over two doses per day |0130] Approximately 2:20 patients per tmatmeit gmop will fed itedomlip In tfeis study. Stratification wtf he by gender Dunng tb® ;$pulijp'fefind patfeiti yil ifeprn to the site at Week 3 or 4 ©he week prior to the tasi weekof at the end or the mhdomizdd treatment period for iteicy add safety evalyailfens. '^t^'^The primary dfefactfvB of the study |$ to deteornin© tie; afeaey of COMPOS !Tl(>fV 1 m 2 gmms daily. 3 p-ems daily and 4 g?^m§: dsity,:: place bo, ii 1r)#»0:p4r«i#^ patients with fa sung TO tevete l> 2 f ?0 mg/dL ®wd dAii m0i$L· f01S2| The. secondary awl expiratory oo/mtves cd ;he sfely may include but are not limited in the following objectives [8133] 1, To determine fee safety «dtttiMltijaity of G©MP©SiTION f or it of 2 g daily, 3 g daily and 4 § dally;; 18134] 2, To determine fee effect of COMPOSITION 1 of on lipid pmltes,. inqiudfeg Mal cliioteteFoi:|TO| l^oprotA CAofe HOW!) iow-dwiaiif ilpopfetam cholesterol {LDi-C), high-dift#?^ :|^b.t#steeb| fHOfeGl, and wry !ow~denaity lipoprotein cholesterol CVbDfeGf [01351 3. To determine the affect of COMPOSITION 1 on apofepoprotein A*t {apo A-i), apoilpoprotesn B [apo B), apes Al/apu B raUo, lipopmieNa.) (lp[a]): and ''t^^telrwasacigaj^i:pf»spioHpaae A2 ttp*PLA2); [51361 1 To determine the effect of COMPOSITION 1 on low-density IpapKdeid Ιλ: Ί ' pnru< i<> ιιίιΙχτ j)>t we, on oxifeoxi LDl tinth-s^tsstivrly C-mackvu orofem ihSJRP' to·’ \ C faiKliv*. fif'jh miCRf’t [0137] 5,. lb: determine fee effect of COMPOSITION 1 on Wracalylar adi^ied moieculfel (ICAMO), vascular cell adhO^n~!i§. intecteukin-2 0L-2), interieuWrv^^f^SI 'lnt#rl^3^4:;|M|r' (life 10k mfeSeukfe-12 111-1¾ lria#ykfe-ir ClLfei), imwt: nvcosis factor-alpha (TNFo), tumor necrosis faidnNsfte [TNN3} didd pismfeeged activator inh«bitor-1 (PAM); [0130] t>. To determine the effects of COMPOSITION 1 on nuclear factor kappa-tighbchemmnhaneer of activated B cells ifepepif (gyfld), glycoprotein llbdita |gpt!|fl!fa and other pl^btet [0139] 7, To detemtine the effects of ΟΜΡΟριτίΟΝ 11on E-feel^n, Pfeeteetln,: homocysteine, throfetexine 82 {TXS2)f thrembhxpie ΓΓΧΒ3), thromboxane A3 ITXASI.I.dylfepr fbrombnxaae B2, fee felly aette IFPA or NEFA), serum amyloid AT scrum amyloid A2, serum amyloid A3, serum amyloid A4, IMobarbifurlc afed (TBA) reacting material, adipotmdln COBPfetB), bemoglobfe Ale (HbAlc ), testing insulin, tasting glucagon, fasting plasma glucose, fasting plasma fruefesamine, macrophage oolooy Bflrnytatlng fector fM-CSF) maorophege colony eimoiatlng factor (OM-GSF). P1A©| β. To do!o^in6i lho effan§s ol CO^FOSITlON 1 drr ife^riO^giid fibrin 13-dimer, plafofei Wan tpftfeM Vbium©.· $0¥% pii»f ΜβήφϊΜ diphosphate induced platelet aggregation, piateM ersdothokii >-<<!! nbOt s«<n aunmifo pJ[ CAM \ nc-fo refo and sysfok; <md dkn'fohc fefeotf pressure,: [©1411 3- To determine the effect» of COMPOSITION 1 on fatly acid concentrations (fnduding ERA, DHA and DM} la plasma and red blood ostl membrenea· |&amp;14ai 10, To inyesfigafo fha. refatosfip Mmm- ^ 6¾ ePhifootr^feos .(irvcludirig EPA, OH A ®ηά DRA] Id plpama ifotf red bfodd tfoff mdmfeihea and (h© r©d£rtori^f^|ng'.TG'fev©f^ 1014¾] The primary efficacy variable tor the doubte-PIrnd treatment period is pmw$ change m fasting TG from Pasetee tethe Weed A In 12 appoint [0144] The secondary efficacy variable for die dobbfe-feirfo treatment period ipciiKte feyt am not limited to the following; Percent changes VLOl-C, HOl-O, Lp-PEA2, and apo B from becfitilvto Week 6 !o 12 endpoint, [D14§] Statistical methods- for efficacy evafoatte® on the Ment- to-fneat ιΓΓΠ anti Off Ihe penprotocoi population, Descriptive statistics for the baseline fpdf ppalihaselfoe fneasuremihfo] the baseline am do fee: presented .by treatment p reap ana by visit for aitfo&amp;aey: vinat>tea, [014©] The JgfeMiiy' ifa''irtbttfid^ ©iffcwiy· analyses'll :fc*·. using &amp; analysis of covanance fANCOVA) model with treatment, gender, the type of pfelff therapy and Agnesis of diabetes at TG valve as dlddyadsfe, [0147] in an alternate study design, this Study &amp;3 is ©rfh'^e; dose ifevois of COMPOSITION 2 OR 3 instead of COMPOSITION 1c IS 1481 b>JM>te.l§ [0140} The foltowfog efesenbes p study iSTUOV #Si ie: deformlne thp effect of eompoMtions of the present Invention [0150] The impact an fasting triglyceride levels and ether phaimeeodypamfc: endpoint* of one oi COMPOSITION 1, 2 or 2 am evaluated versus a totetpee compound after ads mnisfiafson under Fa shop or fed #?k|i§pg· hsahhy wfubte^m -m. © .la^rrdani. 4 -vipy cro^ss-over trial design formal VASCSBPA#: compound. of Ϊ4 &amp;eh sublet serve® amtomor Iw owe ttoemai control for comparison pyrpo^® :odder this 4-way crossover design: fndusfon catena tor :t*Mj[ between ages 18*85. of 30-35 27-35) \a^k&amp;$$pe&amp;ftde levels less than 350 mg/dL, who eansume "no more ten 1 1¾ tedl par widl^ ted info are dpt currently presented pharmaoQ-toerag§i for lpfe££ae l^|lpf.rta#0v :lr|^lii^3i^g, .:1¾^. ;:=H#t- -:}smit©<S to fttetoS: emega-3 agefipvadd; nibdia Volunteers oni stele anlSpyperfensive, ar>il-diabetic and toyrtod th&amp;rspy re allowed fen consktomtkm Any person on stable stoUn therapy w oorvudered 4 their triglyceride tevels are less than 350 rng/dL However. the total pomposrt?on of subjects In the etudy:with tvs partioolar pmfjto rs llmiled to no more than 30%.. lil-lif N.:o:rppga-3 oorM>m®cr:ptlon -dietary supplements ere asked to mteto from the®' use 2 weeks prior to toe mnatioo of toe study unti* study cnmpietion, Subjects umon any other non-s'erteej antHnilammatory agents other than acetaminophen are asked to abstain and switch to toP^rfopheo for relief of pain, or grp excluded from study opnsJderatiofc Suhjocis era -excluded if they receive any type of imemone therapy, weight loss agents. HIV therapy, befo-blockers, or are diagnosed with known cardlovascutlh ihClyding heart my m-cldoncd of actie coronary syrtommo. myo^relial infarct, eb^daryiirt^^hypass graft sutg^.fi^tor- ^ioptasty,- [0152) [0153) The effect pf oral administration of the compound® tested *p this tfody Is evofoafocf under fod versus foshng admioietmttohi '<§priditof^s to ddtermi» drug pharmacodynamics and affects on lipids. COMPOSITION Ifof VASCEPMS are doeed:al 4 gtomtodsy in the morning %.adrntoietratton 01::4- ctpeufps confotoi'ng 1 g toil of 0ech: cornpoynd., pi$4| Cpmppundsmre given -ah idygmlght fast, with plasma sate^oo obtained prior to dosing on day 1 and day 14 do&amp;tog. volunteers are ailbwod dcoass to water, and wBlktefined. mm*!-' certain times. Afeoyatos, oompspnd admlrrisffatigo: to stopped tor a 2-4 week washout p^tod^ ead the gronp® are switched with rasped to whieh compound they would receive, meaning thatte group initially mueiying ©OPPOSITION 1 is switched to receive VASCEP.A®. 4¾ vice versa:. Follmvimp-eumpleton of the second 14day dosing· cycte,. ..campbund dosing is stopped tor a 2·4-week washout period prior to toe «nitration of the a sirnila? cycle as above, now with 1 and VASOBPA®) administered together v*jmial, [015$] Baseline plasma tevfcls of fastis seftjm triglycerides are determined on. day -i; ao#|Uyl prior to initiation and pomptetion of either the testing ipoftodi Additonat ypid and otoer i;Rdauitr) that: a® anaiyzui imiedud tola I eho oBoee lOl, HIM Vi PI anil BO A as previously described. |i?^| iftecti m platelet teaetiPrh such m. bidding time md PA&amp;te&amp;issti aggregation are also data twined Standard physiological plasma and urinary safety markers indi^lg limited id etecheiytes* ALT, AS?; BUN, glpcoae, blood gesssare. itocterd gooff dMcai trial guidelines. PI 57] (00012] Tho results of the study show that COMPOSTiSl 1 ha s a bettor tepiyceride lowemig effect than Vbscapb This affect is seen coder fasbog and/or fed administration conditions. Admlaistmilomof COMPOSITION 1 have a bonoicfai effect, versus baseline and verses Vascepa. on other lipid parameters (such as HPi SnS-ai chotesto'ot norvHDL ehatesterei VIDL shotoefemlk on platelet ;fdhdffory: bod ®m·· «swii of the lolfwittgi apdiipophiWh Ad (apo A-I]s apptipoprotein B (apo B). ago A-l/apo 8 mho iipoproteiina) fLpfat? ipopromln-associated phospholipase A2 (Lp-PUVO;, tofy debsiy Ipoprotein (LOL) particle ouraher and siza oxidised LDL C-reacUve protein (CRP1 high sensitively C-reacbyp protelR/fHSCiRPf, lotmcellui&amp;r adhesion moieGyliel IfCtAl^eiA E-spfepbp, j^Pdjdcfkt, vascular cell adhesion molecule 1 (VCAM-t) or duster of differentiation Kid iCD 106), mterieleokin ΊΒ {ll-Ίβ}, miemtukis>2 iit-2), mterieykm-6 cJl-6}, interleukin-S {)L'8}t B^eukhvtO φ1ϊ&amp;: IhttrleukfhOi (MET 'm^rnmiW CMp| inledeohn ·ο \\L ids tumor nenrols, fnrtc’-alona ιΤΝίΑΡ H rrvr ne·, rosis f.nio* tmta(TNF'E). piaaminogen activator irmibitor-1 (ΡΛ1-1/ homocysteine. thmmdoxant? B2 (TXB2), tbmmhoxane A2 |TiS|s A3~di;nor thmmboxana BA tree fatty adds {FFAl, semm amyloid Al.iaerpm amyloid A2, serum Amyloid A3, adFpm anytofct-fMv thief barbituric acid tTBA) reacting maternal. sdipooeoA tOBP~2B). hemoglobin Ale fkfbAic K macrophage gmnolooytp madrophago colony sfimufmieg factor tGtdX3SPL fthnn frdlmer, plaietet dedved- miempartmiss. mean platelet volume fMPV), platelet pphpaputab&amp;ns, heart rale. s-ptolc and diastolic blood presSaiir, enhancer of activated B ceils (NF*k0) adenosine diphosghete phitetet ^ndo theca i colt adnosion moK';nle (PFCAM-1 i wtronenoi receptor m,JM »?*d gycofMofrtri liM!l^jplib;Hli3) TNs effect fc wtlh VASCEPA®, AdimiNsIrahoii of COMPOSITION 1 pra mframsi jmpaci or no imped. on other οοοΉΡΙ, §pid parameters, each as I.DL ohOiesierol ^rmts basalipe and vascepa, inan piternafe:siptfy^ INa;· Study 0$%m^mmMh a paftn^ doss tavst ?ΑΟΟΜΡ08ΓΓ1ΟΝ 2^ COMPOSITION 3 instead of COMPOSITION 1. mm bsss^^ 1. A fatty aatl composition comprising at toast 5Q% o?mHp<$-fatty apcls. tafe of derivatives thateoi. while etmnpnslng pteasapentatrtoic acid rEPA; S20:6At3| apd: doacsapsntaenoic acid (DBA: C22;5»n3) and wherein the EPAiPHA rain is higher than 20Ί. 2. A fatty acid composition ddmpdefhf at sails or derivatives thereof, white ^ρρ$φ§*ϊ!^λοΙο Oi0:S-n%aml dosasapentaenoic aad (DPA; C22:5-n3) and wherein the EPA;DHA ratio Is higher then 20:1. | A tatty acid compoiffi#· i&amp;fttprmiog :it'.:fesst:'?0% OA5a§a-3-ia# Λ,Λδΐ (ddnyati^ditheiadf, ®hlfe:pdrnpnsriig eloosnpemaoeote aoid iEAA; O20:S-n3f and (^dddsapatdaahpfc add |0PA; C22;S-m3| add wfWMn the EPAiOHA tsdio is higher than 20:1, 4 λ i iit> and comm m<o-> com; >,- · <j a' l mi .%‘S omegas imiv axis <a!ts or derivatives themof, white comprising picosapedMdgcjo CERA; C20;iAt2|:and docosapehtaphOig a-'d (DPA; C22;S-n3} and #ietMn the ERAiPHA ρΙΙο Μ hig her: ftiap 20:;1 ly A fatty: acid cornpivetmn compdr-irra at: least 6l1% amsgadSdahy adds,, salts dr derfeatlyps thereof wh4a ggmph^ng e^cdsApanfainOfc;: add piPA; :C20'6-rt3t and dodpsfppnmenGic anto {DPA Ci2 5-n3) and wherein *$!&amp;'** hlgherlhap: 20:1, A f<*% imposition comprteirvg at least |;S% Mlf% .S^iS or derivatives thehsof, white composing cscosappolaoook' acid {ERA; C20:5-n3) and d ooo so p o ru a e η ο s c acid (DPA; 022'5ό3) ami who·*:?; the ERA:DHA ratio is higher than 20’ 1. 7 A tatiy acid cars position composing at least 90 A orrurge-2 dotty acids sails or daayghves thereof, white comprising mcosapentaenoc add (ERA, C20· 5~n% and docosapentaaoc'sc acid iDPA; C2£.5-n3) and wherein she EPA DMA ratio m dohar than 20:1. 8, A fatty aad composition comprising aUeast 96% omega-3-fatty acidsc salts or derivatives thereof, while composing eicosapeeiaenok: acid {EPA: 02(3:5m3) and digpo^opcntaanoic aad (DFA; C22.S-n3) and whardip th# EPAiSHA ratio is higher thao 20 ;i, §( A somfidslIPh according to ana of the prgfhrrect embodiments 1 thAyughthroygh 8. composing if. toast 2% Poeosapeptaepetoaefd (ORA; 022:Sm3p 10.A composition according to one of the preferred ambodlmerds 1 through thmyghS* compnsviy at teas! 4% doeasApehtsencko acid fDRA; 22:2:3-1131,. 1%A composition according to one of tho prettmed embodiments 1 through throyghB, comprising at toast 5% doooaaponteenad add (DRA; C22:fhii3}, 12 A composition according ttJ cos of tile preferred embodiments 1 ihro-igh IhroughS. comprising at feast Cf% dgcoiagentaanoki ect-d (DRA; €22:::5913), 13. A composition according to one of fie preferred embodiments' 1 tArhugh hmuyhS, comprising at least ?% dooosapontaeoek.: sc id (DPA: C2£v5-n3). 14. A composition according to one of the preferred embodiments 1- thrmtgb throuyhS. comprising at teas! 8% doensapentaenoic add tDPA; C2£'5-n3).. 15. A composition according to one of the preferred embodiments 1 through through?? comprising at least 1032 docosepehiaenolc acid {DPA. €22 b 15 A composition according to one of the preferred ambc&amp;mynts t ttrough t brought! composing at kmet 12% doeosepentaeriott: aoxi (E)RA C22 %n3i 1?.A one of the preferred embodiments.' 1 thfpfgh throffh% mmpmng at least 1S% Aoppsapfotaeoefc adkl (ORA; €22::5-03). 1S.A odPtpoiAioh according to one of lie preferred embodiments 1 throygh -through 1 7. comprising no mom than 95% ERA., IS.A composition· according to one of the preferred -embodiments. 1 through; through 1 7. comprising no more than 10% ocnegu-S· fatty acids 20. A composition according to one of ihe preferred emtfediments 1 fhmugh h 17 compriciog op more than 7% 00^090-6 Mty poidp: ft. A mmpoiitfeB according to one of toe pmfened embodiments t throyih: ^'oughl *' comps ivn more then ο '0 omego 0· feto acids 22; A- composition; according to btfe; of the preiocrod ep?l^djmostt$i 1 ttepgh: ii muqh 1 ?, com fir*-ο? q no morn than 3 omogmd f^tt nofe ;2:feA: oompoetfeh: sccordihg: to ope; of the prelected mobodtmerip f ttwpogti rthmuihSfi^oo^prfetngvno sreo^P tioo 5% amchklotife acid iC22:4fe6). 21, A composition according to opptpf the prefepad eiebodsmepli | H.'in thmygh22, comprising 0© mom:thih4% amchidoPto apld;C022i4-n@). 2§:.:A. composition aecprdieg to mm:-M 1 thmogfi thropgli:22. pgfepnsing 00 mottthpPrlSt

Mih oomppiltipo aooordirtgi lo one of the preferred opbodtrsdots 1 through fcroyghfi, oontpriaiog m room than 2% areshidonic acid p22:4m8l 2?Λ oomposition according to one of Use preferred embodiments 1 through thn>ugh2? comprising m mom than s% araohido^:dcW:|C22t4^®), 28 A composition according to one of the preferred embodiments 1 fhmugh ihfeugh27, also composing henek:osopentdeooic acid (C21:5-o;3), 2tb A somposihon sccofemg: to opo of fed pfetferad #mfe>dirnd?tfe t thmupti; toruugh2?. composing at feast 0,131% honcmcsoponP'Kmofe >1 if21 5-nY; 30. A composition according td ooe- oi ihe preferred embodiments 1 through thiooghf?, composing at least 0.1% heneieosapentaeoofe add ¢021:1-032 31:.A ; oomposUipp aPcOfdhtg; fe thb preferred: .pobodimenfe T through thfebQflf f l comprising Obfeistadd (€21 :S-n3), '•3l2A:. .iiEaisnii^sitibh· according to pod of the preferred embodiments I through: !h*ough2?, comprising at least 0.5% heoeioesapentaeooio add (C21:3-n3}. 33.A composition according to οπό of the preferred emWimerits 1 through through^? compris«ng at least 1% heTOicos^p^h^enoic -v'ic ,C21:3-:3)}. ;p.A cximiposiligp according2:lp doe of fee ptfteffedllembedirndhts: 1 thfepgh thmughf?* ddfepdafeg at hdneicosapdnfeenofe odd (€21:5--03). 3.8-A egmpbiii0!n.-'«SOnd.ing-:--iS! -m®· pf fee preferred arotxfeimenfs 1: Ihiough feiouqhfef ©oimpi ferny at feast 3% hrsiescosapem-u· noic a·: d «02 1 3 mo 3d. A composition according' to one of the preferred embedisncnts * thmpgh through^?. comprising at feast 4% HenefecsaperCne;sac; acid «C21 5m?) ;3AA sompiMiffei ^ preferred f through thro ugh 2 7, comp#tni hi toast M% hihothhpapefi^«rsofe acid (C21 :5-«3)< BSiA «omposttk^r :«0r4tog|.v|t:.,tRe .**·· "Φ® pfArsd sinfertwetfe. 1 thfedgti throughd'A cornpo^ng no more than 5A omega··· 3 fatty acsdc that are not omega- S-pentaeoolo Acidic 3¾. A cofppppttsoo at^thfeg to om- of tH# prdfehhd embodiments 1 through thmugha?, eom?)o*?ng ou morn dvm 4% omega-3 tatty ao-ife hve <**»> not -μν 3-pontoanoiC aods. 4t>rA composition aceofdtng Ια -.pt#: pdf ]$m profeo-od o.mhodsrna?lt$: 1: through ihroygh3?, comprising m more #ph 3%idihega~3 fatty ee-ds that ardinql omega-u-uenfaenosc aocis.

At. A ^imposition aceorchm;) to one of the preferred emDodimems 1 through through^ composing no more than 2% omega-3 tatty aoris met ore not omega* tvpontnonosc acids 42Λ oompgsitiop aoeordfeg to one of tho preferred .embodiments 1 throi^h mroughs7; comprising m more than 1.5% emegmu fatty are oof ornegge-3-pentaenoio:: astiii: 43. A oompoeifion fe ii preferred pmtedlmords 1 throic^h thmughST, oamprisfeg no moro thoo 1,25% omoga-3 fatty acids that are hot ismoga-S-pontaenoin acidic 44. A composition according to one of the preferred omhodimoots i through thmyghd?, f% omege-3 ^^ecids that are oat omegas 3-panfaonoio odds. 4CA ;w on#.-0 the preferred embodiment* i through fesugh44, wherein the EfAA:GPA ratio is between 98:1 end 40. A composition according to one of the preferred embocbnmnls 1 through *-hnx,gh44 wo^rmn tfe·'ΓΡΑ ΟΓΛ r»mc> rs r^Aweeo Od t ο no 5 on 4fiAc©etttpo^|tlort:0adi»fltw -Is mm:·· of me p^eeed emeodlment* f through !.hmu:gh44., wherein the ilAA:BFAratio Is ifet^eg^ 1:10.. ':^ one of the hfefeifed embedment# 1 through fhmugb4-4 wherefe the if%DRA ratio is between 40:1 and 1:3.. 49 A compose on .mnnming to one ot the profound embodiments 1 through thmughdd. whiretr the iiFA:OPA mwp-mtmm®: 40:Ί odd 1:¾. 50 A composition according to one of ex? preferred embodiments 1 through ttirodgii^4,: tho EFfeDPA ratio is between 48:1 and 1:1, 11. A composition aocptoigg: to 000 ¾ pfefert^d· 1 v though; thraugMA wherein the fcPA DP A ratio ts between 30:1 and 1'1 82&amp;:<βοιιφοιΜίοτΐ· according to-'im^-ifie preferred ambodimiti&amp; i vftreugti thraugh44, where jo the EPAtDPA ratio is between 20:1 and 1:1 53, A composition according to one of the preferred emP&amp;dtmems 1 through thraugh44i: whora-to the EPAiOFA ratio is between 10:1 end I lf,: 54, A composition according to png; of the pr$|gfi$&amp;· 1 titotJgfe tbrouglvfe, wherein thd, EPAtDPA ratio is botweeh §:f and 1;1> 55, A composition acoeetaftpior '«t tof .Ifes prefernid emb^imonfe 1 ttrangh: ibfeu9h44,:wh^ :rptip 14 bblween 18:1 and 2:1, 56 A composition according to one of the preferred embodiments 1 thrao§h mrough44< wherein Ihe ERA: DP A ratio is between 2D1 add ill , 5? A composition according to one of the preferred embodiments 1 through jhrough44, wherein the ERA QPA ratio is between 38Ί and 2:1, 58,A imposition according to one of the preferred embodiments 1 through through#, wherefe the iBAipPA ratio tifee^e on 40:1 and 2:1, 88, A composition accord log to one of : the preferred embctoimaofe:: 1 : thraugh 50:1 and 2i, 60. A composition uncording to one of the preferred enfeodimpnts::i thtbygh thro ugh 44, wherein the ERA: QPA ratio is between 10:1 and 3:1, 51 , A: composition ;agpbrdig§ IP one tof the pmferred eimbediments T through \iud-ugh44; whpfelh4hp ERA:DPA : fetidis between 20:1 arid 3:1,. 62. A composition raonotofeg to one of the prefemsd: 1: fetough throuyti44, wherein the EPA.DPA ratio is between 304 and 3:1. 63. Λ composing ppcording to one of the preferred PmfetdimePfe 1 though EPA:DPA ratio is between 40:1 and3:1, @4,A PeinpeSittog abdording to orfe of the praferrsd emhodimoole 1 through through44, wherein the EPA:PPA ratio Ie between 58:1 ^bd Sil.: 85:A cernpoeitton according to one of the preferred emhodimonfs 1 through :thraugf>44. wherein the: 1PA;DPA ratio is between &amp;D:1 and 3:1, §6, A composition aamfelhg to one of the preferred emt»din'setos 1 thmigh thmugh44. wherein the EPA:DPA ratio is between 18:1 and 5:1. according to ά® : of tie preferred embodiments 1 thf^ph wfiorOiiitfei^feWA retie ss btowoeb 20:1 and 5:1, IB.A composition according to one -of lie preferred embodiments 1 through througMd wherein the EPA:OPA ratio ;s between 30 A end 51 6§;A compostioh according to one of tie through44, wherein the EPA:DPA ratio to between 40:1 end 5:1.

TfeA compoplioh: according to one of fie preferred emiodtmeots 1 through throngh44,:whorein the iPA;:BPA ratio ts between iOi sid 5:1, 71, A comparison according to one of the preferred embodiments 1 through thfOitgh^A, wherein the ΕΡΑίΟΡ^Α mtio Is between §9:1 And 5:1, 72, A ^.mm of tie paferred embodiments 1 through hrqngh-i-l, wherein the EPA. DP A ratio is between to) 1 and 10Ί 73 A composition According to one to tie pmferpd 1 through l.hfough44; wherein the iF»A:BPA ratio to between 50:.1 and 10:1=. 74 A composition according to one of the preferred embodiments 1 through ihroughAA, wherem the EPA DPA ratio is between 40:1 and 10:1. 75.A composition according to one uf toe preferred embodimetos t ftiugh thmugb44, wherein thu ERA:DPA ratio 10:1*: 75. A composition according to; cog to fie pmfermd : etoiedtoionts 1. .through throughAA, whereto the EPA; DP A ratio ss between 60.1 and 10. t. 77. A composition according to one of the preferred embMietotos 1 fhtoi^ A4, wtemfethn EPA'QPA mwts, between Hl-OP and 10:1. :7&amp;Χ ddmpasihoo according to one of the preferred embdd*totoii$ '1; .44,.

comensirig iX'tween 56% and 55% ERA 7if A composition according to one of the preferred -¾ cdmprfpiig befwoen 60% and 95% EPA,

Sp; A cotopesgiao according to boo to the prtoeowd emtoxiimonto 1 ttobuii 44: comprising between 65% and 95% EPA, B1,A toidtoeiigh according to one of the prtoermd embadimonto 1 through 44, comprising between 70% end 95% EPA. S3,A composition according to one tothe ptotoifod emb^ comprising between ?S% and 95% EPA, S3; A accordini to mm of the preferred 44,: comprisiii between id%end il% £1¾. 34..A composition accenting to can of the preferred embodiments f through 44, composing botvtoen SS% bed 95% ERA;. 4. A composition according to one of the preferred embodiments t through 44. 0%: :ER4 86 A composition «οΛ|1ώ one of the preferred orhbodtfeer^ i fhroogh 44,: 3% D-PA, :^pii^t^:'· liccordwy to ono of tf$: pr#f^^vfe.rii^^nls:·· :f 443 composing hetmreen t% and 5% DPA, 63 A cernporAion according to one ol the preferred embodiments 1 through 44 oempnpng between 2% and 1034 DRA. 89. A <^^p§ifei3f)!;:Bd€orcjing 'fe -grw of the preferred enfebdlmenta 1 through 44, comprising between 3% and :29% SPA, 90, A composition according to one of the prefeueo embodiments t through 44, comprising between 3% pod 30% DPA. 9 A A composition according to one of the preferred embodiments * through 44s comprising between 3% and 5034 DPA. 92. A composition according to one of the preferred embodiments 1 through 44. comprising between 3% and 75% DPA. fa A: composition according to «0 of the preferred omtedlfflents 1 thmugh 44 Compifeigg between 334 and 90% DPA. t4A faffe acid composition according to one rtf tte preferred ^bodimortfe 1 through 93, in which the fatty acids ero present as ethyl deters. 95.A fatly add composition according to one of the preferred embodiments 1 iftodgb 93:, in which the fatty acidfeife present as free taffy odds. 14 A fety acid composition .according te one of the preferred ^nbodlmonfs 1 through 93, in which the fatty acids ere present as esters in dr-dec-ende form. §7. A feiy eokf composition according to one of the preferred embodlmenfs 1 fhmugfi 93, in whidhi the feity acids are present as estore In tngfyeende ferm, M< A taffy acid compogiion gomrding to one of the preferred embofemgnfs 94 Ihreogh::§%;cfed comphsing a suifebie anti oxidant in a CMseatretioo soitofeof to protect the fatty acids of the composition from oxidation. 99:. ^.:;.^rfhad^PicaS!iy' §.y8^fe- ferredtition comprising erfe yd the bompcdlferfe according to preferred emhodlmonts 94 through 98,- "b': enmsspeofaeoaie arid plus dcxtosapcmigencMC sad ts presen! m sin amount between 11¾ and 19,099 mg, 100. Λ pbarfnaceutjcatiy.suliabie tot mutator* or doeage ferni df:te CTfnposibons according to preferred embodiments 94 through 93, in which the: aoioyrd of aicoc^pentoeneid acid «ckT pre^i#jr*.:;si$ amount between. 250 and 1,250 mg. 101. A pharmacauticatly suitable formuisiton or dosage form comprising one of tb« esdodling to piBferred embcKlimeits: i# fhmugh 9¾ in which the amount of oh ctoipintaenotc add pins dooosapentaenolc acM % propent in an • amount hctweon S00 and 1,100 mg, 19$, A pharmaceofloatly suitable torrpytaiup w&amp;my» Ssrm eprnprfeing one of the c*>m|uvuttnns according to preferred embodiments 94 through 98, m Which the amount of ecosapentrmnom add plus ctocesapentaenoic acid is present m an amount between: 100 and 10 >000 mg, 103. A method of administration m- treaiment to a subject of a fbrmyiatksn or ddsage form aoqo^lng to one of the preferred et®dsneri§ 94 through 102 at a cadly dose between 100 and 10,,000 mg, 104. A mdfhpd of sKfmtnlsfratton or treatment to a subject of a formulation or dosage form thrai^li iOlat e da% dose betvveon 500 and §5000 mg, 105 A method of administration or treatment to a subject of a fomiuiahoe or through 162 at a ,10’' / osuse between 1,506 end 4 100 mg i jo. A method of treatment according to preferred e emhodiments 193 through 10¾ ih which the subject is a patient diagnosed with wry Mgh togtycertdes fapyet or more then 590 mgfdl}. < 11 A moihud nf freummto ao-toiding A) pres'ired emhomnvnto 10¾ toreogh 105 in which the subject is a pedant diagnosed with Mph tngiycerides fegyef to or more than 200 mgfdL hut less tteh 509 toildll 108- A method of treatment 19§< in which the subject is a patient already undergoing treatment with a statin and then diagnosed with high togiyceridea ($φύ to or these mg Ail but: toee then 509 mgtob ). 109, ap-soWirig 'ι«>_'^piragggNrr^ ^-'; in -A'hk,h the vuhjeci n patient diarxxavid with rr.i.vxl dysl;pisorn:a with TG 200 · 409 roq/dt a?m LQt-cho^Ge?o:: egoai O'» or mon than 193 moM.,

11D, A method of treatment according to prefer ted embodiments 103 through 105 in which tha subject is a patient ding nonod with mued dyoaprdemo with TG 309-700 mqh.il. and LDL-c hnfosierol equal to o: more than 199 mg dL 111. A method of treatment according to preferred emixsdimeots 1Q3 through 105. 50 which the subject is a patient diagnosed with mixed dysispidaroia with TG 200-409 rogldTsind nob-nDL-cheiesteroi ©quel to or Ηί$ί&amp;ι&amp;βΐβ h^b. HE. A method of treatment according to preferred Αφ 103 through 10$, In which the subject is a patient diagnosed with !$&amp;* 700 mg/<JL end non-HDL-ehotesterol equal to or more than 200 mcydl. 113:. A method of treatment according to ptefetmd emfenditnorts 103 ttwby^ 10¾ ih wblcb the aebject is a patient diagnosed with mixed dpfptdemle Λ T02CKA 490 myfdf. and LDt-ef-soiestero! equal to or mere than lOO mgdSLv 114v A method of treatment according to pmferrod #βν·:

Id which the subject is a patient diagnosed whh mixed .:#p;W' 3.00*· 709 mg/dt And ti3Mdf#jS$terni aqua! topr 119: A rodthbddfl accoroirrg to pxTanrod embodiments 103 through 10S:

Ip wtiidh the vsyhjdptls alpstiotit diagnosed with mixed 49S rngrdL and non-HOL-cholesfemt eqnai to or 116. A method of treatment: according to preferred embodiments-103 through I6ft| :n which the subject Is a pahem diagnosed with mixed tfyslplietpfa wilt TG 3QCA ?00 mg-'dl and norv-HDL-chotestarol equal to or more than 160 rog/dL 117 A method of treatment according to .preferred embodiments 103 through 1¾¾ n which the subject ss a patient diagno^i'^^'-imbiedl dypfpdemle ^h TG 2p0-490 rogldl and LDbcholesterol eqdii #:# Ajj$$ ISOm^lT:. 11B, A method of treateonl ecoordlng to profiled emb^^eA TiS through 105? : 'iti'#-:MS#mixed dystipldoroia with TG 300-TOGfnA^ LBL-choiesmrni egyal fa ormore tharr 1-.30 mg/dL ITS. A mefbod nf fmatmert apobdirig to preferred eo^ddimeA..10$^i thfouib T0S: in which the subject sc a patient diagnosed with mixed dyaiipidemla with TG 200· 4S9 n-tg/dL and rmmNGL«ohofaetereI equal to m mowilhan i&amp;mgtf&amp;ii 120- :A method of treatment according to preferred embodiments 1Q3 iHfeygO 105, Ih which the subject Is a patient diagnosed wf8n mixed dysllpidemle TO 300-im mgfbi and non«HDL«choteis^rol equal to Of mom than 130 mg/dt, 11:1:, A method of treatment according to preferred embodiments 103 through 105. In whfch: fh® gybpcf d® a pationt gfe^lallfigk for camfeyafeute ®¥®iife. 1:2¾. A ^1¾¾¾ of to prefepip :0m|®df?PPfts:. 103 tttouf li; liOi;,' Ιλ wbMslfe subject: is m:.pii[tet diagnosed wibidbb®te'·.· 121 A method of treatment according to preferred embodiments 1Q3 through 105. fh i#4cb the subject is a patient diagnosed with pm-diabetes or metabolic sjdidtoma 12:4, AKhiAthod of treatment according to .ctie s# Di$ 3$$· ftroigh: 12:3, ip which the treatment resetis to flood, serum or plasma mglycende levels 125. A method of treatment according to one of the preferred embodiments 103 through 123, in which the treatment results ip ^pii^ihlr'^t^OR of blood, serum or plasma ingtyoehde levels while not significantly Increasing blood, 4#pm or plasma LDL-choiesferol levels, 126; A method of treatment accordiriq to Oho <#'$$ '· im'jygh 123, in which the treatment mmM .te.:.^^^iirtt" idf blood, serum or plasrYio toial-choiosteroi levels. 122, A method of treaihenr aooording to one of fee preferred #mlK>dsm®nte 16¾ tmnugh 123, in which die treatment results m significant rednccon of blood, -mum or plasma noh-HDL-cholesterol levels, 12&amp; A method of treatment according to one of the^preferred omhodatiAnta 1½ through 123, in which the treatment results m sipnificanl mducban: of btoad, .· mtv of plasma L Dt. -cholestei ol levels 129. A method of treatment according to one αί'Φ» -1 $i; through ll3:J in t#ldb :1¾ results to significant reduction: of btobd, serum or plaama 130, A method of treatment recording to on® of lb® pmisodlbirta 18¾ thfpuih 123, In which the tnestmonf Fastis lb serum or plasma ViDL-cbo!est®roi levels tw$tijr ,ln^aslr^; blood, serum or plasma tDL-cholesterol levels 13¾ A, at trnniment mreordmg to nnn of me nmhmre erm-xNsei'is 133 through 123 m which the tmatmeri tt®U|s -¾ ^igorflcaM mdMctbii of bloody serum or plasma apo-8 levels,· 132 A method of tmatiiienf apoospllag to o«;tt|i|^#ni^pwts -t$| Shrough 123. m which the treatment etis # etpfcfi mddcie^ of htoo€ serum or piasme: apo-C-lil ferete- 133: A piithpd: of headlight; : ag^rdlng to one of the pmfsrred embodiments 103 though 1.23, in whtdir .'te^aitoint results m egolleant ipduei&amp;n # tjlnod, serum or plasma LP-PLA2 levels 134. A method of treatment according .to· one of the 103 through 123, In which the mlwM&amp;n -of’· bf©Q*^ serum or plasms hs-CRP levels 130,: A method df treatment according to one W tie pmfened ^Oodlnints 103 through 123· m which hie treatment results In eigniflc&amp;rt fiis35eaw:.^f-.lfe^i' serum or plasma HDlmhofesterei lovers I3u. A method of treatment acoardtgg to one of the-piieiirmd' fhreegh 1:23,: in which the treatment reeuils; to eipelieeot seruhi dr plasma apwA lAvels,, 1371 A method of: Irpetom-m according to one of the .prilpf’od · ttough 12:3, In whtefvthe treatment rseubs in siga&amp;oam reduction of tie riefe ef $'JVu ό certoi ! cdftk vns*. -4? everts. 130, A method of administredon or treatment under low '"si meal conditions according to one of me preferred emhocbrnonm I0i ihrcmqh 106 resuming in a fmii of B hours or toss 139, A roobxsd of edrnintetraPoo or treatment umter low fat meal eomifens according to one oi the preferred embodiments 103 through 10§ resulting in a Tmax uf o house or less 140, A method uf admsniSirePon :pr Ifealmenl under low· fatvmeai cond&amp;om according to one of the preferred embodiments 102 through 1PS resulting in a Tmax of 5 hours or less 141, A method of admlnistralon or treatment: ur^er low fat • hf the preferred embodiments 133 trough 10S pspillng in a

Tmax of 4 hours or less ife A «fed of odsTjlrfi^iiftoo ;orUdcler fcwttns o:feii»ous according f©; onA o! the prefemmi gmhhbtmente 103 through 106 resulting m i Turn of 8: hoy or of fees 143 A method of admimsuahon or treatment under feting eorKjitions mxhrdiOG to nog ol ffie prtfMmd: emitodim-eriis 103 through lOS mtutisig in &amp; Tm®: of 6 hoyrs or less 144. A method of adroTMratior! or treatment under fet ing conditions according to gne of the profemd: embtfenants 103 through 105 resulting in a Tmax of 6 hours or less 140. A method of administration or treatment under feting In one of the preferred, embodiments 103 through 105 rafeting In a Tmax of 4 hoot^iof tops 14fi A method of administration or treatment under tow fat meat conditions aowding fe one of the preferred embodiments 103 through 106 fesotttng In on EPA^-DPA+'DHA T max' fees then the BRArDPA-DHA Trnax for LOfeZAT· : me or fe same aomintstraiion conditions 14?. A method of administration or treatment under fasting conditions according to one of the preferred embodiments 103 through 103 resulting m an E PA HOP A r DHA Tmax less than the EPA+PPA*DHA Tmax for IOYAZAS und® fe Ohnie administration conditions 14S; A fethod of administration or treatment under few fat meat conditions aoofefe fe one of the preferred embodiments 103 through 105 resetting in an EPAH3PA Tmax less titan the EPA+DPA Tmax lor AMR101 urtder the eamA adraliistraiioh csodiians 1:411, A method of administration or treatment under lasting conditions according to one nt the pretence: embodiments H)3 through 105 Uhrofeng in an EPA^QPA Tmax loss than the EPA+DP A Tmax for AMR101 under the same ηΤοιηίΑιηίίοη €€0441000: 150: A method; of dr treatment under tow fat meat conditions according to onp of thmprofemd ombadlmcaifs 103 through 106 resuming in ah Total Gmaga~3 FA Tmax less than the: Total Omgga-3 PA Tmax for LOVAZAtf under the same administration cafefcns 1ST Λ method of adrnimetmtion or treatment under fasting conditions according to one of the preferred emtxxhrnems 103 through 105 msuTnq in an To mi Omega- 3 FA Tmax iese ten F>^ Tc)lal Om©gB-3 F:A LOVAZA® ante the iim#,Adm*nistmp<m ortelttorm 152. A meted of administration or treatment under low fat meat conditions according to one of the preferred embodiment 103 through 1(35 seauSUng in on Total Omena--3 FA Trnax iocs than the Tnidf Omegas® FA Titer tor ΑΙΙ^ΙίΙΙ tmdpf the same administration concj«hnos 153', &amp;, teted gf^-isiniiinfstation or treatment: apder"toittog :fpndiprt^^^iAlf0g to .ooe preten-ect: embodiments.103 through 1(35resulting in an Total Omegaa 3 FATtex tesa tAap ftl Total Omega® fA Toia# tor AligTOi nnd# admihisimfiop oapdttteha 15A A . Footed of admiolfWIon or taimeet iteer high, fat te®5 oondtipna Aptofdlng to 2)na of ito: ffaferttl; etoitotoments IPS fhteigti! 1¾¾ msgiing W m. EPA*OPA +DHA Cmax or Total Pmega-3 FA Cripx of at feast 11015 Of te EFA-MDPA+DHA Cmax or Total Omega-3 FA Cmax for LOVAZAi? under the same administration conditions 155, A method of admmisiration or freaimeri under ftlph fat meal maMem according to one of the preferred embodiments 103 through 105 resulting m an EPATPPA^Om Cniax ar Total Omega-3 FA Cmax of at least 12031 of the EPA+DPA*OHA Cmax or Total Omegas FA Cmax for LDVAZA# under The s^ii®:;^drnlhyr^pi dfodlttonc 150, A metted of administration or treatment under nigh fat treat conditions ®ci^tdlnptO:-or»'OfTili:''peterreft embodiments 103 through 106 msuinng in an EPAtePAteFiA Ctesx or Totai Omega-3 FA Cmax of at least 100% m the EPA^DFA+DHA Cmai Of Total Omega-3 FA; Ctex tor tOVAZA# dRder Th^ 15?. M- or tm^frth^t Air^cfer htigli? larmeal oondidPt iccdrilAg to dee of the preferred embodiment# 103 thneuib 105 to^&amp;sglp aP EFATOFA+DHA Cmax or Total Omega® FA,Cmax of at toato: i40%- of the EPAWAAOHA Cmax: or Total Omega-3 FA Cmax for LOTAZA® under fiw same admifMmttoa eondiieos 1SS, A ' FiFiildd at τχγ Tp^alrriferst:: oOdar high fAt: medl oohdlisns eccordmg to one of the preferred embodiments 103 through 105 resulting in an EPA*DF¥V*OF&amp;&amp;: Cmax or Total Omega® FA Cmax. of at least 153¾.. oi the E^A+DPA+DMA Cmax η» Tobit Omega-3 FA Cirtax for LUVAZAO uncsr me conditions 110, :: df administrate A ar ImpImfAt under k>w fat meei i'-onmnons accordistg to one of the prgforred embodiments U>3 through 10¾ resulting >n an EPA*DRAiDHA Cmax or Total Omega-® :-FA Gmaxcof/isr least 1¾¾ nt ifu> iPA^W&amp;AOHA- Cht^X dr fetal Omega-3under the same administration conditions 1i0t A method of administration or tn^menf under i* lit; meal ^ndiloris according to one of the preferred ombtxknents 103 through 10¾ resulting m an EPA*DPA+DHA Cmox or Total Omega-3 FA Cmax of at least 200% of '&amp;m £PA*ORA«DHA Cmax or Total Omega-3 FA Cmax for LOVAEA® undoi the same ndntinitration conditions lit; A method of administration or treatment under top vat tk at- 'de^pt^p according to one of the preferred embodiments 103 through 105 resulting In m EPA^OPAtDHA Cmax or Total Omega-3 FA Cm ax of at less! 300% of the £PA*DPA+DHA Cmm or Total ©me§&amp;-3 FA Omax for IL0VA1A®. Under the some administration opodiidns 100, A diethpt of administration or treatment onder low fat: meal com® ions addoAlng to on© of tie prefers;© ernbodimofits 103 through 106 mauling in an EPA+DPA+OHA Cmix jtr Tbtdl €1¾ of the EPA*BPA*OHA Cmax or Total Omar^a-S FA Cmax for CDVAZA# omier the same edmwst imioo mondffcne 163 A method of administration or treatment ostler lew lei meal conditions according to one of the preferred embortlments 103 through 105 resulting in on EFAtBRfeDHA Cmax or Total Omega-3 FA Cmax of at least 500% of the EPA+DPA*DHA Crnax or Total Omega-3 FA Cmax for tOVAZAd' coder the same admonishatioe condrtu>ns 104. A method cl rfenmcrmiion os treatment code; low fat meal aimtfeds according to one of tire preferred embodiments an EPA*OFA*DHA Cmax or Total Omega-d FA Cmax oTaf fsaM 600% of the EPA^OPA^DHA CmsA or Tela! Omega-3 FA Cmax te:i0VAZ^.UrKiii'.'lh@' same administration conditions 105, A method of admloietradon or treatment under %sti«g ssnditioes aooordiog I©· one of the preferred embodiments 103 Ihmygh 1¾ mseting id an EPA:+OPA*ONACmax or Total Ome§a~3 FA Cmax for LOVAZAtP ynder th# same adufeiistmion. coeds I sons 1IC &amp; method of administration or treatment under fasting <y.'Hd?t?ons according to ane of the profened embodiment*» HB thrm^ih tos resu&amp;rig ;ri m

EFAA0PA*OHA OdiPx 6t Tot# CStieg#^ FA Cm#; dffef jfeg« ;Z0l)%. df tfid ;&amp;PA*PiPA+OH# Cma.x or Terfel ©foegdZf FA OfesX MAd«r tAA mm&amp;· ad mm is? ration:: eo nsilt Ions 1;I7.: ; admimstration or treatment under failing: cdAdi&amp;nd ascordihg In φΜ; g! the preferred embodiments t03 thfeygh 1156 fesyfeng ip ad ΕΡΑαΟΡΑτΟΗΑ Cmax: or Total Omega-O FA Cmax of rat !ea$F300*l of. tte PFA^DPA+DHA Of ax or Total Omega*! FA x for'· 4j$#r ϊ$έ· same administration condition? 168, A method of administration orfmetaentrundpr fesimg conditions accord ino to one of the preferred embodiments 103 through 105 resetting In an EPAHDPA+OHA Cmax or Total Omega-3 FA Cmax Sfi-M- crfmfNr £PA*DPAiDHA Cmax or Total Omega-3 FA Cmax for LDVAm« odder tte oondfifeoss 1 §§< A mgf hod of admfefefpiton dr treafemrst under aooprdiop id one of im preferred emdefetmedts 103 through 105 resulting in an IPA^DPAaOHA Cmax or Total Omega- 3 FA Cmax of at feast 500%· of the IPA*DPAaOHA Cmax or Total Omega-3 FA %m: same adailnistradon cogiitferrs 170. A method of admlnistratfen nr treatmep imdtr faslhg oondifens according to one of the preferred wib€Kimsrtt#r lOS msutttng to an EPAtDPA^DNA Omlx or Tata! Omoga-3 F.A Cmax el at feast 600% of fee IFATDPA-rDHA Cmax or Total Omega-3 FA Cmax for LOVAZA# under fee seme administration condlfeos 171. A method of administration orTreatment udder faafir|p^ one of the frefonfed embodiments;: 106 105 Msufeng fe am E»-«ATbHA €«I dr Total Omega-T FA Cmax of at feast 7(M}% of the EFAiOFA^OHA Cmax dr Total Omega# rA Cmaxfor LOVAZAT under the same administration additions 172. A method of high M m^i! condition# according to one of iterprsferri^'-oml^Irrli^is. iM^mugh· 165 respiting In an EPA*QFA '>DHA AUC or Total Omeom3 FA AUC of a! ieast 110% of tho EPA-* DPA*DHA AUC os' Total Omega-3 FA AUC for tOVAZA'^ under the some administration conditions 173. A method of administration or treatment under high fat meal conditions * -Oiifext to ure of tN px A rr^xt nmt^iOvmer fe ,hf m ' * * ρ^'Ήΐη ' n in “^A-PPA" "ΉΑ AUt a rn*i iMurs? fA >VC ot n aae ,3' me EPA-*DFAU>HA AUC or Total Omega 3 FA AUC for LOVATAA ^noar tne same adrmnlstration conditions 174 A: method of administration or teatmantlBiitfar high fat rneof

Of the preferred #5 respitingIn An EPA+OPA+DHA AUC or Total Om*ge«$ FA AUC of at ioife 130% of the EFAtUPATUHA AUC or Total Omega-3 FA AUC for LOVAZA# under: Ite same administration conditions ITS. A method.-oT.^mintstapO· m troatmerA undar 0¾ according to oho aTthe 1 Igi:'#';

Ei^TDPA+DMA AUC or Total Omega-3 FA AUC of at feast 140% of th# P*A*OPA+DHA AUC or Total Omeii»0 FA AUC ad msN stratferi dondtfioho t?§, A method of admioistratior< nr treatment under logh M maa! rxmefitlons aecordsng to on# of the preferred embodiments 103 through 105 rosing in an EPATDPA'iDHA AUC or Total Omega-3 FA AUC of at least 150% ot the £ PA* DP A + D HA AUC or Total Omega-3 FA AUC for LOVAZA'T under ton xavm an ministration co not got is

177 A method of administration or tmaiment under so* fat mom condition;-according to one of the preferred e*n£>MM!$*-1 OS imiftip·^^3^6'ITM EPA^DPA+OHA AUC or i odd OmogaAl FA ALlC of at feast 1¾%. of th# EPAnCFATpHA AUC or Total OrndJfeS FA AUC far L OVAZAfi unddflAo same administration ffeodtldnS 178. A method of administration o* treaitnent ooder low M mafe odndifes aegording to one of the preferred erndodimenis 1© fefeygh 165 fesolflog in ad; EPA+DPA+DHA AUC or Total Omega-C FA AUC of at feast :260% of the AUC or %fg Omeg^8;FA AUC for Lp\i&amp;zm urrdsr iAe sa^m φ0Μ^0Φί: 1?9.. A method; e# a<!miliMlraife » teairwl under low tei mete conditions ;#sx)Pdmg to ons of the preferred embodiments 103 through 106 resetting in an EPA4DPA+DHA AUC or Tola! OrnegaCjm AUC of at least 350% of the EPA-*DPA+DHA AUC or Tola! Omega-3 FAAJttG fer LO^AZA^ under tee same administration nnndliona 180, A method of oaittinistrito dr tmatrnoPt under lb# tel mail oondifens according to one of the preferred embodimonte 1D3 through 106 msuteng in an EPA*DFA+DHA AUC or Total Omega-3 FA AUC of at least 400% of Ids EFAeDPAtDHA AUC or Tola! Omega-3 FA AUC for LOYAZAA under in© same administration conditions l-STv A meihiiKi of a-dntidlatratidn or treatment, under Id# tel thdal conditions: according id one of tea pAteimsd emoodtments 103 temutgti 1¾ wsuftteg in an EP.As-OPA-i-PHA AUC or Total Omegm-3 FA AUC of a! least 300%·: of tfi# EPMDPA+QHA AUC or Total OmegoC FA AUC far lOYAIA# under tine SAdte ad m inistratiorviconditfona lit, A method of administration or treatment under law fat meal conditions; adpbrbfng Id pnprof the preferred embodiments 103 terdbgh 101 an £PA*DPA+DHA AUC or Total Omega-3 FA AUC of at least §®% of tea EpA^DPA-t'CHA; AUC or Total OmegaO FA. AUO^for:.EOV^^#'';M^^:'ttto seme administration: conditions 183. A method of administration or treatment under fasting cnndteons- according to one of the preferred embodiments 103 through 105 resulting if pi; £PA*DPA*DHA AUC or Total Omega-3 FA AUC rf at least 1i0% of tee EPA-r-OPA+DHA AUC or Total Omega-3 FA AUC for LOUA2AO under the same MminfiifAiloB eopditibht 1:84. to

Afte of the preferred embedments 103 through 105 reaitllng in in 1FA*BPA*0HA AUO or Thtaf Oraegi^P FA AUC of at least of tee ΕΡΑ*0ΙΡα^ΟΗΑ AUC orItetef Cmega-I FA AUC for IOVAZA® under the same administration conditions 185. A method of administration or treatment under fashng oondreoos according to one of the preferred embodimante Iffi terbl^i; IQS rdSbttfnd In an FA AUC of at fca* 300% of φ FA AUC for L0VA?A® under tho -mm ad mm «si m ifoi ) conditions 106. A mot hod of administrator) or treatment «.meter iashftg cofUltiOns ec cording to ene Of the pmformd ernbodlmente 103 through 1§S msufhng m an HPAaDIAA*0I1A: AUC or top! Omegadf FA AUC of at least 400% of foe EFA+PPA*OHA AUC or Iota! Omoga-3 FA AUC for LGVAZAi) under the same mi intriif ratten 107. A according to ene eF the pfefarred embodiments 103 firoupO 130 mseiilng -to' EFATOI^eDHA AU€ or Total Omega-3 FA AUC of at least 600% of Ilia iPAtOFAI'DHA AUC dr Top! CfofogfoT FA Αύ^: for U^UA^Ati: under safoA administration conditions 101,. : . A molded of ddmlntiffsttod or Imafmenf underfed according to dde of the preform# embodiments 1Θ3 lltewgp 106 resetting m an EFAaPFA^HA AUC or Tolof Omeppl PA AUC of at least 000% of :«m EPA+DPA-DHA AUC or Total Omega-3 FA AUC for lOVAZAO under foe same ad Wpipfitidn gondiifons

Mi, A method Of-aocordfog to qoe of the preferred embodiments 163 through 106 resulting in an EPA+DPA+DHA AUC or Total Omegas FA AUC of at lei# 700% of the EPA*OPA+DHA AUC or Total Omega-3 FA AUC for LOVAZASP umfor the same admmistrahon condiffons tm A method of pdrntnielmtlon pr teatmoit under high Μ meal corfoitiooi according to one ©! the preferred embodiments 103 through 106 resulting m an IPA^OPA Cmax or Total Omega-3 FA Oma# ofp foast 110% of the EPMDPA Cmax or Total Omegs-3 FA-€®m #r A«lWi»?%';Shdi' conditions 181. A method of administration or treatment under high tat meal conditions according to one Pf lffo preferred ^emhefolmeris 103 ihmngh 106: resulting Id an EPA+DPA Crnax or Iota! Omega-3 FA Cmax Of at lea# 120% of the EFA^PPA Cmax or Total Omega-3 FA Cmax for AfdRIOl under the same admfoMrfofon conditions 1M. A memorf of m tedtferfet: undar hip fetmpi phpi<mi aocdriiog.towe=df fho· ©^bddJHi^^ 103 through iiSrr©sy!i:ng l^ m LPAxOPA Cmax or Total Omen,#- FA Cmax of at mm A * 3GA>*T the ΗΡΛ: QPA Omp: dr Total Omegs-3 FA Cmax for v^iMRIDI under the same administration miidfi» 193, A method of admiriiAtrilip or phlitiip ;:uopr high fit piai condition* according to one of too protocol embodiments 1)3 through IDS resulting «η an EPA^QPA Ciw.sr Total Omega-3 FA Crmx of at least '140% of the EPA+PPA Cmax or Total Omega# FA Cmax for AMRf 01 under the sams administration conditions 194 A method of admlntstmloh or treatment under high inf mas! conditions according to one of the preferred embodiments 103 through IDS resulting so an EPA*OPA Cmax or Total Omega-3 FA Cmax of at least 1§Q% of the EPA^DPA Cmax of Total Omega-3 FA Cmax For AMR191 under the same administration conditions 195 A method of admiolstralioh m Imahnoht yhier iom S meal condlions according to one of the preferred embodiments 103 through 105 resulting m· an EFATOFA Cmax or Tdfe! Omegi# FA Cmax of at feast 130% of the EFA:^FA Cmax or Total OsnepPS Mi€ti« :ler AMR191 uridir: donditidos 1M A method of ddnifeistmlbri hr treatment up# low fat meal coddilohf oocoofiog te-ο» of the pmfensd ooitodlmonts an EPA+DPA Cmax or Total OmepFS FA Cmax-of at feast 200% of ffie IPAtPPA Cmax or Total Omega# FA Cite for APPI01 undar tfe same admmCiratlon conditions 197. A method Of sdmmisiretton r.r treatment under low fat meaii conditions according to one of the preferred ^rnhodireents 19S through 106 resoling: In an EPA-f DPA Cmax: or Total Omagm3 FA Cmax of ai feast 300¾¾ of the EPAH9FA Cm jn . Total > FA t ku AIARH" > rn aim1 '"fr ddnditions 19®. A method el administration or treatment under low fat meal conditions according to one of the preferred embodiments f0S rasofeng in an

EPA+DPA: Cmax: oCTota! Omerp# FA Cmax of of Ida# 400% of feo EPA^OFA

Cmax or Total ;fesr AfoR1;f t Igpdr the ^^;^.ifi|fslsl^{^i: itonditohs 199·. A ftptiloci 4af. ;:^·5Τΐ:ίΡΐβίϊ^|ί0Ο, OSr M. according to one of too preferred embodiments 103;ilimijgO 105 resulting to an EPA*DFA Otos-or Total Omsga-3 FA Cmax oi at teariDO^ or the ΕΕΆ+ΟΡΑ Cmax or Total Omega-3 FA Cmax for ΑΜΑΤΟί yoder the aarrsa adailatotj'aOoa coodtoons 900.: A mattel of aOoilaistraltoo; or tmotooot tmder tow Htv mmi oonOtftona aetforilng te 000 of the preferred %mbodsm&amp;f# '1#:;te!^N::'1#:

Bm*®m Cmax or Total Ctaggp^.-FA Omm of at EPA fDFA

Cmax or total Omaga-3 m 0mm for AMRfCH -pond 1 fktoi :201. A method of administration or treatment under fording oorxiitsans according ia one of the preferred embodiments 103 though 105 resuittog sn an EPA+DPA C max or Total Omega-3 fa Cmax of at toast 150% of foe ERA* DP A Cmax or Total Omega-3 FA Cmax for AMR 101 under too seme edmtototmilon emadittons OX: A method of administration or treatment under fasting conditions according to one of toe preferred embodiments 103 fstough 105

Cmax or Total Qmega-3· FA Cmax of at least 200% of tNb EPAi;DPA Gfna^: or Total Omega-3 FA Cmax forAfoiTTOT under toe aaow aOmfoMratton cdadiffons ftp: A method of administration or treatment under fasting conditions according to one of toe preferred embodiments 103 through 10§ resaltidg to an €FA^8FA Cmax or Total Omega-3 FA Cmax of at least 300% of Ido EPA+DPA Cmax or Total Omega-3 FA Cmax tor AMR101 under ihe same adnxnisfmbon conditions 2¾ A method of admtolsfmildo or treatment uwtet fasting conditions asmrdfo§ to one of toe preferred: embodiments 103 through H3S resulting in an EPA*DPA Crnox or Total OmegaAI; FA Cmax of at least 400% of trie EPA+DPA Cmax or Total Cfotega-3 FA Cmax for AMR101 under the some administration sondifkma fOfo A method -,-5 utowtoto-toon or treatment undc> iast-ng -m-idtoons according to one of the preferred embadlmerrti 103 through TCi resuItog In en ΕΡΑΤ0ΡΑ Cmax or Total Omega-3 FA Cmax of at toast 50015 of the ΕΡΑ+0ΡΑ Cmax. or Txdal Omega-3 FA Cmax for AMR 101 under the same administration conditions 260; A method of admMstratton or treatment under fashrm eooddtons according: to one of the preferred embodiments 103 through IDs re suiting so an ΕΡΑΗ3ΡΆ

Cmax or Total Omana-C FA Cm ax of at team 303% of the EPA-OPA Cmax or Total Omega-3 FACma:rifof AMR101 uoierihe oaroH administration eendffcns 20f .: A method d admtnfxtreum or ynt^ fearing rxfed&amp;ons accruing to dee of the preferred embodiments 103 thiito§h 10§ resulting fe an EPA+DPA Cmax Or Total Omeyfe'3 FA Cmux of at least ?'00-C of feu EPA-UPA Cmax or Total Omega 3 FA < '«iax ro? Afe:R lOf uneer m** Same udmrvtdreoon conditions 2pft A feofeod of lioilollirtftiofi: ,# treatment under high fat moot conditions aeeorrilrti to one of ;:|^ιβ^γγ-^Ι-. 103 msgifo®: In an SPA*DFAAUC or Total Omega-3 FA AUC of at least 110% of feo EPA*0PA AtJCx iOF Total Omeg^S FA AUC for AMR 101 under the earns administration rxmditfeos 200 A method of administration or treatment under e*gh fet r*\d , ,^iUans mm0mQ to one of the preferred embefetmenfe 1C3 thmegh TOi Msufeog in m EPA*OPA AUC or Total Omega-3 FA AUC of at feast 120% of fee EPA-xOPA AUC or Total Omega-3 FA AUC for AfeRIOI conditions 210. A method of administp|ph;V^,:|^^fe^tc#pd^ high fht meal condiliom according to one of fee preferred embodiments 103 through 103Apofeng to *r EPA+DPA AUC or Total Omopa-3 FA AUC of at feast 130% of the EPA^PPA AUC or Total Omega-3 FA AUC for AfeRlOl orefer tm sums acsmin^tranon conditions 211 A; method, of adoiifeiifralldrtxbr trealrneht under high fat meal t^ndittom acpifeiog· :tp tone: of the preferred err modimip^ f PS; ,feeulllri|i::: In on; EPATUPA AUC of Total pmeqo-3 FA AUC of at feast 140% of the iPATOPA AllD:-or fd&amp;f 'Omega-S PA AUC tor .AMRtOi under fef->cs«iw .admlhlst$®tlo«i·' conditions· 212.. A method of administration or treatment under high' fat meal conditions x> ί,οιΟ "g to "! P ! x prefei * d > m ^ λ * v «eC 1w + 0 ^ s EPAhdPA:AliC or Tptai Omega-3 FA AUC of^aTIeaef :l30%;of tha EPA+OPA AUO: gr Total Omega-3 FA AUC for ΑΈΡΙΟΙ -ml*? conditions 213, : Ax method of adpIhlitfAilpp or ^ M ; meal oodtlSIppe;

aoourdmg to one of the preferred embodiment 103 #iK>.joh 1δ§ resulting fe an iPATOPA AUC or Total Omega-3 FA AUC of at feast 150% W the EPA+DPA AUC or Total (¾¾¾¾ AMRIiT wtoer the same administration eoeditoes 214.. A melhoil of administration os tovdment under tow tot meM conditions according to one of the preferred emdodlmems 103 thimygtt 105 meyltiog id an EFA^DftA AtJC or Total Omega-3 FA AUC of at feast 2£Mt% of the EPA^DPA AUC or Total Omega-3 FA AUG tot AMR 101 under the some administration eortoliioAi 21S. A method of administrattoo or treetmtmt M^kr:ievr.%£4»Mf' .oor^ifeW' according to one of the preteoed embodiments 103 through 103 resotong in an &amp;&amp;&amp;φΡ&amp; MJC or Total Omega-3 FA AUG of aFtoasi 9m% 0 ttfe lPATpFA AUC or Total Omega-3 FA AUC tor AMR 101 under the same aOrnrhlstrafen conclitiooo

Ifi. A method of administration or treatment under tow tat mial conditions according to one of die prefemei embodiments IGS'ldro^ls: 1US resulting in an EPA+DPA AUC or Total Omega-3-FA AUC of at tepst 460% of ft# EFA^OEA AUC or Total Omege-3 FA AUC tor AMR1Q1 odder The eame admintolfatioh conditions 21T. A method oi administration or treatment under Ιον» tot meal oondlffeos poofemg to one of too pretonud embodimeoto^ICOthiddgh in an ERATPFA AOCCor Total OmegaCS FA AUC of at least B03% of tU# IPArBFA AUC or Total Omega-3 FA AUC tor AMR1Q1 under conditions

213. A method of 4η1ηιιο^Μΐ»οη or treatment under low tot meal c(«nditione eceordiog to one M It» pieferred embodiments 103 through 106 resulting In an EPA-rOPA AUC or Total Gmega»3 FA AUC of at least 600% of the EPA-rOPA AUC dr Toi-j! Omjaga-3 FA AUC tor AMRlOl :¾¾ amdfltoriA 210. A method ef edmioistratton or: treatment under fasting one of toe preferred efe^dlriepi| lli fhfedid ICS resuitto(| to an EPA+DPA AUC or Total Omega-3 FA AUC of at tonal 1 S0%M /th^ERA+ORA^y^or Tsfaf. Omega-3 FA AUC tor AMR 101 under the same admmrstfahun eondtonne 220. A method of administration or treatment underf^in^ according to

one of the preferred emhodlmenie 1S3 through I PS resulftog to on EPA^OPA AUC or Toon On mum i l· A AUC of at least 2U05 of the EPA*DPA AUC or Total 0m®gs3-3 PA AUC fo; AMRU.'I under she f-asm .miminnd ration COishtJUi- 221 A method of udmimsyaben or treatment un>2a mom g conditions aceo: Ong n one of the pmleued emdcCimsnts 103 throng n Am moOum in an EPA $ DP A. AUC or TotO Omega-3 FA AUC of at least 300' ; a On FPA^DPA AUC or Tom! Gmega~3 FA AUC for AMR101 uodei the same tom· nmon· ion conditionS. 222h A method oi udmirusnauen or treatment uncfor Cmiing e/vi<i:tiort&amp; ar<'mdfog to one of the preferred ernboUimeofs 103 through 105 resGhng m an EPA^DFA AUCdf Total Omega-3 FA AUC of at feast 400¾ of ths· EPAtDPA AUC or Total Omega-3 FA AUC for AMR 101 under the same *0 ministration eornifeoris 223. A onethad of adaiinrstmtron or treatment adder fasting conditions ηοοο^ιηρId the preferred embodiments IOC thfoUffo TtlS reiyftthg in an foPAPGFA AUC or 1 eta! Omega a FA AUC or af feast 500'·'. of the C:.P h+ DP A AUC or Toni GtnegaoS FA AUC for AMR101 undo? the samo sdminsstrahe??* conditions 224. A method of administration or treatment under fasting conditions according to

one of the preferred emfxtdiments 103 ftltdupfe 10i raeultfoi In an EFA*DPA AUC or Total Omega-3 FA AUC of at !east60d%o^ or®W pfodgiPI f-A A1JC for AllR101 undar fho sarne ndrThnMrMfon condition® ,22§. A ntefted nf admlrfetratforr or traaimont yrfoer foMtnp ^ndP&amp;ns asfflhing t© on® of foe preferred embodiments 103 through IDS reselling In an EFAADPA AUC ®r Total Omoga-C FA AUC of at foe®! 700¾ ¾ foe EPA+DPAAUG orlofof OmegaeD FA AUO for AMIR101 under the oame a^folstrotfoni oondlons I2E A method of or Ifoatrnent ynd®r high fat pid! condhfons: agoorfong to one of the preferred embodiments 103 through 105 resulting m an EFA^OPA^DHA Cmax or Ifefai 0®®«ρ§ FA Omax of al least 100% of f® EPAH3PAPOHA Umax or Total Omeg.m;3 FA Umax for FRANC VA^ under foe; same administration: conditions 12T, A method of administration or treatment under h,gh. fat moat oondfeons ec cording to one of the preferred embodiments AC to'ottgh " 30 resulting m an EPA^DPA-^OHA Cioax or Tdtii Cmoia-3 FA Cmih'Of at least 105% of the EPA-rDPA^CHA Cniax for EFANOVA™ under the soma admfoistRilfon conditions 22:0, A otofftod of odrnioistrsfiorr Or treatment ondef hfoh fat -«tea* ;i©©i1dits©W&amp;:· according to one of the prelfofod embodiments 100 fenxfoh 10S resuming to an ΕΡ Α+Ό FA·* D Η A Omegn-CFA Cmax nfat feast 110% #: th# EFA+DPA*DHA Cmax dr Total^ ΡΆ Emsx Ibr EMlMOVAm under the same administration conditions :22C . · $i ·heatmonf under high fat meal conditions aodOftfeg &amp;ene of:the pmferrf i&amp;nibr^isiients TG3 through lOi m$uthng in an Epfepp^## Ordiit or To^! ;Omega·· 3 FA Cmax of at l#Sf 120% of the EPA+OPA^ON^rOtpist or totof OO'^oa-3 FA Cmex for FPANOVA^ :^310-M sdmfn^traliPn eoodfens:: 230, -A method of administration or treatment. under high fat meal conditions according to one of the preferred embodiments 1Q3 through 105 msutttng in an EPAi-DFA+OHA Cmsx or Total: Qmo§a~l FAOmax of atleast 130%. of the E;PAtOPA*D^ or : Qmdga-2 FA Croax for EPAN0VAm under ttw same administration conditions 231.. A method of adntinistrato.n-^rl^iiTO^f-si^if: high M modi oondfttet according to one of the omferrod embodiments 103 through 105 meriting in an EFA^OFA-tOHA Cmax or Total OmogsKl FA Cmax of at least 140% of tie EPA*QPA*DHA Cmax or Total Omega-3 FA Cmax for EPANOVA^ under the same administration conditions 232, A method of Administration or tealhmht ynfer lew M meal oonditSona according to one of the orefurrad embodiments 103 through 105 resulting *n an SPA »QPA*DHA Cmax or Total Omega 3 FA Cmm* of at. least 130% of the iPA^OPAvOHA Cmax or Total Omogmi FA Cmax for EPANOVA^ - under the isama adimmisrratlOn conditions 233, A method 0ff'^dmin{stratkinTl#:;::f!aatmeir1|l?: under low fat accenJIng;: » oae of the dreierrod srgfeod'menis lil through 10F resufling lp ah FFA-φΡΑί-θΗΑvCma* or Total Omega-3 FA Cms* d at least 105% at the EPAaOPAtONA Cuiaxcf Total 0:mega-3 FA Cmax for EFANOVA** under the same admlelslrahod e»«d It ions 234, A method of administration or treatment umler low fat meal conditions according to one of the preferred embodiments W3 thmrfgh105 resulting In an EPA^SPA-fPHA Cmax nr Total Omegm-3 FACrnax of ailnasi 110% of the EPAfOPAtPHA Cmax or Total OmegaO FA Omax luf EPANOVA^ under- the: same adralnisf ration oomiiohs

i3§, A method of adminAlral:An or treatment coder few fat meal epndliSPS of tie preferred embodiments 1SS tbreugh 10i re^ulipg fa-m EPA* DPA-*-DHA (>nux uf Tola? Omega© FA Doxax of u? feme 120% of the EPA+DPA^DNA Of Tola! Omegas FA Cmax for EMM<3\#^· ydftoAttfe adailoMraitet coodilens 236. A method of admirusfmlion or treatment under tow fat meal conditions according to on© pf fto prcfccpd ernPociiconic 103 through 106 fcsyiPPg in Aft ΕΡΑ+ΟΡΆ+DHA Cmax or ToM 0me®x3 FA .at-te9$t 130% cl ttfo EPA+DPA r OHA iSmasc: or Total Omega-© FA Cmax for EFAMDVA™ under the samp administration imftotoomi 237. A method of admlpMrelon m treatment under tow fat meal conditions fescrdlng lp one of the preierrefi embodiment :163 TOS rsaoiirig in an IPA+OPAi-OHA Cmax or Total Omega-3 FA Cmax of at feast 14014 cl the EPA+DPA+DHA C-tnax or Tefal Omega© FA Cmax for ΕΡΑΝΟVA™ under fee saroe administration conditmns 238. A method of administration- or according to any of the pfMcrmd embodiments ife threugh 106 mipltlng M an EPA*DPA*QHA Ofrtax: 6r Tote! Otofg^l PA Cmax of at feast 100% of tic EPA+DPA^-OHA Cmax of Iota! Omepdi-FA ©max for EPANQVA^ unde r the same administration conditions 239. : A method of administration or treatment under fasting conditions according to one. pt fee preferred emoodimoofs T96 throegh 1SS msufeiKj In m. EiP^&amp;PAAlill^·, $CQaK m Total OmeifeB PA:-;'Cm«x cf at least iCto% yf Are; EFA-xOPA * DHA Cmax or Into! Omega© FA Cmax for E PANOVA^ under fee came sdnsmatratfen conditions 24(). A method of administration or treatment under fasting conditions according to one of the preferred embodiments tOS through 105 resoling m en EFA+DFA+DMA Cmax or Total Omega-3 FA Cmox id at feast 110-% of toe IF ATi PA* OH A ©max or Total ©mepto$ FA Cmaxfer EPAAOVAT:Sl; under the same administration comliferts 241. A method of cdmmsstmhcn or treatment under fasting conditions according to one of the preferred embodiment 1-93 through 109 meriting id &amp;h EPA-A3FA+0§m Cmax or Mai Omega-3 FA Cmax of at feast 120% of the :E:PA*DPA*DHA; Cmax m Total OmegmS FA Cmax Mr tinder 11¾¾ sania adiminfelraitoil esnbiflous 242 A method ol administrators or treatment under fashng corvdrions according to one of the preferred emUxUaierds 103 through 130 resulting -n an EPA+DPA+DHA Crnax or Total Orneng-3 FA Cmax of at mast 13Q%. of the EPA+DPA+DBA Cmax or Tooa Omega-3 FA Ceu <. for EPAUQVSO* undes the same administration conditions 243 A method of administrator* or treatment : Uddarfabtiby: <»n&amp;^-WOOtHrifoQ to one ol the preferred embodiments 103 through 105 resulting in an EPA+DPA+QHA Cmax or Total Omega-3 FA Cmax of at feast 140% of too EPA+DPA+OHA Cmax <>r Total Omoga-3 FA Cmax for E PANOVAϊν under the same administration conditions

244. A method of administration or treatment acopdthfi -M one of the preferred embedments 103 hfbm#T 10i? msuking in an EPA+DFATDHA Cmax or Total FA Cniax of at least 130% # diti# iRAl'DPATCIHA Cmax or Total paff0K4f f&amp;^rngx ’forpPANGVA** under lire soma f dmlrlpration conditions 24% A df'' #mMslpta ιφ M conditions aecorditif to one: of the 103: ihifeiygh -101 1ϊμ» iPAtPRA^P» AUC omToM OmegoC FA AUC iOf at tot 100% of the iPA+SPA+QHA AUC oh Iota! Omega-3 FA AU0 fer imitf&amp;W»* onefet m? same administration comfticms 246. A method of administration or treatment under high fat meal conditions according to one of the preferred embodiments 1©3ftmy§h^ 105 radeltlng in an EPA+DPA+DMA AUC or Total Omega-3 FA AUC of at least 105% of the EPA+DPA+DHA AUC or Iota! Omega-3 FA AUC for EPANOVA,M under the same idrolnimratfen ddhdilohs 24% A: method of administration or froatmanl ypdor hlfh -Mr Piiaf dohdttlphi afeordlnidtO: ooi of lia .profcAed entbodim#AM:'iS3fiti^h 105 resulting in an EPA+DPA+DHA AUC or Total Omega-3 FA AUC of a! least 110%· of fhe tzPA*DPA+DHA AUC or Total Omega-3 FA AUC for- EPANUVA<A> under: tile same; sdmin*etiation COndmone 148. "A method of admthtetrsttdh or treafrnent udder high Μ' ΐΛ seditions aOdordtog to one of the preferred embodifri&amp;afg 103 ihrdstJ^.'^P^ ·$&amp;ΜΦΐδ in iP: EW*UPA+OFf A Omega-3 FA AUC of At least 1|0% of the ΕΡΑ·Η3ΡΆ*ϋΗΑ AUC or Total Qmtggdl PA AUC: fer ΕΡΑΝΟνΑ^ undecfi® same ad m! K50: ©poiipsa 24¾ A method of administration or treatment under high fat moAi conditions according to one of the protorrod onrhodsrneoF: l(C through 105 m^oOr-q >n an EPA«OP A*DHA AUC nr Total Omega-E FA AUC ot of feqst 130¾.. m the EPA*DPA*DHA AUC or Total Omega-3 FA AUC for E PANOVA**5 under the same administration condition 25lT A molted of tetef#fmtSte m troatmont iiaatr fefgb fat meal cohditlohs acconiling to onn of the preferred embodiments 103 through 105 rasufeng in an ERATDPA^PEA AUC or Total Om©ga~3 FA AUC of at teate 140% of the EPA-f OPA^DHA AUC or Tolal pmegfe-3 FA AUC for ERAfeOW^ erfeerfee same adrdlhiaifafioii oandtlohi: III . A rnaitod oT adatiolaattea @r md®?:· bm. fat. maal oond&amp;Rs according to one of the Deferred embodiments 103 through 10S recoiling to an EFA*OPA * DMA AUC or FA·. AUC at « Ueaaf 100^ si the

EFA+PPA*DHA AUC or Tolai OmopFS fA samai Wstraifea conditions 2:52, A felted of administration or treatment under tev fat meil conditions aiMtniding tg Ona gf tta proiormd omhcdimants 103 through TOE;m&amp;uHing In an EPA^UPAiDHA AUC or Total 'Orn©ga*3 FA AUC of at least 10S% of the EPMOPA+DHA AUC or Total Onega-3 FA AUC far EPANOVA^ under the some administration conditions A method of administration or treatment under low fat maas cones mons accetertg ίο one of the preferred emtedlmertfs 103 through 105 ms Ann .n an EPA-s-DPAtOFIA AUC or Total Omega-3 FA AUC of at least 110% \A u>. EPA^DFATOHA AUC or Total Omega-3 FA AUC far EPANOVA**1 under U a ttMMf admiotetOAion cote itlo-ns 154, A method of administration or treatment under tow tat meal conditions according to one of the preferred impairments 103 through 105 resulting in an EPA < QPA'DHA AUC or Torn! Cteagite FA AUC ..of a! least 120% of EPA+OPA^DHA AUC or Total Omega-3 FA AUC for ΕΡΑΝΟνΑ*** under the same atfministiratsar * sendmoot :2IS, A method <jjf · @r yhidr Iph? fa! mAai i^Mniom hording to 0¾ ¾ ¾ preferred e»abtirn«ms H>J through 105 resulting m an EPA*DPA+DHA· mC or Total Om#|p*3 FA AiK>, of' #·. Im®l·· 1 §0%: .pf the EPA+QPA+DHAr&amp;UC or Total Qm0$ FA AUC for EPANPVA^ under the $*m>« adroir»st mien oood it sons 256. A method of- adrosnisfrahon or treatmont under tow tat nieal coadTons according to one of the preferred embodiments 103 through 105 resetting mi an iFA*DPA*OHA AUC or Total Oinept-3 ΨΑ -AU£ .s$,:at test· ·1#9% of >the EPA·*· D PA % DBA AUC Or Iota! Omegm3 FA AUC for ΕΡΑΝΟVAm under the s$nm pOoitofitriiort oond moos 157, A method of-admintstmtioo oonditorw :»<^rding"t&amp; one of file pretonmd embodiments 103 through 106 resulting in m ERA+DPA*DHA AUC or Tifif Omeya~3 FA AUC of at toast 100% «I the EPA+QPA+DHA AUC or Total OmegasS FA AUC tor ffiAFi<^MTM life She same administration conditions 2Sa A method of administration one nf the preferred·:· arrsbeliments 103 itoyph 106 remiting m an EFA+DFA*DHA AUC or 'Total Ornii»^;FA AUS nf at toast 105% of |io EPAM'DPAaDHA AUC or Total Cmogo^ FA AUC tor EPANOW* wdw too firoe sirninllffitlQn ogncitians 2Si, A method of adnamaifetoon or treatment unctor tosttog one ©f the petered -erebodireertto· 103 through 18® iBmtItoig: in art. EPAtPPAdOHA. AUG or Total Gmiegml FA AUC of at least 110% of the EFA^PftVDHA .AUC or Topi Cmegmf FA AUC for EPAN^W» hW#r :ttm ssama adm mist* atioo chndifons- 260·. A method of adnifmitratidn .dr oraidltioos aitcofding to doe: of fm pmfemid orripodlmonts 1153 tHroMih IPS minting id an EPA-DFA+QW, AUC or Total dmep*3 FA AUC of M tet 120% of the gPA6B»*%A AUC m Total Ompp-TFA AUC for EPAUCCA^ under the same pdmlnipto-hson condition 261:, A Pidfhod pt ndmi n jss mt ion or troatmont undpr fasihi hondilorts adding to one of Ihp ptnferrod embodiments T®3 throt#t 10S msulihg m- an FFA·*·UFA·;·QHA AUC sr W Omega-3 FA AUC of at Soast 110% of the: EPA+DPA+DHA AUC or Total Omega-3 FA AUC for EPANOVA™ under the same administration conditions 262. A method of administration or treatment under fasting conditions according to one of the preferred embodiments 103 through 105 resulting in an EPA+DPA+DHA AUC or Total Omega-3 FA AUC of at least 140% of the EPA+DPA+DHA AUC or Total Omega-3 FA AUC for EPANOVA™ under the same administration conditions 263. A method of administration or treatment under fasting conditions according to one of the preferred embodiments 103 through 105 resulting in an EPA+DPA+DHA AUC or Total Omega-3 FA AUC of at least 150% of the EPA+DPA+DHA AUC or Total Omega-3 FA AUC for EPANOVA™ under the same administration conditions. 264. The composition of claim 1, wherein the ratio of EPA to DPA (EPA:DPA) is between 15:1 to 8:1. 265. An orally administrable composition comprising fatty acids, wherein at least 50% by weight of the fatty acids comprise omega-3-pentaenoic acids, salts, esters, or derivatives thereof, wherein the composition comprises eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA), and wherein the ratio of DHA to EPA (DHA:EPA) is less than 1:20, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising”, will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

Claims (32)

1. THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS: Claim 1. An orally administrable composition comprising fatty acids, wherein at least 50% by weight of the fatty acids comprise omega-3 fatty acids, salts, esters, or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA), and wherein the ratio of DHA to EPA (DHA:EPA) is less than 1:20, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1.
2. Claim 2. The orally administrable composition of claim 1, wherein the ratio of DHA:EPA is less than 1:50.
3. Claim 3. The orally administrable composition of claim 1, wherein the ratio of DHA:EPA is less than 1:99.
4. Claim 4. The orally administrable composition of any one of claims 1-3, wherein the ratio of DHA:DPA is less than 1:1.
5. Claim 5. The orally administrable composition of any one of claims 1-3, wherein the ratio of DHA:DPA is less than 1:5.
6. Claim 6. The orally administrable composition of any one of claims 1-5, wherein the ratio of EPA to DPA (EPA:DPA) is between 30:1 and 1:1.
7. Claim 7. The orally administrable composition of any one of claims 1-5, wherein the ratio of EPA to DPA (EPA:DPA) is between 20:1 to 5:1.
8. Claim 8. The orally administrable composition of any one of claims 1-7, wherein the composition comprises EPA in an amount between 55% and 95% of the total amount of fatty acids.
9. Claim 9. The orally administrable composition of any one of claims 1-7, wherein the composition comprises EPA in an amount between 65% and 90% of the total amount of fatty acids.
10. Claim 10. The orally administrable composition of any one of claims 1-9, wherein the composition comprises DPA in an amount between 1% and 50% of the total amount of fatty acids.
11. Claim 11. The orally administrable composition of any one of claims 1-10, wherein the composition comprises HPA in an amount between 1% and 20% of the total amount of fatty acids.
12. Claim 12. The orally administrable composition of any one of claims 1-11, wherein the composition comprises DPA in an amount between 1% and 50% and comprises HPA in an amount between 1% and 20% of the total amount of fatty acids.
13. Claim 13. The orally administrable composition of any one of claims 1-12, wherein the composition comprises DPA in an amount between 2% and 40% of the total amount of fatty acids.
14. Claim 14. The orally administrable composition of any one of claims 1-13, wherein at least 90% by weight of the fatty acids comprise omega-3 fatty acids.
15. Claim 15. The orally administrable composition of any one of claims 1-10 and 1314, wherein the composition further comprises heneicosapentaenoic acid (HPA) in an amount of at least 0.10% of the total amount of fatty acids.
16. Claim 16. The orally administrable composition of any one of claims 1-15, wherein the composition further comprises an HMG-CoA reductase inhibitor.
17. Claim 17. The composition of any one of claims 1 -16, wherein the composition comprises an amount of EPA and DPA of between 500 and 1,100 mg.
18. Claim 18. A method of treating a condition in a subject in need thereof, comprising administering the composition of any one of claims 1-17, wherein the condition is selected from the group consisting of: hypertriglyceridemia; hypercholesterolemia; mixed dyslipidemia; coronary heart disease (CHD); vascular disease; cardiovascular disease; acute coronary syndrome; atherosclerotic disease and related conditions; heart failure; cardiac arrhythmias; coagulatory conditions associated with cardiac arrhythmias; ischemic dementia; vascular dementia; hypertension; coagulation related disorders; nephropathy; kidney or urinary tract disease; retinopathy; cognitive and other CNS disorders; autoimmune diseases; inflammatory diseases; asthma or other respiratory disease; dermatological disease; metabolic syndrome; diabetes, diabetes mellitis or other form of metabolic disease; liver disease; non-alcoholic fatty liver disease; disease of the gastrointestinal tract; disease of the male or female reproductive system or related secondary sexual organs; a cancer of any type, including lymphomas and myelomas; and an infection caused by a virus, bacterium, fungus, protozoa or other organism.
19. Claim 19. A method for treating cardiac events, cardiovascular events, vascular events or reducing symptoms associated with cardiac events, cardiovascular events, vascular events in a subject in need thereof, comprising administering the composition of any one of claims 1-17 to the subject.
20. Claim 20. A method of reducing cardiac events, cardiovascular events, or vascular events in a subject in need thereof, comprising administering the composition of any one of claims 1-17 to the subject.
21. Claim 21. A method of reducing triglyceride levels in a subject in need thereof, comprising administering to the subject the composition of any one of claims 1-17.
22. Claim 22. The method of any one of claims 18-21, comprising further administering an HMG-CoA reductase inhibitor.
23. Claim 23. The method of any one of claims 18-22, wherein the LDL-cholesterol level of the subject is not substantially increased.
24. Claim 24. The method of any one of claims 18-22, wherein the LDL-cholesterol level of the subject is reduced.
25. Claim 25. The method of any one of claims 18-22, wherein the triglyceride level of the subject is 500 mg/dL or higher.
26. Claim 26. The method of any one of claims 18-22, wherein the triglyceride level of the subject is between 200 mg/dL and 499 mg/dL.
27. Claim 27. A method of reducing triglyceride levels under fasting conditions comprising administering to the subject the composition of any one of claims 1-17, resulting in an AUC of EPA+DPA of at least 150% of the AUC of EPA+DPA for AMR101 under the same administration conditions.
28. Claim 28. A method of reducing triglyceride levels under fasting conditions comprising administering to the subject the composition of any one of claims 1-17, resulting in an Cmax of EPA+DPA of at least 150% of the Cmax of EPA+DPA for AMR101 under the same administration conditions.
29. Claim 29. Use of the composition of any one of claims 1-17 in the manufacture of a medicament for treating a condition in a subject in need thereof, wherein the condition is selected from the group consisting of: hypertriglyceridemia; hypercholesterolemia; mixed dyslipidemia; coronary heart disease (CHD); vascular disease; cardiovascular disease; acute coronary syndrome; atherosclerotic disease and related conditions; heart failure; cardiac arrhythmias; coagulatory conditions associated with cardiac arrhythmias; ischemic dementia; vascular dementia; hypertension; coagulation related disorders; nephropathy; kidney or urinary tract disease; retinopathy; cognitive and other CNS disorders; autoimmune diseases; inflammatory diseases; asthma or other respiratory disease; dermatological disease; metabolic syndrome; diabetes, diabetes mellitis or other form of metabolic disease; liver disease; non-alcoholic fatty liver disease; disease of the gastrointestinal tract; disease of the male or female reproductive system or related secondary sexual organs; a cancer of any type, including lymphomas and myelomas; and an infection caused by a virus, bacterium, fungus, protozoa or other organism.
30. Claim 30. Use of the composition of any one of claims 1-17 in the manufacture of a medicament for treating cardiac events, cardiovascular events, vascular events or reducing symptoms associated with cardiac events, cardiovascular events, vascular events in a subject in need thereof.
31. Claim 31. Use of the composition of any one of claims 1-17 in the manufacture of a medicament for reducing cardiac events, cardiovascular events, or vascular events in a subject in need thereof.
32. Claim 32. Use of the composition of any one of claims 1-17 in the manufacture of a medicament for reducing triglyceride levels in a subject in need thereof.